PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34896572-5 2022 Tween 80 inhibited the basal ATPase activity of P-gp and MRP1 in a dose-dependent manner (0.0002% to 0.02%) and demonstrated significant reversing effects on the doxorubicin, paclitaxel, and vincristine resistance at the concentration of 0.001% (7.63 muM). Paclitaxel 175-185 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 33793827-15 2021 CONCLUSIONS: PG can enhance the sensitivity of PTX-resistant ovarian cancer cells SK-OV-3/PTX to PTX, and this effect is related to inhibiting NF-kappaB from entering the nucleus and down-regulating the expression of P-gp protein. Paclitaxel 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 217-221 34896572-5 2022 Tween 80 inhibited the basal ATPase activity of P-gp and MRP1 in a dose-dependent manner (0.0002% to 0.02%) and demonstrated significant reversing effects on the doxorubicin, paclitaxel, and vincristine resistance at the concentration of 0.001% (7.63 muM). Paclitaxel 175-185 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 34723530-2 2021 Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo(1,5-a)pyrimidine derivative WS-898 as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC50 = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. Paclitaxel 186-196 ATP binding cassette subfamily B member 1 Homo sapiens 149-154 34648615-6 2021 Transient overexpression of MDR1 increased drug tolerance of HCT-8 cells on paclitaxel, doxorubicin HCl and vincristine sulphate (2.11- to 2.27-fold increase), but not on cyclosporin A, daunorubicin HCl and nitazoxanide. Paclitaxel 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 34858183-6 2021 Results: ABCB1 was significantly higher expressed in tumor tissue compared to esophageal tissue, during both the first and last cycle of paclitaxel (cycle 1: p < 0.01; cycle 5/6: p = 0.01). Paclitaxel 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 9-14 34927791-6 2022 By generating a DSB in the regulatory region of the ABCB1 gene using a lentiviral sgRNA vector, we can induce the formation of Taxol-resistant colonies. Paclitaxel 127-132 ATP binding cassette subfamily B member 1 Homo sapiens 52-57 34977876-5 2021 Reversal of MDR against ABCB1 chemotherapeutic drugs increased intracellular accumulation of (3H)-paclitaxel accumulation, and decreased drug efflux activity was observed in MDR SW620/Ad300 cells after ABCB1 gene knockout. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 34977876-6 2021 Further tests using the 3D multicellular tumor spheroid model suggested that deficiency in ABCB1 restrained tumor spheroid growth and restore sensitivity to paclitaxel in MDR tumor spheroids. Paclitaxel 157-167 ATP binding cassette subfamily B member 1 Homo sapiens 91-96 34313784-8 2021 Uptake of both Rho123 and paclitaxel was decreased in SNAI1-transfected cells, and this decrease was blocked by verapamil, a P-gp inhibitor. Paclitaxel 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 125-129 34313784-9 2021 The reduced susceptibility of SNAI1-transfected cells to paclitaxel was reversed by elacridar, another P-gp inhibitor. Paclitaxel 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 34723530-2 2021 Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo(1,5-a)pyrimidine derivative WS-898 as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC50 = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. Paclitaxel 198-201 ATP binding cassette subfamily B member 1 Homo sapiens 149-154 34723530-3 2021 WS-898 inhibited the efflux function of ABCB1, thus leading to decreased efflux and increased intracellular PTX concentration in SW620/Ad300 cells. Paclitaxel 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 34723530-7 2021 The results suggest that WS-898 is a highly effective triazolo(1,5-a)pyrimidine-based ABCB1 inhibitor and shows promise in reversing ABCB1-mediated PTX resistance. Paclitaxel 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 133-138 34617400-6 2021 Moreover, compared with paclitaxel, PTX-OCT conjugates induced lower expression of MDR-1 gene both in vitro and in vivo. Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 34347777-0 2021 Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 34745981-8 2021 The mechanism underlying Paclitaxel resistance resides in a significant increase in P-glycoprotein expression and, when this drug efflux pump was blocked with Verapamil, cells re-acquired Paclitaxel sensitivity. Paclitaxel 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 84-98 34268580-8 2021 BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available. Paclitaxel 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 4-7 34268580-8 2021 BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available. Paclitaxel 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 76-79 34835622-0 2021 A Multifunctional Polymeric Micelle for Targeted Delivery of Paclitaxel by the Inhibition of the P-Glycoprotein Transporters. Paclitaxel 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 97-111 34835622-9 2021 The orally administered PT-R-Ms efficiently overcome intestinal barriers and inhibit the P-gP efflux pump, resulting in increased bioavailability of PTX (up to 8-fold) in comparison to pure PTX. Paclitaxel 149-152 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 34835622-9 2021 The orally administered PT-R-Ms efficiently overcome intestinal barriers and inhibit the P-gP efflux pump, resulting in increased bioavailability of PTX (up to 8-fold) in comparison to pure PTX. Paclitaxel 190-193 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 34347777-8 2021 ABCB1 expression was upregulated in paclitaxel-resistant TOV-21G (q < 1x10-300), OVCAR3 (q = 7.4x10-156) and novel ovarian tumor organoid (p = 2.4x10-4) models. Paclitaxel 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 34347777-10 2021 We tested a panel of tyrosine kinase inhibitors for the ability to sensitize resistant ABCB1-overexpressing ovarian cancer cell lines to paclitaxel. Paclitaxel 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 87-92 34347777-12 2021 Silencing ABCB1 expression in paclitaxel-resistant TOV-21G and OVCAR3 cells reduced paclitaxel IC50 by 20.7 and 6.2-fold, respectively. Paclitaxel 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 34347777-12 2021 Silencing ABCB1 expression in paclitaxel-resistant TOV-21G and OVCAR3 cells reduced paclitaxel IC50 by 20.7 and 6.2-fold, respectively. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 34347777-13 2021 Furthermore, we demonstrated direct inhibition of paclitaxel-induced ABCB1 transporter activity by both lapatinib and poziotinib. Paclitaxel 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 34347777-14 2021 In conclusion, lapatinib and poziotinib combined with paclitaxel synergizes to inhibit the proliferation of ABCB1-overexpressing ovarian cancer cells in vitro. Paclitaxel 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 108-113 34360846-6 2021 ATC paclitaxel-resistant cells highlighted an overexpression of ABCB1 and a hyper-activation of the NF-kappaB compared to sensitive cells. Paclitaxel 4-14 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 34270886-4 2021 We found that expression of KDM5A and P-glycoprotein (P-gp), which plays a critical role in the development of paclitaxel resistance, were significantly higher in PTX-Calu-3 cells compared to SK-LI-1, Calu-3, and A549 cells.. We observed a significant increase in the expression of mesenchymal markers N-cadherin and vimentin, and a concomitant decrease in expression of E-cadherin and alpha-catenin in PTX-Calu-3 compared to SK-LI-1, Calu-3, and A549 lung cancer cell lines. Paclitaxel 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 34270886-4 2021 We found that expression of KDM5A and P-glycoprotein (P-gp), which plays a critical role in the development of paclitaxel resistance, were significantly higher in PTX-Calu-3 cells compared to SK-LI-1, Calu-3, and A549 cells.. We observed a significant increase in the expression of mesenchymal markers N-cadherin and vimentin, and a concomitant decrease in expression of E-cadherin and alpha-catenin in PTX-Calu-3 compared to SK-LI-1, Calu-3, and A549 lung cancer cell lines. Paclitaxel 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 34022909-6 2021 TPP promoted the targeting of the DA-P-SS-T/PTX nanomicelles to the mitochondrial outer membrane to decrease the membrane potential and ATP level, resulting in inhibition of P-glycoprotein and suppression of drug resistance and cancer metastasis. Paclitaxel 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 174-188 34280009-0 2021 ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 34280009-5 2021 Methods: We extracted genomic DNA from samples collected from 92 Egyptian female breast cancer patients receiving weekly paclitaxel and used them to genotype ABCB1 G1236A (rs1128503) and ABCB1 G3435A (rs1045642). Paclitaxel 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 158-163 34280009-5 2021 Methods: We extracted genomic DNA from samples collected from 92 Egyptian female breast cancer patients receiving weekly paclitaxel and used them to genotype ABCB1 G1236A (rs1128503) and ABCB1 G3435A (rs1045642). Paclitaxel 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 187-192 34280009-13 2021 Conclusion: The ABCB1 G1236A, BSA, and history of diabetes are valid predictors of PIPN, which can enable the personalization of paclitaxel dosing to prevent PIPN. Paclitaxel 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 34276826-8 2021 P-gp and CYP450 inhibitors incorporation further improved the oral bioavailability of PTX to 42.60%, 8-fold increase compared with that of PTX itself (4.75%). Paclitaxel 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 34276826-8 2021 P-gp and CYP450 inhibitors incorporation further improved the oral bioavailability of PTX to 42.60%, 8-fold increase compared with that of PTX itself (4.75%). Paclitaxel 139-142 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 35533911-11 2022 RESULTS: Compared to parental cells, HeLa/Tax cells overexpress P-gp and MRP2 and are approximately 100-360 fold more resistant to the anticancer drugs PTX, docetaxel, and vinblastine. Paclitaxel 152-155 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 35533911-13 2022 Knockdown of P-gp with small interfering RNA partially reversed MT2-induced sensitivity to PTX in HeLa/Tax cells. Paclitaxel 91-94 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 35449387-8 2022 All selected selenoesters inhibited P-gp efflux in a dose-dependent manner while simultaneously altering the expression of the ABC genes, especially P-gp in paclitaxel-resistant breast carcinoma cells (MCF-7/PAX). Paclitaxel 157-167 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 35240035-4 2022 Taxol and other microtubule interacting agents bind to both P-glycoprotein (ABCB1), a drug efflux pump that reduces intracellular drug accumulation, and the tubulin/microtubule system. Paclitaxel 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 35240035-4 2022 Taxol and other microtubule interacting agents bind to both P-glycoprotein (ABCB1), a drug efflux pump that reduces intracellular drug accumulation, and the tubulin/microtubule system. Paclitaxel 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 76-81 35330134-3 2022 In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan. Paclitaxel 198-208 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 35330134-7 2022 Interestingly, our data showed that Carboplatin, Paclitaxel, and Topotecan bind specifically to Asn510 residue in the transmembrane domains 1 of the MRP1. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 35327403-3 2022 Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox). Paclitaxel 197-207 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 35327403-3 2022 Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox). Paclitaxel 209-212 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 35327403-7 2022 As expected, no apoptosis was found in ABCB1-overexpressing cancer cells treated with PTX, Dox, or BGJ 398 alone. Paclitaxel 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 35186774-0 2022 Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein. Paclitaxel 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 35173861-9 2022 After Apa intervention, PTX-resistant MGC803 cells showed decreased cell migration, invasion and proliferation, reduced MDR1, P-gp and VEGFR2 levels, and increased Bax protein level. Paclitaxel 24-27 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 34031188-8 2021 Finally, the highest eribulin IC50 quartile (>~1 nM) exhibited significantly elevated mRNA expression of the drug pump, ABCB1, a defined resistance mechanism to eribulin and paclitaxel. Paclitaxel 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 120-125 35533911-1 2022 Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2. Paclitaxel 22-32 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 35614289-5 2022 Among non-cytotoxic synthetic analogs (1-14), several derivatives effectively and significantly sensitized MDR cells by interfering with the drug transport function of P-gp to three anticancer drugs, vincristine, paclitaxel, and doxorubicin. Paclitaxel 213-223 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 35350768-7 2022 The incubation with 3 microM of palbociclib for 2h significantly increased the intracellular accumulation of (3H)-paclitaxel, a substrate of ABCB1, in ABCB1 overexpressing KB-C2 cells but not in the corresponding non-resistant parental KB-3-1 cell line. Paclitaxel 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 141-146 35350768-7 2022 The incubation with 3 microM of palbociclib for 2h significantly increased the intracellular accumulation of (3H)-paclitaxel, a substrate of ABCB1, in ABCB1 overexpressing KB-C2 cells but not in the corresponding non-resistant parental KB-3-1 cell line. Paclitaxel 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 151-156 35350768-8 2022 However, the incubation of KB-C2 cells with 3 muM of palbociclib for 72 h decreased the intracellular accumulation of (3H)-paclitaxel due to an increase in the expression of the ABCB1 protein. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 178-183 35205672-0 2022 DKK3, Downregulated in Invasive Epithelial Ovarian Cancer, Is Associated with Chemoresistance and Enhanced Paclitaxel Susceptibility via Inhibition of the beta-Catenin-P-Glycoprotein Signaling Pathway. Paclitaxel 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 168-182 35205672-12 2022 DKK3 was lost in paclitaxel-resistant cells, while beta-catenin and P-glycoprotein were upregulated. Paclitaxel 17-27 ATP binding cassette subfamily B member 1 Homo sapiens 68-82 33960504-1 2021 BACKGROUND AND PURPOSE: Paclitaxel is a widely used anti-neoplastic agent but has low oral bioavailability due to gut extrusion by P-glycoprotein (P-gp). Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 131-145 34011375-1 2021 BACKGROUND: Paclitaxel (PTX) has been suggested to be a promising front-line drug for gastric cancer (GC), while P-glycoprotein (P-gp) could lead to drug resistance by pumping PTX out of GC cells. Paclitaxel 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 113-127 34011375-1 2021 BACKGROUND: Paclitaxel (PTX) has been suggested to be a promising front-line drug for gastric cancer (GC), while P-glycoprotein (P-gp) could lead to drug resistance by pumping PTX out of GC cells. Paclitaxel 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 34011375-5 2021 With near infrared (NIR)-irradiation, PTX@GO-PEG-OSA could generate excessive reactive oxygen species (ROS), attack mitochondrial respiratory chain complex enzyme, reduce adenosine-triphosphate (ATP) supplement for P-gp, and effectively inhibit P-gp"s efflux pump function. Paclitaxel 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 215-219 34011375-5 2021 With near infrared (NIR)-irradiation, PTX@GO-PEG-OSA could generate excessive reactive oxygen species (ROS), attack mitochondrial respiratory chain complex enzyme, reduce adenosine-triphosphate (ATP) supplement for P-gp, and effectively inhibit P-gp"s efflux pump function. Paclitaxel 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 245-249 33960504-1 2021 BACKGROUND AND PURPOSE: Paclitaxel is a widely used anti-neoplastic agent but has low oral bioavailability due to gut extrusion by P-glycoprotein (P-gp). Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 33795638-7 2021 Significantly, UTD1 exhibited stronger effect on inducing apoptosis than paclitaxel and 5-FU, especially in HCT15 cells which is ABCB1 high-expression. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 129-134 33729781-1 2021 Many chemotherapeutics, such as paclitaxel, are administered intravenously as they suffer from poor oral bioavailability, partly because of efflux mechanism of P-glycoprotein in the intestinal epithelium. Paclitaxel 32-42 ATP binding cassette subfamily B member 1 Homo sapiens 160-174 33289076-8 2021 Hence, FA-PTX co-loaded, RGD-functionalized PAMAM G4.5 dendrimers may be considered as an effective therapeutic strategy to induce apoptosis in P-gp-overexpressing, multidrug-resistant cells. Paclitaxel 10-13 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 33360797-7 2021 Mechanism studies indicated that compound 10c increased the accumulation of P-glycoprotein (P-gp) substrates rhodamine 123 and Flutax1 in KBV cells and MCF-7T (paclitaxel-resistant breast carcinoma) cells, that is to say, compound 10c exerted the reversal effect of tumor MDR by inhibiting the efflux function of P-gp. Paclitaxel 160-170 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 33545700-2 2021 Cabazitaxel, a second-generation taxane, exhibits greater anticancer activity than paclitaxel and docetaxel and has low affinity for the P-glycoprotein (P-gp) efflux pump because of its structure. Paclitaxel 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 33289076-0 2021 PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 33289076-1 2021 In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 173-187 33289076-1 2021 In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 189-193 33289076-1 2021 In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Paclitaxel 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 173-187 33289076-1 2021 In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Paclitaxel 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 189-193 33289076-3 2021 FA improved intracellular availability of PTX via P-gp modulation in drug-resistant cells. Paclitaxel 42-45 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 33326171-0 2021 GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer. Paclitaxel 95-105 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 33875073-4 2021 The drug-loaded micelles increased the chemosensitivity of MDR tumor cells (MDA-MB-231/MDR1) to PTX and activated mitochondria-dependent apoptotic pathways (the IC50 was 2.22-fold lower than that of PTX alone). Paclitaxel 96-99 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 33360797-7 2021 Mechanism studies indicated that compound 10c increased the accumulation of P-glycoprotein (P-gp) substrates rhodamine 123 and Flutax1 in KBV cells and MCF-7T (paclitaxel-resistant breast carcinoma) cells, that is to say, compound 10c exerted the reversal effect of tumor MDR by inhibiting the efflux function of P-gp. Paclitaxel 160-170 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 33506275-0 2021 Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells. Paclitaxel 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 33506275-6 2021 We demonstrated that ABCB1 and ABCG2 expressions gradually elevated and reached a maximum level in Taxol 8x cells. Paclitaxel 99-104 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 33506275-9 2021 Our findings suggest that higher expressions of ABCB1, ABCG2, and KLF4 might be considered as putative indicators for paclitaxel resistance in LSCC patients. Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 33163405-3 2020 Sapitinib significantly increased the efficacy of paclitaxel and doxorubicin in ABCB1 overexpressing cells without altering the expression or the subcellular location of the ABCB1 transporter. Paclitaxel 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 33506900-16 2021 Finally, the increased levels of MDR1 were significantly reversed following with adding DDX53 si-DDX53-CNE1-TR exosomes, and the increased IC50 to Taxol was obviously reversed. Paclitaxel 147-152 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 33506900-18 2021 The transferred DDX53 could upregulate the expression of MDR1 in NPC cells to promote the resistant capacity to Taxol, which provided a novel insight for understanding NPC and might be a potential therapeutic target for NPC. Paclitaxel 112-117 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 33207738-6 2020 Furthermore, combination treatment with the mitotic kinase PLK1 inhibitor volasertib and the USP7 inhibitor P22077 showed a strong synergism through down-regulation of MDR1/ABCB1 in paclitaxel-resistant lung cancer. Paclitaxel 182-192 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 33207738-6 2020 Furthermore, combination treatment with the mitotic kinase PLK1 inhibitor volasertib and the USP7 inhibitor P22077 showed a strong synergism through down-regulation of MDR1/ABCB1 in paclitaxel-resistant lung cancer. Paclitaxel 182-192 ATP binding cassette subfamily B member 1 Homo sapiens 173-178 33429062-5 2021 In vitro studies of these formulations and fluorescent nanoparticle analogs demonstrate that Genexol-PM allows paclitaxel to overcome P-glycoprotein efflux, but Abraxane behaves as a free drug formulation. Paclitaxel 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 134-148 33280384-2 2020 In this work, we reported the structure-based design of triazolo[1,5-a]pyrimidines as new ABCB1 modulators, of which WS-691 significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC50 = 22.02 nM). Paclitaxel 206-216 ATP binding cassette subfamily B member 1 Homo sapiens 165-170 33280384-2 2020 In this work, we reported the structure-based design of triazolo[1,5-a]pyrimidines as new ABCB1 modulators, of which WS-691 significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC50 = 22.02 nM). Paclitaxel 218-221 ATP binding cassette subfamily B member 1 Homo sapiens 165-170 32489129-5 2020 Released APA effectively inhibited the function of the P-glycoprotein (P-gp) drug pump and improved the sensitivity of MDR cells to chemotherapeutic agents, leading to the recovery of PTX chemosensitivity in MDR cells. Paclitaxel 184-187 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 33050126-4 2020 Moreover, the A549/T CM-HNPs sensitized MDR cells to PTX by suppressing P-glycoprotein (P-gp) activity by 3.2-fold and induced effective apoptosis (70%) in homologous A549/T cells. Paclitaxel 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 33050126-4 2020 Moreover, the A549/T CM-HNPs sensitized MDR cells to PTX by suppressing P-glycoprotein (P-gp) activity by 3.2-fold and induced effective apoptosis (70%) in homologous A549/T cells. Paclitaxel 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 32887626-4 2020 GA not only overcame the multidrug resistance of PTX by inhibiting P-glycoprotein (P-gp) activity in MCF-7/ADR cells, but also inhibited MDA-MB-231 cells migration and invasion, playing a crucial role in preventing and treating the lung metastasis of breast cancer caused by PTX; meanwhile, the synergistic anti-tumor effect of GA and PTX has also been verified in vitro and in vivo experiments. Paclitaxel 49-52 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 32643224-4 2020 This PTX-chemogene conjugate can self-assemble into spherical nucleic acid (SNA)-like micellular nanoparticle as a carrier-free DDS, which effectively knocks down the expression of P-glycoprotein first and subsequently releases the FdU and PTX to exert a synergistic antitumor effect and greatly inhibit the tumor growth. Paclitaxel 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 181-195 32643224-4 2020 This PTX-chemogene conjugate can self-assemble into spherical nucleic acid (SNA)-like micellular nanoparticle as a carrier-free DDS, which effectively knocks down the expression of P-glycoprotein first and subsequently releases the FdU and PTX to exert a synergistic antitumor effect and greatly inhibit the tumor growth. Paclitaxel 240-243 ATP binding cassette subfamily B member 1 Homo sapiens 181-195 32564116-0 2020 ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers. Paclitaxel 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 32564116-9 2020 The risk association between ABCB1 c.1236C>T and moderate-to-severe nephrotoxicity following paclitaxel/carboplatin chemotherapy was also present among non-diabetic patients (ORadjusted 2.16; 95% CI 1.22-3.82). Paclitaxel 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 32564116-11 2020 CONCLUSIONS: ABCB1 c.1236C>T and ERCC1 c.118C>T might serve as potential biomarkers for the risk of moderate-to-severe toxicities to carboplatin/paclitaxel chemotherapy of gynecological cancers. Paclitaxel 145-155 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 32887626-4 2020 GA not only overcame the multidrug resistance of PTX by inhibiting P-glycoprotein (P-gp) activity in MCF-7/ADR cells, but also inhibited MDA-MB-231 cells migration and invasion, playing a crucial role in preventing and treating the lung metastasis of breast cancer caused by PTX; meanwhile, the synergistic anti-tumor effect of GA and PTX has also been verified in vitro and in vivo experiments. Paclitaxel 49-52 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 32984343-3 2020 Previous, we uncovered that the Bruton"s tyrosine kinase (BTK) inhibitor ibrutinib is a potent reversal agent to overcomes paclitaxel resistance in ABCB1-overexpressing cells and tumors. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 148-153 32275773-0 2020 P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients. Paclitaxel 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 32275773-2 2020 The role of P-glycoprotein (P-gp) in the neuronal efflux of paclitaxel was assessed using a translational approach. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 32275773-2 2020 The role of P-glycoprotein (P-gp) in the neuronal efflux of paclitaxel was assessed using a translational approach. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 32275773-5 2020 Paclitaxel neurotoxicity was exacerbated with concomitant P-gp inhibition by valspodar and verapamil, consistent with increased intracellular accumulation of paclitaxel. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 32275773-6 2020 Cancer patients treated with paclitaxel and P-gp inhibitors had a 2.4-fold (95% confidence interval (CI): 1.3-4.3) increased risk of peripheral neuropathy-induced dose modification, a 4.7-fold (95% CI: 1.9-11.9) increased risk for patients treated with strong P-gp inhibitors and a 7.0-fold (95% CI: 2.3-21.5) increased risk in patients treated with atorvastatin. Paclitaxel 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 260-264 32569926-3 2020 These P-gp inhibitors were dramatically effective than verapamil in sensitizing the human ABCB1-overexpressing ABCB1/Flp-In -293 cells and MDR KBvin cells to a series of chemotherapeutic agents, including vincristine and paclitaxel, as manifested by multi-fold decreases in the respective IC50 values to therapeutically attainable levels. Paclitaxel 221-231 ATP binding cassette subfamily B member 1 Homo sapiens 6-10 32569926-3 2020 These P-gp inhibitors were dramatically effective than verapamil in sensitizing the human ABCB1-overexpressing ABCB1/Flp-In -293 cells and MDR KBvin cells to a series of chemotherapeutic agents, including vincristine and paclitaxel, as manifested by multi-fold decreases in the respective IC50 values to therapeutically attainable levels. Paclitaxel 221-231 ATP binding cassette subfamily B member 1 Homo sapiens 90-95 32872293-5 2020 We found that HL156A inhibited the expression of MDR1 by inhibiting the HOXC6-mediated ERK1/2 signaling pathway and increased the sensitivity to paclitaxel or doxorubicin in MDR cells. Paclitaxel 145-155 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 32984343-5 2020 We found that RN486 significantly increased the efficacy of paclitaxel and doxorubicin in both drug-selected carcinoma cells and transfected cells overexpressing ABCB1. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 162-167 32497533-8 2020 Therapeutically, co-treatment with LCL161 at low cytotoxic concentrations restored the sensitivity to the known ABCB1 substrate, paclitaxel, in ABCB1-expressing cancer cells and increased the sensitivity to tamoxifen in MCF7-TamC3 cells. Paclitaxel 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 112-117 32497533-8 2020 Therapeutically, co-treatment with LCL161 at low cytotoxic concentrations restored the sensitivity to the known ABCB1 substrate, paclitaxel, in ABCB1-expressing cancer cells and increased the sensitivity to tamoxifen in MCF7-TamC3 cells. Paclitaxel 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 32707710-4 2020 In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. Paclitaxel 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 32903706-5 2020 In ABCB1-overexpressing cells, nontoxic dose of peptide HX-12C inhibited drug resistance and increased the effective intracellular concentration of paclitaxel and other ABCB1 substrate drugs. Paclitaxel 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 3-8 31967866-0 2020 Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Novel Curcumin Analogues in Paclitaxel-resistant Human Breast Cancer Cells. Paclitaxel 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 32353410-7 2020 Besides, we found that FNDC5 increased paclitaxel chemosensitivity in paclitaxel-sensitive or resistant NSCLCs cell lines via downregulating multidrug resistance protein 1 (MDR1). Paclitaxel 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 173-177 32353410-9 2020 FNDC5 promotes paclitaxel sensitivity of NSCLCs cells via inhibiting NF-kappaB/MDR1 signaling, and FNDC5 might be a novel therapeutic target for the treatment of NSCLCs. Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 32707710-4 2020 In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. Paclitaxel 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 205-210 32707710-5 2020 It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR. Paclitaxel 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 77-82 32707710-5 2020 It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR. Paclitaxel 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 150-155 32108588-1 2020 P-glycoprotein (P-gp) and betaIII-tubulin overexpression-mediated drug resistance leads to clinical therapy failure for paclitaxel. Paclitaxel 120-130 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 32457290-3 2020 Paclitaxel- and doxorubicin-resistant cancer cells showed higher expression of MDR1 and HSF1. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 32156786-9 2020 Finally, taxol-resistant breast cancer cells expressing high levels of multidrug resistance transporter ABCB1 remained sensitive to decitabine, suggesting that the drug could be used as second-line treatment for chemoresistant patients. Paclitaxel 9-14 ATP binding cassette subfamily B member 1 Homo sapiens 104-109 32176509-7 2020 Tariquidar release from this nanocarrier suppressed the P-gp function of MCF-7/Taxol cells and significantly increased the intracellular paclitaxel level (p < 0.01 versus the PTX group). Paclitaxel 79-84 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 32536602-3 2020 We previously reported that TEC resist paclitaxel treatment via upregulation of ABCB1. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 32536602-10 2020 In vivo, the ABCB1 inhibitor combined with paclitaxel reduced tumor growth and metastasis compared with paclitaxel alone. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 32108588-1 2020 P-glycoprotein (P-gp) and betaIII-tubulin overexpression-mediated drug resistance leads to clinical therapy failure for paclitaxel. Paclitaxel 120-130 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 32108588-4 2020 EM-E-11-4 was able to recover the effects of paclitaxel in inducing arrest at G2/M phase and apoptosis in both A549/Tax (P-gp overexpression) and Hela/betaIII (betaIII-tubulin overexpression) cells, respectively, at a non-cytotoxic dose. Paclitaxel 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 31993509-5 2020 Cellular uptake of rhodamine 123 and calcein-acetoxymethyl ester (calcein-AM), P-glycoprotein substrates, decreased in paclitaxel- or eribulin-treated LS174T cells. Paclitaxel 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 79-93 32092870-11 2020 Furthermore, WYE-354 increased the intracellular accumulation of paclitaxel in the ABCB1-mediated MDR cell line, without affecting the corresponding parental cell line, which indicated that WYE-354 could compete with other chemotherapeutic drugs for the ABCB1 transporter substrate binding site. Paclitaxel 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 31846802-8 2020 MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells. Paclitaxel 62-65 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 31846802-8 2020 MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells. Paclitaxel 62-65 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 31846802-8 2020 MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells. Paclitaxel 154-157 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 31846802-8 2020 MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells. Paclitaxel 154-157 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 31993509-1 2020 This study examined the effects of microtubule-targeting anticancer drugs (paclitaxel, cabazitaxel, and eribulin) on the expression of drug efflux transporter P-glycoprotein, which is encoded by MDR1. Paclitaxel 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 159-173 31993509-1 2020 This study examined the effects of microtubule-targeting anticancer drugs (paclitaxel, cabazitaxel, and eribulin) on the expression of drug efflux transporter P-glycoprotein, which is encoded by MDR1. Paclitaxel 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 195-199 31993509-2 2020 Paclitaxel and eribulin induced MDR1 promoter activity in a concentration-dependent manner, while cabazitaxel had little effect in human intestinal epithelial LS174T cells. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 31993509-3 2020 Overexpression of the nuclear receptor pregnane X receptor (PXR) gene (NR1I2) enhanced paclitaxel- and eribulin-induced MDR1 activation, but expression of the nuclear receptor co-repressor silencing mediator for retinoid and thyroid receptors (SMRT) gene (NCOR2) repressed MDR1 activation. Paclitaxel 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 32401925-5 2020 Administration of beta-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells. Paclitaxel 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 31937590-8 2020 The most discriminatory miRNA, with the highest fold change , was miR-451a, which regulates the expression of the drug-transporter protein P-glycoprotein, potentially promoting paclitaxel resistance. Paclitaxel 178-188 ATP binding cassette subfamily B member 1 Homo sapiens 140-154 31628941-0 2020 Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Paclitaxel 140-150 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 31628941-10 2020 Combining CUR and 1,25(OH)2D3 to PAX caused a downregulation in both MDR-1 and ALDH-1 gene expression in MCF-7 besides a decrease in their protein levels. Paclitaxel 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 31628941-14 2020 Overall, the present study showed that PAX, as a monotherapy, demonstrated acquired resistance possibly by increasing MDR-1 expression and enriching CSCs population, as evidenced by increased ALDH-1. Paclitaxel 39-42 ATP binding cassette subfamily B member 1 Homo sapiens 118-123 31867270-10 2019 In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1). Paclitaxel 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 283-288 31476282-5 2019 Further mechanism studies demonstrated that 479 increased the accumulation of paclitaxel and mitoxantrone in cancer cells by interrupting the efflux function of transporters and stimulating ABCB1/ABCG2 ATPase activity. Paclitaxel 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 190-195 31801248-4 2019 In this study, tetrandrine showed synergistic cytotoxic activity in combinational use with chemotherapeutic drugs, such as Doxorubicin, Vincristine, and Paclitaxel, in both drug-induced and MDR1 gene-transfected cancer cells that over-expressed ABCB1/P-glycoprotein. Paclitaxel 153-163 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 31536779-6 2019 Molecular and pharmacological targeting of ABCB1/P-gp did not modify its cytotoxic effect in NCI-H295R cells, while it increased the paclitaxel-induced toxicity. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 43-48 31467112-5 2019 Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro. Paclitaxel 348-351 ATP binding cassette subfamily B member 1 Homo sapiens 299-304 31467112-6 2019 Our results suggest the existence of a ZEB1/KLF5-mTOR-CCND1/ABCB1 axis in human cells that could be involved in PTX response pathways and functionally regulate inter-individualized breast cancer susceptibility and prognosis. Paclitaxel 112-115 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 31467112-7 2019 Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis. Paclitaxel 151-154 ATP binding cassette subfamily B member 1 Homo sapiens 198-203 31571407-11 2019 For non-small cell lung cancer (NSCLC) patients, those harboring ABCB1 2677 and 3435 site wild-type patients had longer median progression-free survival (PFS) in the paclitaxel subgroup (3435 site: TT 3.87 vs. TC 9.50 vs. CC 14.13 months; P < 0.001; 2677 site: TT 4.37 vs. TG 9.73 vs. GG 12.1 months; P = 0.013). Paclitaxel 166-176 ATP binding cassette subfamily B member 1 Homo sapiens 65-70 31350703-3 2019 The MDR1 gene was only detected in RMG-1 cells, in which the amounts of Gb4Cer, Leb and GM3 were higher than in the other cells, which reflected their much higher resistance to paclitaxel and docetaxel compared to the other cells. Paclitaxel 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 31570440-0 2019 Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter. Paclitaxel 18-28 ATP binding cassette subfamily B member 1 Homo sapiens 97-102 31570440-9 2019 RESULTS: A549/PTX cells had significant resistance to PTX and higher expression of ABCB1 compared to A549 cells. Paclitaxel 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 31570440-13 2019 CONCLUSION: Apatinib reverses the drug resistance to PTX in A549 PTX-resistant cells through inhibiting the function of ABCB1 and resumes anti-cancer effects. Paclitaxel 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 120-125 31570440-13 2019 CONCLUSION: Apatinib reverses the drug resistance to PTX in A549 PTX-resistant cells through inhibiting the function of ABCB1 and resumes anti-cancer effects. Paclitaxel 65-68 ATP binding cassette subfamily B member 1 Homo sapiens 120-125 31350703-1 2019 We previously reported that anti-paclitaxel-resistant ovarian carcinoma cells characteristically expressed the MDR1 (multidrug resistance 1) gene with enhanced synthesis of glycolipids, i.e., LacCer, Gb3Cer, Leb and GM3, and that anti-cisplatin-resistant cells lost GM3. Paclitaxel 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 31350703-1 2019 We previously reported that anti-paclitaxel-resistant ovarian carcinoma cells characteristically expressed the MDR1 (multidrug resistance 1) gene with enhanced synthesis of glycolipids, i.e., LacCer, Gb3Cer, Leb and GM3, and that anti-cisplatin-resistant cells lost GM3. Paclitaxel 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 117-139 30367323-5 2019 In the in vivo model, placental tissues isolated from pregnant cancer patients treated with paclitaxel were analyzed to assess the protein expression of ABCB1/P-gp and ABCG2/BCRP. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 153-158 30367323-8 2019 The protein expression of ABCB1/P-gp increased by 1.3-fold after paclitaxel administration. Paclitaxel 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 30367323-9 2019 Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel. Paclitaxel 130-140 ATP binding cassette subfamily B member 1 Homo sapiens 35-40 30367323-9 2019 Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel. Paclitaxel 208-218 ATP binding cassette subfamily B member 1 Homo sapiens 35-40 31350703-6 2019 Thus, MDR1, and increased amounts of Gb4Cer, Leb and GM3 were suggested to be involved in the anticancer drug-resistance to hydrophobic paclitaxel and docetaxel, and GM3 was to basic cisplatin. Paclitaxel 136-146 ATP binding cassette subfamily B member 1 Homo sapiens 6-10 31404980-9 2019 Furthermore, the number of colonies formed from EMT cells and paclitaxel-treated EMT cells after passing through a constriction were found to be 95 +- 10 and 79 +- 4, respectively, confirming that the EMT cells were more drug resistant with a concomitant two-fold higher expression of the multi-drug resistance (MDR1) gene. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 312-316 31196356-2 2019 However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 208-222 31103263-9 2019 Increased drug sensitivity was observed with Pgp silencing or inhibition as determined by drug IC50s of paclitaxel-response of silenced Pgp and doxorubicin-response of inhibited Pgp, respectively. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 45-48 31103263-9 2019 Increased drug sensitivity was observed with Pgp silencing or inhibition as determined by drug IC50s of paclitaxel-response of silenced Pgp and doxorubicin-response of inhibited Pgp, respectively. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 136-139 31103263-9 2019 Increased drug sensitivity was observed with Pgp silencing or inhibition as determined by drug IC50s of paclitaxel-response of silenced Pgp and doxorubicin-response of inhibited Pgp, respectively. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 136-139 31123858-3 2019 OBJECTIVE: To evaluate the role of ABCB1 1236C>T, 3435C>T; CYP2C8*3; CYP3A5*3C variants on paclitaxel/carboplatin toxicities. Paclitaxel 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 35-40 31127007-7 2019 In silico docking of compounds 3 and 8 was performed using the recently solved atomic structure of paclitaxel (Taxol)-bound human P-gp. Paclitaxel 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 31127007-7 2019 In silico docking of compounds 3 and 8 was performed using the recently solved atomic structure of paclitaxel (Taxol)-bound human P-gp. Paclitaxel 111-116 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 31336860-5 2019 Pre-exposure of paclitaxel-resistant ovarian cancer cells to gliotoxin inhibited the expression of multidrug resistant-associated proteins (MDR1 and MRP1-3), disrupted the mitochondrial membrane potential, and induced caspase-dependent apoptosis through autophagy induction after subsequent treatment with paclitaxel. Paclitaxel 16-26 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 31196356-2 2019 However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 224-228 31196356-2 2019 However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux. Paclitaxel 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 208-222 31196356-2 2019 However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux. Paclitaxel 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 224-228 31248184-5 2019 The tested compounds were found to increase the intracellular accumulation of Rho 123, and to enhance the efficacy of paclitaxel in P-gp overexpressing cells. Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 31190887-0 2019 Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells. Paclitaxel 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 30317630-0 2019 Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells. Paclitaxel 110-115 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 30317630-1 2019 We report here that the androgen receptor (AR) and ABCB1 are upregulated in a model of acquired taxol resistance (txr) in ovarian carcinoma cells. Paclitaxel 96-101 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 30317630-3 2019 AR activation using the agonist dihydrotestosterone (DHT) or sublethal taxol treatment upregulates ABCB1 expression in both txr cells and AR-expressing HEK293 cells. Paclitaxel 71-76 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 30317630-12 2019 While the phosphatidylinositol 3-kinase (PI3K)/serine/threonine protein kinase (AKT) pathway is significantly activated by taxol, taxol-induced ABCB1 expression, histone posttranslational modifications, and p300 binding to ARE4 are suppressed following inhibition of the PI3K/AKT cellular pathway. Paclitaxel 130-135 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 30317630-13 2019 These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance. Paclitaxel 116-121 ATP binding cassette subfamily B member 1 Homo sapiens 79-84 30317630-13 2019 These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance. Paclitaxel 172-177 ATP binding cassette subfamily B member 1 Homo sapiens 79-84 31190887-14 2019 Conclusion: P-gp is highly expressed in mitochondria of taxol-resistant ovarian cancer cells and ovarian cancer tissues and mediates the drug efflux, which probably protect cancer cells from chemotherapy. Paclitaxel 56-61 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 30790579-4 2019 Five flavonoids, including tangeretin, sinensetin, isosinensetin, sciadopitysin and oroxylin A exhibited significant inhibition on P-gp in MDR1-MDCKIIcells, which reduced the P-gp-mediated efflux of paraquat and taxol and consequently increased their cell toxicity. Paclitaxel 212-217 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 31156720-8 2019 Results: Treatment with Plk1 inhibitors markedly reduced the expression of MDR1, MRP1, and Plk1 in the paclitaxel-resistant cancer. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 31106148-6 2019 Glesatinib suppressed the efflux function of P-gp to [3H]-paclitaxel and it didn"t impact both the expression and cellular localization of P-gp based on Western blot and immunofluorescent analysis. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 30230544-3 2019 ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells. Paclitaxel 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 30790579-4 2019 Five flavonoids, including tangeretin, sinensetin, isosinensetin, sciadopitysin and oroxylin A exhibited significant inhibition on P-gp in MDR1-MDCKIIcells, which reduced the P-gp-mediated efflux of paraquat and taxol and consequently increased their cell toxicity. Paclitaxel 212-217 ATP binding cassette subfamily B member 1 Homo sapiens 175-179 30894541-6 2019 MDR1 inhibition in a fusion positive ovarian cancer cell line increased sensitivity to paclitaxel more than 50-fold. Paclitaxel 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 30911326-0 2019 Combination of shikonin with paclitaxel overcomes multidrug resistance in human ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation. Paclitaxel 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 30391357-8 2019 The combination of IPI-549 with paclitaxel showed that IPI-549 potentiates the anti-tumor effects of paclitaxel in P-gp-overexpressing MDR SW620/Ad300 xenograft tumors. Paclitaxel 32-42 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 30911326-14 2019 Conclusions: These results reveal a P-gp-independent mechanism through ROS generation for the SKN/PTX combination to overcome MDR in ovarian cancer. Paclitaxel 98-101 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 30765569-2 2019 We determined the 3.5-angstrom cryo-electron microscopy structure of substrate-bound human ABCB1 reconstituted in lipidic nanodiscs, revealing a single molecule of the chemotherapeutic compound paclitaxel (Taxol) bound in a central, occluded pocket. Paclitaxel 194-204 ATP binding cassette subfamily B member 1 Homo sapiens 91-96 30765569-2 2019 We determined the 3.5-angstrom cryo-electron microscopy structure of substrate-bound human ABCB1 reconstituted in lipidic nanodiscs, revealing a single molecule of the chemotherapeutic compound paclitaxel (Taxol) bound in a central, occluded pocket. Paclitaxel 206-211 ATP binding cassette subfamily B member 1 Homo sapiens 91-96 30711936-0 2019 AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 30711936-7 2019 Knockdown of MDR1 sensitized the cells to paclitaxel, but not to carboplatin or cisplatin. Paclitaxel 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 30711936-8 2019 CONCLUSION: AS602801 chemosensitized ovarian CSCs to paclitaxel by reducing the expression of MDR1. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 30391357-8 2019 The combination of IPI-549 with paclitaxel showed that IPI-549 potentiates the anti-tumor effects of paclitaxel in P-gp-overexpressing MDR SW620/Ad300 xenograft tumors. Paclitaxel 101-111 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 29956630-4 2019 Also, many studies have proved that paclitaxel is a substrate of the membrane-bound drug efflux pump P-glycoprotein (P-gp), therefore it often shows limited efficacy against the resistant tumors and oral absorption or uptake. Paclitaxel 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 29956630-4 2019 Also, many studies have proved that paclitaxel is a substrate of the membrane-bound drug efflux pump P-glycoprotein (P-gp), therefore it often shows limited efficacy against the resistant tumors and oral absorption or uptake. Paclitaxel 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 29504705-0 2018 ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 30401501-6 2018 The cellular thermal shift assay (CETSA) showed that WS-10 was able to bind to ABCB1, which could be responsible for the reversal effect of WS-10 toward paclitaxel and doxorubicin in SW620/Ad300 cells. Paclitaxel 153-163 ATP binding cassette subfamily B member 1 Homo sapiens 79-84 29777024-7 2018 The brain-to-plasma ratios of P-gp substrates in hMDR1-MAC mice were much lower than those in Mdr1a/1b-knockout mice, and the brain-to-plasma ratio of paclitaxel was significantly increased by pretreatment with a P-gp inhibitor in hMDR1-MAC mice. Paclitaxel 151-161 ATP binding cassette subfamily B member 1 Homo sapiens 213-217 29777024-7 2018 The brain-to-plasma ratios of P-gp substrates in hMDR1-MAC mice were much lower than those in Mdr1a/1b-knockout mice, and the brain-to-plasma ratio of paclitaxel was significantly increased by pretreatment with a P-gp inhibitor in hMDR1-MAC mice. Paclitaxel 151-161 ATP binding cassette subfamily B member 1 Homo sapiens 231-236 30150104-6 2018 The cellular thermal shift assay (CETSA) showed that WS-10 was able to bind to ABCB1, which could be responsible for the reversal effect of WS-10 toward paclitaxel and doxorubicin in SW620/Ad300 cells. Paclitaxel 153-163 ATP binding cassette subfamily B member 1 Homo sapiens 79-84 29777711-0 2018 UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Paclitaxel 13-23 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 30008912-6 2018 Treatment of beta-elemene-paclitaxel arrested the cell cycle and decreased cyclin-dependent kinase, cyclin-B1, P21 and P27 expression levels and decreased resistant genes alterations of ATP binding cassette subfamily B member 1, LDL receptor related protein and TS in U-2OS cells. Paclitaxel 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 186-227 29971911-0 2018 Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. Paclitaxel 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 92-97 29971911-8 2018 In summary, our results reveal the potential regulatory mechanism of FTH1P3 on breast cancer paclitaxel resistance through miR-206/ABCB1, providing a novel insight for the breast cancer chemoresistance. Paclitaxel 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 131-136 29777711-6 2018 Mechanistically, UCA1 silencing induced PTX sensitivity of SKOV3/PTX and HeyA-8/PTX cells by de-repressing ABCB1 through sponging miR-129. Paclitaxel 40-43 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 29777711-7 2018 Collectively, our study elaborated a novel UCA1/miR-129/ABCB1 regulatory axis underlying PTX resistance of OC cells, providing a potential therapeutic target for OC. Paclitaxel 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 29550143-4 2018 Moreover, paclitaxel is a substrate for p-glycoprotein, which shows a decreased accumulation of drug within the cancer cell expressed by a p-glycoprotein. Paclitaxel 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 29550143-4 2018 Moreover, paclitaxel is a substrate for p-glycoprotein, which shows a decreased accumulation of drug within the cancer cell expressed by a p-glycoprotein. Paclitaxel 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 29550143-5 2018 Therefore, the purpose of this study is to prepare a paclitaxel-loaded liposome and evaluate the effect of d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) as an inhibitor of p-glycoprotein on the paclitaxel-loaded liposome. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 187-201 29760419-0 2018 PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Paclitaxel 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 29766327-13 2018 The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin. Paclitaxel 167-177 ATP binding cassette subfamily B member 1 Homo sapiens 120-123 29861863-4 2018 Further, high salt induced P-glycoprotein (P-gp) mediated paclitaxel drug resistance in breast cancer cells. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 29861863-4 2018 Further, high salt induced P-glycoprotein (P-gp) mediated paclitaxel drug resistance in breast cancer cells. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Paclitaxel 159-169 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Paclitaxel 191-201 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 29701706-16 2018 In conclusion, mansorin-II synergizes the anticancer effect of paclitaxel in colorectal cancer cells, which might be partially attributed to enhancing its cellular entrapment via inhibiting P-gp efflux pump. Paclitaxel 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 28771725-1 2018 We report here that toll-like receptor 4 (TLR4) and ABCB1 are upregulated in SKOV3 ovarian carcinoma cells that acquired resistance to the anticancer drug taxol. Paclitaxel 155-160 ATP binding cassette subfamily B member 1 Homo sapiens 52-57 29517223-0 2018 Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of beta-Tubulin and the Multidrug Resistance Associated P-Glycoprotein. Paclitaxel 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 29517223-1 2018 Several next-generation taxanes have been reported to possess high potency against Taxol-resistant cancer cell lines overexpressing betaIII-tubulin and/or P-glycoprotein (P-gp), both of which are involved in drug resistance. Paclitaxel 83-88 ATP binding cassette subfamily B member 1 Homo sapiens 155-169 29517223-1 2018 Several next-generation taxanes have been reported to possess high potency against Taxol-resistant cancer cell lines overexpressing betaIII-tubulin and/or P-glycoprotein (P-gp), both of which are involved in drug resistance. Paclitaxel 83-88 ATP binding cassette subfamily B member 1 Homo sapiens 171-175 29517223-7 2018 The mechanisms involved in drug resistance are multifactorial, and the effectiveness of new Taxol analogues depends on the interaction between the drugs and all possible targets; in this case the two major cellular targets are beta-tubulin and P-gp. Paclitaxel 92-97 ATP binding cassette subfamily B member 1 Homo sapiens 244-248 29649113-8 2018 Short-term exposure to PAC led to increased expression of the MDR1 and BCRP genes in the A2780 and W1 cell lines. Paclitaxel 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 28771725-8 2018 Consistent with these results, ectopic expression of TLR4 in taxol-sensitive SKOV3 cells enhanced ABCB1 expression and conferred resistance to taxol. Paclitaxel 61-66 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 28771725-10 2018 These results demonstrate that taxol activates the TLR4-NFkappaB pathway which in turn induces ABCB1 gene expression. Paclitaxel 31-36 ATP binding cassette subfamily B member 1 Homo sapiens 95-100 28771725-3 2018 A sub-lethal dose of taxol induced ABCB1 protein expression in taxol-resistant SKOV3 cells. Paclitaxel 21-26 ATP binding cassette subfamily B member 1 Homo sapiens 35-40 28771725-3 2018 A sub-lethal dose of taxol induced ABCB1 protein expression in taxol-resistant SKOV3 cells. Paclitaxel 63-68 ATP binding cassette subfamily B member 1 Homo sapiens 35-40 28771725-6 2018 Notably, the NFkappaB pathway was significantly activated by taxol, and inhibition of this pathway suppressed TLR4-regulated ABCB1 expression. Paclitaxel 61-66 ATP binding cassette subfamily B member 1 Homo sapiens 125-130 29486476-8 2018 RESULTS: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 90-95 29408042-5 2018 Interestingly, siRNA knockdown of MDR1 further sensitized the cytotoxic activity of paclitaxel when co-administrated with H6. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 29251928-5 2018 Selected compounds were shown to reverse paclitaxel resistance in HEK293 cells overexpressing P-gp and were selective toward P-gp over CYP3A4. Paclitaxel 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 29251928-5 2018 Selected compounds were shown to reverse paclitaxel resistance in HEK293 cells overexpressing P-gp and were selective toward P-gp over CYP3A4. Paclitaxel 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 125-129 29208281-5 2018 Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein. Paclitaxel 145-148 ATP binding cassette subfamily B member 1 Homo sapiens 181-195 29208281-5 2018 Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein. Paclitaxel 204-207 ATP binding cassette subfamily B member 1 Homo sapiens 181-195 29072615-0 2017 The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 125-129 29162114-0 2017 A computational study of the inhibition mechanisms of P-glycoprotein mediated paclitaxel efflux by kinase inhibitors. Paclitaxel 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 29162114-2 2017 One P-gp substrate is the widely used chemotherapy drug paclitaxel. Paclitaxel 56-66 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 29162114-3 2017 Co-administration of paclitaxel and another drug that inhibits P-gp may enhance the therapeutic effectiveness of paclitaxel by preventing its efflux from tumor cells. Paclitaxel 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 29162114-3 2017 Co-administration of paclitaxel and another drug that inhibits P-gp may enhance the therapeutic effectiveness of paclitaxel by preventing its efflux from tumor cells. Paclitaxel 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 29162114-4 2017 RESULTS: Here we present a computational approach that combines docking studies with mass action kinetic modeling to investigate how kinase inhibitors may inhibit P-gp mediated paclitaxel efflux. Paclitaxel 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 163-167 29162114-6 2017 The relative scales of these two competitions are TKI dependent and determined by the relative affinities of paclitaxel and TKIs to the SBD and NBD of P-gp, and their membrane partition coefficients. Paclitaxel 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 29399166-7 2018 It was identified that the expression levels of Twist, TOPO IIalpha, MRP and P-gp were upregulated and LRP was downregulated in human breast cancer tissues, which was consistent with the expression of these proteins in the Taxol -resistant MCF-7 cell model. Paclitaxel 223-228 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 29054369-10 2017 Additional model simulations indicate that within clinically achievable PTX concentrations, the contribution of exosomes to active drug efflux increased with drug concentration and exceeded the p-glycoprotein efflux when the latter was saturated. Paclitaxel 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 194-208 29270012-6 2017 The results of in vitro studies show that, compared to the control group, the DSF and PTX co-loaded micelles with charge reversal exhibits more effective cellular uptake and significantly increased cytotoxicity of PTX to MCF-7/ADR cells which may be due to the inhibitory effect of DSF on the efflux function of P-gp. Paclitaxel 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 312-316 29163177-5 2017 Methods: An extensive panel of five polymorphisms on four candidate genes (ABCB1, CYP2C8*3, CYP3A4*1B, XRCC3), previously validated as significant markers related to paclitaxel and Docetaxel toxicity, are analyzed and discussed. Paclitaxel 166-176 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 29072615-8 2017 Collectively, our data show that LSS-11 is a potent naphthalimide-based chemosensitizer that could enhance cell death in paclitaxel-resistant lung cancer cells through the DR5/PARP1 pathway and STAT3/MDR1/MRP1 STAT3 inhibition. Paclitaxel 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 200-204 29085518-9 2017 The TxR cells also exhibited an increased expression of MDR-related proteins including MDR1 and MRP-1, which led to a substantial increase (5.4-fold) of the paclitaxel efflux from TxR-cells. Paclitaxel 157-167 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 28485901-0 2017 Synthesis of a Fluorescent Analogue of Paclitaxel That Selectively Binds Microtubules and Sensitively Detects Efflux by P-Glycoprotein. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 28411377-0 2017 miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. Paclitaxel 74-79 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 28411377-5 2017 The results indicated that the expression of MDR1 in the above cells or tumours was suppressed and that subsequently the drug accumulation in the MDR cells was decreased, cell death was increased, and tumour growth was inhibited after treatment with taxol-doxorubicin, demonstrating increased drug sensitivity. Paclitaxel 250-255 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 28322937-6 2017 Although Western blot analysis showed that P-gp expression levels were similar in Mock and Snail-overexpressing cells, the results of P-gp functional assays with P-gp substrates rhodamine123 and paclitaxel indicated that P-gp is activated in Snail-overexpressing cells. Paclitaxel 195-205 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 28322937-6 2017 Although Western blot analysis showed that P-gp expression levels were similar in Mock and Snail-overexpressing cells, the results of P-gp functional assays with P-gp substrates rhodamine123 and paclitaxel indicated that P-gp is activated in Snail-overexpressing cells. Paclitaxel 195-205 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 28322937-6 2017 Although Western blot analysis showed that P-gp expression levels were similar in Mock and Snail-overexpressing cells, the results of P-gp functional assays with P-gp substrates rhodamine123 and paclitaxel indicated that P-gp is activated in Snail-overexpressing cells. Paclitaxel 195-205 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 28502672-0 2017 DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. Paclitaxel 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 90-104 27008163-0 2017 Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug. Paclitaxel 136-146 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 29069726-8 2017 However, although RPE-20 cells displayed enhanced TUBB3 levels, we find that simultaneous up-regulation of the P-glycoprotein (P-gP) drug-efflux pump is responsible for the resistance to taxol. Paclitaxel 187-192 ATP binding cassette subfamily B member 1 Homo sapiens 111-125 28260803-1 2017 P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma. Paclitaxel 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 28260803-1 2017 P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma. Paclitaxel 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 28260803-1 2017 P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma. Paclitaxel 131-134 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 28260803-1 2017 P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma. Paclitaxel 131-134 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 28260803-4 2017 PTX-loaded PSST micelles (PTX/PSST-M) designed to display synergistic functions, including reversible inhibition of P-gp, intracellular redox-sensitive release and potent anticancer activities. Paclitaxel 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 28599410-7 2017 It was indicated that cell lines overexpressing ABCB1 exhibited similar resistance profiles to nab-paclitaxel and paclitaxel. Paclitaxel 95-109 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 28599410-7 2017 It was indicated that cell lines overexpressing ABCB1 exhibited similar resistance profiles to nab-paclitaxel and paclitaxel. Paclitaxel 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 28599410-8 2017 Cabozantinib and crizotinib sensitized tumor cells to nab-paclitaxel and paclitaxel in the same dose-dependent manner in cell lines overexpressing ABCB1, without altering the downstream signaling of tyrosine kinases. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 147-152 28599410-9 2017 These results suggest that the overexpression of ABCB1 confers resistance to nab-paclitaxel in urothelial cancer cells. Paclitaxel 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 28441715-0 2017 Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line. Paclitaxel 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 28447211-0 2017 Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 28588737-4 2017 The multidrug resistance (MDR)-1/P-glycoprotein has previously been demonstrated to be associated with the acquisition of paclitaxel resistance in certain ovarian tumors. Paclitaxel 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 4-32 28588737-4 2017 The multidrug resistance (MDR)-1/P-glycoprotein has previously been demonstrated to be associated with the acquisition of paclitaxel resistance in certain ovarian tumors. Paclitaxel 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 33-47 28588737-9 2017 It was also determined that the pre-incubation of ovarian cancer cells with a lower dose of myricetin was able to increase the cytotoxicity of paclitaxel, due to the significant downregulation of MDR-1 in these cells. Paclitaxel 143-153 ATP binding cassette subfamily B member 1 Homo sapiens 196-201 28599410-0 2017 Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells. Paclitaxel 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 67-72 29069726-8 2017 However, although RPE-20 cells displayed enhanced TUBB3 levels, we find that simultaneous up-regulation of the P-glycoprotein (P-gP) drug-efflux pump is responsible for the resistance to taxol. Paclitaxel 187-192 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 29145976-3 2017 Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated, resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein overexpression, and multidrug resistance (MDR). Paclitaxel 117-127 ATP binding cassette subfamily B member 1 Homo sapiens 155-160 28470171-3 2017 In this co-delivery system, PTX was covalently conjugated to poly (D,L-lactide-co-glycolide) polymeric core by redox-sensitive disulfide bond, while TET was physically capsulated spontaneously for the aim to suppress P-gp in advance by the earlier released TET in cancer cells. Paclitaxel 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 217-221 28423731-3 2017 The faster release of curcumin from the folate-conjugated curcumin and paclitaxel-loaded lipid nanoparticles enables sufficient p-glycoprotein inhibition, which allows increased cellular uptake and cytotoxicity of paclitaxel. Paclitaxel 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 128-142 28423731-4 2017 In western blot assay, curcumin can efficiently inhibit the expression of p-glycoprotein, conformed the enhancement of cytotoxicity by paclitaxel. Paclitaxel 135-145 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 29145976-3 2017 Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated, resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein overexpression, and multidrug resistance (MDR). Paclitaxel 117-127 ATP binding cassette subfamily B member 1 Homo sapiens 282-296 28077325-0 2017 Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 28260091-5 2017 The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 28260091-5 2017 The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 134-137 28260091-5 2017 The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 275-278 28260091-5 2017 The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 275-278 28260091-5 2017 The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity. Paclitaxel 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 275-278 28260091-5 2017 The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity. Paclitaxel 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 275-278 28260091-6 2017 The promoter activities of MDR gene 1 (MDR1) and nuclear factor (NF)-kappaB, and the expression levels of NF-kappaB and p-IkappaB-alpha were all enhanced in the cells cultured with paclitaxel alone. Paclitaxel 181-191 ATP binding cassette subfamily B member 1 Homo sapiens 27-37 28260091-6 2017 The promoter activities of MDR gene 1 (MDR1) and nuclear factor (NF)-kappaB, and the expression levels of NF-kappaB and p-IkappaB-alpha were all enhanced in the cells cultured with paclitaxel alone. Paclitaxel 181-191 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 28260091-7 2017 NF-kappaB DNA-binding activity and the binding ability of NF-kappaB to the MDR1 promoter were also enhanced in the cells cultured with paclitaxel alone compared to the control cells. Paclitaxel 135-145 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 28260091-9 2017 On the whole, our findings suggest that TET prevents paclitaxel-induced MDR by inhibiting Pgp overexpression through a mechanism that may involve the inhibition of NF-kappaB signaling in osteosarcoma. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 90-93 28253574-11 2017 Compared with A2780/Taxol group (1.78+-0.27) , MDR1 mRNA was significantly down-regulated in A2780/Taxol+CRM197 group (0.79+-0.13, P<0.05). Paclitaxel 20-25 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 28253574-16 2017 Conclusion: CRM197 reverses the resistance of ovarian cancer to paclitaxel by increasing caspase-3 activity to advance apoptosis via EGFR/MDR1/P-gp pathway. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 28077325-12 2017 This data indicates that 14-3-3sigma contributes to P-gp overexpression through interaction with PXR with rifampin and paclitaxel treatment. Paclitaxel 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 28427190-7 2017 Second, over-expression of Pygo2 facilitated the expression of P-glycoprotein, which acts as a drug efflux pump, by promoting the transcription of Multi-drug resistance 1 (MDR1) at the MDR1 promoter loci, resulting in acceleration of the efflux of PTX. Paclitaxel 248-251 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 28427190-7 2017 Second, over-expression of Pygo2 facilitated the expression of P-glycoprotein, which acts as a drug efflux pump, by promoting the transcription of Multi-drug resistance 1 (MDR1) at the MDR1 promoter loci, resulting in acceleration of the efflux of PTX. Paclitaxel 248-251 ATP binding cassette subfamily B member 1 Homo sapiens 147-170 28427190-7 2017 Second, over-expression of Pygo2 facilitated the expression of P-glycoprotein, which acts as a drug efflux pump, by promoting the transcription of Multi-drug resistance 1 (MDR1) at the MDR1 promoter loci, resulting in acceleration of the efflux of PTX. Paclitaxel 248-251 ATP binding cassette subfamily B member 1 Homo sapiens 172-176 28077325-1 2017 In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model. Paclitaxel 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 28077325-2 2017 Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90beta-PXR-MDR1 pathway. Paclitaxel 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 28077325-10 2017 P-gp overexpression was induced only when 14-3-3sigma transfected LS174T cells were treated with rifampin and paclitaxel, whereas 14-3-3sigma inhibition by nonpeptidic inhibitor, BV02 and 14-3-3sigma siRNA reduced rifampin induced PXR and P-gp expression. Paclitaxel 110-120 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 27746331-2 2016 To reverse MDR and improve the chemotherapy effect of paclitaxel (PTX), we propose a new drug delivery system based on mixed micelles constructed with d-alpha-tocopheryl poly(ethylene glycol) 1000 succinate (TPGS) and the mPEG-SS-PTX conjugate with consideration that TPGS is a P-gp inhibitor that can block the cancer cell action of pumping drugs outside of cells and can enhance the anticancer effect. Paclitaxel 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 278-282 27854072-5 2017 Here, we investigated an inhibition effect of SH003 on MDR1 activity in paclitaxel-resistant MCF-7/PAX breast cancer cells. Paclitaxel 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 27854072-7 2017 Paclitaxel-resistant MCF-7 cells showed an increase of MDR1 activity, which was confirmed by measuring an amount of accumulated rhodamine 123 in the cells. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 27854072-8 2017 Also, qRT-PCR and Western blot assays confirmed that paclitaxel-resistant MCF-7 cells exhibited high MDR1 expression level. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 27123551-10 2017 Our results demonstrate SSA could increase the chemosensitivity of P-gp overexpressing HepG2/ADM and MCF-7/ADR cells to doxorubicin (DOX), vincristine (VCR) and paclitaxel. Paclitaxel 161-171 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 28104912-0 2017 Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 27810470-5 2017 The functional role of P-gp in limiting the permeability of the anticancer drug paclitaxel (Ptx) was assessed in MDA-MB-436 cells. Paclitaxel 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 27810470-5 2017 The functional role of P-gp in limiting the permeability of the anticancer drug paclitaxel (Ptx) was assessed in MDA-MB-436 cells. Paclitaxel 92-95 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 28031414-7 2017 Intracellular concentrations of known P-gp and BCRP substrates [(3H)-paclitaxel and (3H)-prazosin, respectively] were significantly higher (indicating less efflux) in NIH-3T3-MDR1 and MDCK-BCRP cells in the presence of 6-OH-BDE-47, but not BDE-47. Paclitaxel 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 27854072-10 2017 We also found that a combinatorial treatment of SH003 and paclitaxel in paclitaxel-resistant MCF-7 cells caused apoptosis in synergistic manner, which was due to SH003 inhibition of MDR1 expression. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 182-186 27854072-10 2017 We also found that a combinatorial treatment of SH003 and paclitaxel in paclitaxel-resistant MCF-7 cells caused apoptosis in synergistic manner, which was due to SH003 inhibition of MDR1 expression. Paclitaxel 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 182-186 28031414-7 2017 Intracellular concentrations of known P-gp and BCRP substrates [(3H)-paclitaxel and (3H)-prazosin, respectively] were significantly higher (indicating less efflux) in NIH-3T3-MDR1 and MDCK-BCRP cells in the presence of 6-OH-BDE-47, but not BDE-47. Paclitaxel 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 175-179 27878971-13 2016 Furthermore, the hydroxylation products of Taxol analyzed by HPLC were increased in comparison to the SR12813 untreated group, indicating that high expressions of CYP2C8 and P-gp enhanced the resistance of A549 cells to Taxol. Paclitaxel 220-225 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 27878971-0 2016 Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol. Paclitaxel 102-107 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 27878971-3 2016 We aim to research the effect of PXR on Taxol-resistant non-small-cell lung cancer (NSCLC cells) via regulating CYP2C8 and P-gp. Paclitaxel 40-45 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 27878971-13 2016 Furthermore, the hydroxylation products of Taxol analyzed by HPLC were increased in comparison to the SR12813 untreated group, indicating that high expressions of CYP2C8 and P-gp enhanced the resistance of A549 cells to Taxol. Paclitaxel 43-48 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 27878971-15 2016 The cell viability, cell proliferation, and Taxol metabolites were regulated by the expressions of PXR, P-gp, and CYP2C8. Paclitaxel 44-49 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 27878971-16 2016 That is, PXR expression has an important effect on the resistance of NSCLC cells to Taxol via upregulating P-gp and CYP2C8. Paclitaxel 84-89 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 27664577-9 2016 Employing mRNA expression profiling of all known human ABC transporters and subsequent Western blot analysis of the expression of selected transporters, we demonstrated that only the ABCB1/PgP and ABCC3/MRP3 proteins were up-regulated in both paclitaxel-resistant sublines. Paclitaxel 243-253 ATP binding cassette subfamily B member 1 Homo sapiens 183-188 27941276-5 2016 Moreover, we found that siRNA mediated ABCB1 knockdown successfully restored drug sensitivity in both paclitaxel and docetaxel resistant esophageal cancer cell lines. Paclitaxel 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 27812204-9 2016 However, stratified by chemotherapy regimen, inverse correlation between high ABCB1 status and poor OS, PFS and TR were only found in patients underwent platinum-based chemotherapy but not in patients received standard platinum/paclitaxel-based chemotherapy. Paclitaxel 228-238 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 27664577-12 2016 Silencing of ABCB1 expression using specific siRNA increased significantly, but did not completely restore full sensitivity to both paclitaxel and doxorubicin. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 27664577-13 2016 Thus we showed a key, but not exclusive, role for ABCB1 in mechanisms of paclitaxel resistance. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 27572875-6 2016 Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 27422607-9 2016 Collectively, these data indicated that DUSP1 may induce the resistance against paclitaxel through the p38 MAPK-mediated overexpression of p-glycoprotein in human ovarian cancer cells. Paclitaxel 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 27262378-0 2016 Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines. Paclitaxel 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 22-27 27262378-3 2016 The aim of this study was to investigate whether a naturally occurring diet-based phenolic acid, ferulic acid, could sensitize paclitaxel efficacy in ABCB1 overexpressing (P-glycoprotein) colchicine selected KB Ch(R)8-5 cell line. Paclitaxel 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 150-155 27262378-3 2016 The aim of this study was to investigate whether a naturally occurring diet-based phenolic acid, ferulic acid, could sensitize paclitaxel efficacy in ABCB1 overexpressing (P-glycoprotein) colchicine selected KB Ch(R)8-5 cell line. Paclitaxel 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 172-186 27262378-6 2016 Cytotoxicity assay reveals that ferulic acid decreased paclitaxel resistance in KBCh(R)8-5 and HEK293/ABCB1 cells, which indicates its chemosensitizing potential. Paclitaxel 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 27588398-8 2016 Inhibition of ABCB1 partially restored paclitaxel and doxorubicin sensitivity. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 27422607-0 2016 DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells. Paclitaxel 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 27574448-0 2016 Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Paclitaxel 110-120 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 27467397-0 2016 Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates. Paclitaxel 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 27415012-0 2016 ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 27415012-0 2016 ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 7-11 27415012-8 2016 Active efflux of paclitaxel, olaparib, doxorubicin and rucaparib was confirmed in drug-resistant cells and in ABCB1-expressing bacterial membranes. Paclitaxel 17-27 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 27415012-9 2016 CONCLUSIONS: We describe a common ABCB1-mediated mechanism of paclitaxel and olaparib resistance in ovarian cancer cells. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 27131064-6 2016 In particular, the compound 5a sensitized ABCB1/Flp-In -293 cells toward paclitaxel, vincristine, and doxorubicin by 16.1, 21.0, and 1.6-fold at 10 muM, respectively. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 42-47 27295567-9 2016 Collectively, our data establish a hitherto unknown liaison among MDR1, BMI1 and TIP60 and provide mechanistic insights into cisplatin-induced MDR1 expression resulting in acquired cross-resistance against paclitaxel, doxorubicin and likely other drugs. Paclitaxel 206-216 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 27467397-6 2016 Compared with PTX, PGNPs did not induce the Pgp overexpression in drug-sensitive H460 cells after long-term treatment and also avoided being pumped out of cells by overexpressed Pgp molecules in H460PTX with a 17-fold lower EC50 compared to PTX. Paclitaxel 199-202 ATP binding cassette subfamily B member 1 Homo sapiens 178-181 27216424-7 2016 It has been found that quercetin and rutin were the highly desirable flavonoids for the inhibition of P-gp transport function and they significantly reduced resistance in cytotoxicity assays to paclitaxel in P-gp overexpressing MDR cell lines. Paclitaxel 194-204 ATP binding cassette subfamily B member 1 Homo sapiens 208-212 29599904-5 2018 BHPI increased sensitivity of MDR1 overexpressing multidrug resistant OVCAR-3 ovarian cancer cells to killing by paclitaxel by >1,000 fold. Paclitaxel 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 27382749-9 2016 In conclusion, the MDR1 gene could be silenced by siRNA-PTX-SLNs, which could promote the growth inhibition efficiency of PTX on tumor cells, leading to synergetic effect on MDR tumor therapy. Paclitaxel 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 27304668-3 2016 Our data showed that the administration of GLU pre-treatment significantly enhanced PTX anti-proliferative effect in ABCB1 over-expressing KB cells. Paclitaxel 84-87 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 27284014-0 2016 Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. Paclitaxel 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 27284014-2 2016 The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers. Paclitaxel 259-269 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 27284014-2 2016 The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers. Paclitaxel 259-269 ATP binding cassette subfamily B member 1 Homo sapiens 142-147 27284014-2 2016 The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers. Paclitaxel 271-274 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 27284014-2 2016 The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers. Paclitaxel 271-274 ATP binding cassette subfamily B member 1 Homo sapiens 142-147 27284014-4 2016 We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin. Paclitaxel 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 27284014-5 2016 We found that feedback activation of TUBB3 can be triggered through the FOXO3a-dependent regulation of ABCB1, which resulted in the accentuation of induced PTX resistance and encouraged multiplicity in acquired cross-resistance. Paclitaxel 156-159 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 27284014-9 2016 In addition, we found that secretome factors from PTX-resistant cancer cells with acquired cross-resistance support a P-gp-dependent association in multidrug resistance (MDR) development, which assisted the FOXO3a-mediated control of TUBB3 feedback. Paclitaxel 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 26608370-5 2016 In this study, we explored the effect of MPT0B169 on apoptosis in AML HL60 and NB4 cells and MDR1-mediated taxol-resistant HL60/TaxR cells and the underlying mechanism. Paclitaxel 107-112 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 26608370-12 2016 Together, these results demonstrated that MPT0B169-induced apoptosis in nonresistant and MDR1-mediated taxol-resistant AML cells through Mcl-1 downregulation and a mitochondria-mediated pathway. Paclitaxel 103-108 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 27060927-11 2016 CDX2 induced MDR1-dependent resistance to vincristine and paclitaxel, which was reversed by treatment with the MDR1-specific inhibitor verapamil. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 27060927-11 2016 CDX2 induced MDR1-dependent resistance to vincristine and paclitaxel, which was reversed by treatment with the MDR1-specific inhibitor verapamil. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 27152196-5 2016 Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells. Paclitaxel 179-182 ATP binding cassette subfamily B member 1 Homo sapiens 145-159 27152196-5 2016 Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells. Paclitaxel 179-182 ATP binding cassette subfamily B member 1 Homo sapiens 161-165 27152196-5 2016 Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells. Paclitaxel 242-245 ATP binding cassette subfamily B member 1 Homo sapiens 145-159 27152196-5 2016 Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells. Paclitaxel 242-245 ATP binding cassette subfamily B member 1 Homo sapiens 161-165 26887049-5 2016 LP117, the compound that exerted the strongest effect on ABCB1, interfered in the investigated concentrations of up to 2muM with the ABCB1-mediated transport of vincristine, vinorelbine, actinomycin D, paclitaxel, and calcein-AM but not of doxorubicin, rhodamine 123, or JC-1. Paclitaxel 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 26887049-5 2016 LP117, the compound that exerted the strongest effect on ABCB1, interfered in the investigated concentrations of up to 2muM with the ABCB1-mediated transport of vincristine, vinorelbine, actinomycin D, paclitaxel, and calcein-AM but not of doxorubicin, rhodamine 123, or JC-1. Paclitaxel 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 133-138 27382749-9 2016 In conclusion, the MDR1 gene could be silenced by siRNA-PTX-SLNs, which could promote the growth inhibition efficiency of PTX on tumor cells, leading to synergetic effect on MDR tumor therapy. Paclitaxel 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 26426537-4 2015 The TPGS component was confirmed able to elevate the intracellular accumulation of PTX by inhibiting the P-gp efflux, and to facilitate the mitochondrial-targeting of the liposome. Paclitaxel 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 27185570-0 2016 Inhibition of P-Glycoprotein Mediated Efflux of Paclitaxel by Coumarin Derivatives in Cancer Stem Cells: An In Silico Approach. Paclitaxel 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 26689156-2 2015 Here we found that nobiletin, a citrus methoxyflavone, significantly sensitized ABCB1 overexpressing cells A2780/T and A549/T to chemotherapeutic agents such as paclitaxel (a 433-fold reversal of MDR to PTX at 9 muM), doxorubicin (DOX), docetaxel and dounorubicin. Paclitaxel 161-171 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 27185570-11 2016 The finding that newly designed coumarins can be exploited for inhibition of P-gp mediated efflux in order to enhance paclitaxel bioavailability and can inhibit breast cancer stem cell growth is significant for designing potent anticancer drugs. Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 25515492-7 2015 Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. Paclitaxel 230-240 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 26516582-7 2015 In the present study, we demonstrate that three of these compounds reversed P-gp-mediated multidrug resistance of cultured prostate cancer cells to restore sensitivity comparable to naive prostate cancer cells to the chemotherapeutic drug, paclitaxel. Paclitaxel 240-250 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 26296969-4 2015 In addition, ORA (3 muM) significantly increased the intracellular accumulation of [3H]-paclitaxel by suppressing the efflux function of ABCB1. Paclitaxel 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 137-142 25801244-8 2015 The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp. Paclitaxel 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 25801244-8 2015 The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp. Paclitaxel 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 25801244-8 2015 The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp. Paclitaxel 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 25801244-10 2015 This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells. Paclitaxel 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 25801244-10 2015 This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells. Paclitaxel 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 25801244-10 2015 This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells. Paclitaxel 170-173 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 25801244-10 2015 This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells. Paclitaxel 170-173 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 26182353-0 2015 Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. Paclitaxel 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 26182353-1 2015 P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance. Paclitaxel 40-50 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 26182353-1 2015 P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance. Paclitaxel 40-50 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 26182353-1 2015 P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance. Paclitaxel 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 26182353-1 2015 P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance. Paclitaxel 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 26626440-0 2015 MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 26626440-12 2015 CONCLUSION: Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-pi. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 141-146 25499884-9 2015 P-glycoprotein is the main mechanism of taxol resistance found in the UPN251 taxane-resistant sublines. Paclitaxel 40-45 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 25888278-4 2015 More importantly, Ptx-induced expression of P-glycoprotein was repressed by the nanocombination both at the protein and gene levels. Paclitaxel 18-21 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 26219569-9 2015 Furthermore, we also observed that the growth-inhibitory effect of 17-DMAG was decreased in A549/PR and H460/PR cells generated to over-express P-gp by long-term exposure to paclitaxel, and these cells recovered their sensitivity to 17-DMAG through the inhibition of P-gp. Paclitaxel 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 25515492-7 2015 Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. Paclitaxel 230-240 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 25515492-7 2015 Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. Paclitaxel 230-240 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 25515492-7 2015 Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. Paclitaxel 230-240 ATP binding cassette subfamily B member 1 Homo sapiens 135-138 25515492-7 2015 Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. Paclitaxel 230-240 ATP binding cassette subfamily B member 1 Homo sapiens 178-181 25769882-7 2015 The up-regulation of MDR1 protein and transcripts in EKVX cells was specifically associated with the expression of wild-type LKB1 and mainly responsible for the increased cellular resistance to paclitaxel. Paclitaxel 194-204 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 25779097-4 2015 Ganoderenic acid B, a lanostane-type triterpene isolated from Ganoderma lucidum, exhibited potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to doxorubicin, vincristine and paclitaxel. Paclitaxel 204-214 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 26054673-3 2015 We found that tumorspheres generated from MCF-7 human breast cancer cells exhibited high proportions of quiescent cells and expressed MDR-1 at elevated levels, leading to resistance to 5-fluorouracil, paclitaxel, and doxorubicin. Paclitaxel 201-211 ATP binding cassette subfamily B member 1 Homo sapiens 134-139 25769882-10 2015 In contrast, in some NSCLC, the presence of LKB1 may facilitate increases in either MDR1 or class III beta-tubulin expression which can lead to paclitaxel resistance. Paclitaxel 144-154 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 25647149-11 2015 The effects of paclitaxel on the multidrug resistance 1 (MDR1), MRP1 and breast cancer resistance protein (BCRP) gene expression were not significant in the MCF10AT cell lineage. Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 33-55 25960213-4 2015 We have used Schrodinger suite 2014, to perform homology modelling of human MDR1 based on Mouse MDR1, followed by Induced Fit Docking with Paclitaxel, Docetaxel, Gemcitabine, Carboplatin and Cisplatin drugs. Paclitaxel 139-149 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 25960213-9 2015 Our results suggest that, Paclitaxel or combination of Paclitaxel+Gemcitabine could serve as a suitable therapy against MDR1 in NSCLC patients. Paclitaxel 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 25960213-9 2015 Our results suggest that, Paclitaxel or combination of Paclitaxel+Gemcitabine could serve as a suitable therapy against MDR1 in NSCLC patients. Paclitaxel 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 25677062-8 2015 RESULTS: Paclitaxel treated cells eventually developed MDR with overexpression of Pgp and MDR1, and with high activity of Pgp, while paclitaxel-NSC23925 co-treated cells remained sensitive to chemotherapeutic agents in both in vitro and in vivo models. Paclitaxel 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 25853126-4 2015 We tested the microchamber device with HeLa cells over-expressing MDR1, an ATP-binding cassette transporter, and succeeded in detecting the transport of fluorescence-conjugated paclitaxel, the anti-cancer drug, at the single-cell level. Paclitaxel 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 26407111-4 2015 Flp-In-293/ABCB1 cells were also resistant to the four guanidine alkaloids as well as taxol and vinblastine compared to Flp-In-293/Mock cells although the four guanidine alkaloids exhibited cytotoxicity against the two Flp-In-293 cells. Paclitaxel 86-91 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 25687880-0 2015 MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Paclitaxel 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 25687880-5 2015 The goal of this study is to evaluate the ability of HA-PEI/HA-PEG to deliver MDR1 siRNA and the efficacy of the combination of HA-PEI/HA-PEG/MDR1 siRNA with paclitaxel to suppress growth of ovarian cancer. Paclitaxel 158-168 ATP binding cassette subfamily B member 1 Homo sapiens 142-146 25510604-1 2015 Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 121-135 25510604-1 2015 Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 25510604-1 2015 Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp). Paclitaxel 12-15 ATP binding cassette subfamily B member 1 Homo sapiens 121-135 25510604-1 2015 Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp). Paclitaxel 12-15 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 26407111-3 2015 The activity of ABCB1 in Flp-In-293/ABCB1 cells were confirmed by typical substrates for ABCB1 (taxol and vinblastine) in MTT assay. Paclitaxel 96-101 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 26407111-3 2015 The activity of ABCB1 in Flp-In-293/ABCB1 cells were confirmed by typical substrates for ABCB1 (taxol and vinblastine) in MTT assay. Paclitaxel 96-101 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 26407111-3 2015 The activity of ABCB1 in Flp-In-293/ABCB1 cells were confirmed by typical substrates for ABCB1 (taxol and vinblastine) in MTT assay. Paclitaxel 96-101 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 25962593-3 2015 METHODS: We determined the effects of cabazitaxel, a novel tubulin-binding taxane, and paclitaxel on paclitaxel-resistant, ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant, ABCC10-overexpressing HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the ABCB1 transporter. Paclitaxel 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 25962593-5 2015 Moreover, cabazitaxel had low efficacy, whereas paclitaxel had high efficacy in stimulating the ATPase activity of ABCB1, indicating a direct interaction of both drugs with the transporter. Paclitaxel 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 115-120 25656118-0 2015 [Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer]. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 25656118-1 2015 OBJECTIVE: To investigate the association between ABCB1 polymorphisms and chemosensitivity of paclitaxel in Chinese advanced gastric cancer(AGC) patients. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 25656118-9 2015 CONCLUSIONS: ABCB1 G2677T/A polymorphisms are associated with chemosensitivity of paclitaxel in gastric cancer. Paclitaxel 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 25985578-1 2014 The effects of ethanol extracts from Thai plants belonging to the families of Annonaceae, Rutaceae, and Zingiberaceae on P-glycoprotein (P-gp) function and multidrug resistance were examined in paclitaxel-resistant HepG2 (PR-HepG2) cells. Paclitaxel 194-204 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 26045195-1 2015 P-glycoprotein (P-gp) overexpression is the main mechanism involved in chemotherapy drug resistance such as paclitaxel resistance and therapy failure. Paclitaxel 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 26045195-3 2015 In this study, EM-E-11-4, a lathyrane-type diterpenoid isolated from Euphorbia micractina, was found to significantly increase paclitaxel uptake in Caco-2 cells, which functionally overexpressed P-gp. Paclitaxel 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 195-199 26045195-4 2015 In vitro transport experiments, carried out in the Caco-2 monolayer model, indicated that EM-E-11-4 significantly reduced the efflux ratio of paclitaxel transport by inhibiting P-gp function without affecting P-gp expression. Paclitaxel 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 177-181 26045195-6 2015 Hence, EM-E-11-4 is an effective potential agent to reverse P-gp-mediated paclitaxel resistance by inhibiting P-gp transport function and increasing the intracellular concentration of paclitaxel. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 26045195-6 2015 Hence, EM-E-11-4 is an effective potential agent to reverse P-gp-mediated paclitaxel resistance by inhibiting P-gp transport function and increasing the intracellular concentration of paclitaxel. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 26045195-6 2015 Hence, EM-E-11-4 is an effective potential agent to reverse P-gp-mediated paclitaxel resistance by inhibiting P-gp transport function and increasing the intracellular concentration of paclitaxel. Paclitaxel 184-194 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 25550688-9 2014 The current study provides useful insight into the distinct ability of DOX and PTX to induce P-gp mediated MDR in breast cancer. Paclitaxel 79-82 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 26045195-1 2015 P-glycoprotein (P-gp) overexpression is the main mechanism involved in chemotherapy drug resistance such as paclitaxel resistance and therapy failure. Paclitaxel 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 25985578-2 2014 All the extracts tested, significantly increased the accumulation of [3H]paclitaxel, a P-gp substrate, in the cells. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 24877693-0 2014 Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Paclitaxel 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 25275030-6 2014 Up-regulation of the MDR1 and CYP2C8 genes were shown to be potential mechanisms of paclitaxel resistance in the resistant cells. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 24993095-0 2014 Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population. Paclitaxel 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 24993095-6 2014 We show that ABCB1 is the functioning ABC transporter in ovarian cancer cell lines, and expression of ABCB1 is associated with a paclitaxel-resistant phenotype. Paclitaxel 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 24993095-6 2014 We show that ABCB1 is the functioning ABC transporter in ovarian cancer cell lines, and expression of ABCB1 is associated with a paclitaxel-resistant phenotype. Paclitaxel 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 24993095-7 2014 Moreover, silencing of ABCB1 using a specific morpholino oligonucleotide results in an inhibition of the SP phenotype and a sensitising of ovarian cancer cell lines to paclitaxel. Paclitaxel 168-178 ATP binding cassette subfamily B member 1 Homo sapiens 23-28 24877693-0 2014 Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 24877693-4 2014 Paclitaxel-resistant human ovarian cancer cells (A2780/PTX) readily formed and released P-gp-containing MVs into the extracellular space compared with the wild-type parental line (A2780/WT). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 24877693-6 2014 MV-mediated transfer of P-gp led to redistribution of the chemotherapeutic drug adriamycin in recipient cells (A2780/WT), which displayed 5- and 5-fold higher resistance to adriamycin and paclitaxel, respectively. Paclitaxel 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 24786296-0 2014 ERalpha directly activated the MDR1 transcription to increase paclitaxel-resistance of ERalpha-positive breast cancer cells in vitro and in vivo. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 25102234-3 2014 High cell cytotoxicity in PTX-resistant human ovarian cell line A2780/T was observed with enhanced PTX accumulation due to the P-gp inhibition by the TPGS moiety. Paclitaxel 26-29 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 25102234-3 2014 High cell cytotoxicity in PTX-resistant human ovarian cell line A2780/T was observed with enhanced PTX accumulation due to the P-gp inhibition by the TPGS moiety. Paclitaxel 99-102 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 24295377-4 2014 RESULTS: The results indicate that tivozanib can significantly reverse ABCB1-mediated resistance to paclitaxel, vinblastine and colchicine, as well as ABCG2-mediated resistance to mitoxantrone, SN-38 and doxorubicin. Paclitaxel 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 303-307 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 303-307 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 217-220 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 217-220 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 234-242 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 25102234-1 2014 To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release. Paclitaxel 234-242 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 24786296-8 2014 Knockdown of MDR1 restrained the effect of ERalpha in MCF-7 cells and sensitized the cells to paclitaxel. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 25289403-9 2014 Our present results showed that TAB could reverse Taxol resistance in MDA-MB-231/Taxol cells,mainly inhibiting the activity of P-gp and down-regulating the expression level of P-gp, and then enhancing the accumulation of chemotherapy agents. Paclitaxel 50-55 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 24805866-8 2014 Twist1 overexpression decreased the sensitivity of cells to taxol as revealed by a significant increase in MDR1/P-gp and IC50 (P<0.05). Paclitaxel 60-65 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 25289403-9 2014 Our present results showed that TAB could reverse Taxol resistance in MDA-MB-231/Taxol cells,mainly inhibiting the activity of P-gp and down-regulating the expression level of P-gp, and then enhancing the accumulation of chemotherapy agents. Paclitaxel 50-55 ATP binding cassette subfamily B member 1 Homo sapiens 176-180 24704556-5 2014 Our results demonstrated that acerinol could increase the chemosensitivity of ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells to chemotherapeutic drugs, doxorubicin, vincristine and paclitaxel. Paclitaxel 185-195 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 24680370-7 2014 It was found that transgelin 2 may mediate the resistance of MCF-7/PTX cells to paclitaxel by up-regulating the expressions of the adenosine-triphosphate binding cassette transporter proteins, including P-glycoprotein (P-gp), multidrug resistance associated protein 1 (MRP1), and breast cancer resistance protein (BCRP). Paclitaxel 67-70 ATP binding cassette subfamily B member 1 Homo sapiens 203-217 24680370-9 2014 In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 24773054-5 2014 Compound 28 at 3 muM reduced resistance in cytotoxicity assay to paclitaxel in P-gp-expressing SW620/Ad300 and HEK/ABCB1 cell lines. Paclitaxel 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 24853187-8 2014 RESULTS: We observed that tumour cells selected with increasing concentrations of paclitaxel alone developed MDR with resistance to paclitaxel and other Pgp substrates, whereas cells cultured with paclitaxel-NSC23925 did not develop MDR and cells remained sensitive to chemotherapeutic agents. Paclitaxel 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 153-156 24853187-9 2014 Paclitaxel-resistant cells showed high expression and activity of the Pgp, whereas paclitaxel-NSC23925-treated cells did not express Pgp. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 24885658-9 2014 These trends predict sensitivity to agents such as paclitaxel (ABCB1 substrate) and imatinib (c-KIT inhibitor) would be altered with extended passage. Paclitaxel 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 24596624-0 2014 Identification of p-glycoprotein and transport mechanism of Paclitaxel in syncytiotrophoblast cells. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 24632038-0 2014 Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 24632038-2 2014 PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells. Paclitaxel 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 133-147 24632038-2 2014 PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells. Paclitaxel 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 24632038-2 2014 PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells. Paclitaxel 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 133-147 24632038-2 2014 PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells. Paclitaxel 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 24284783-4 2014 The incubation of KB-C2 cells overexpressing ABCB1 transporter with beta-elemene (100 microM) significantly augmented the antineoplastic efficacy of colchicine, vinblastine and paclitaxel when compared to KB-C2 cells incubated with these drugs alone. Paclitaxel 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 24284783-5 2014 In HEK293 cells overexpressing the ABCB1 transporter, beta-elemene significantly increased the cytotoxicity of paclitaxel. Paclitaxel 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 35-40 24261922-3 2014 NOSC in a wide concentration range even above the critical micelle concentration showed an effective effect on inhibiting P-gp-mediated PTX efflux, which was remarkably different from the surfactants and the Pluronic copolymers. Paclitaxel 136-139 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 24261922-4 2014 Multiple mechanisms were involved in this effect of NOSC, such as stimulating P-gp ATPase, competitively impeding the binding of PTX with P-gp and reducing the fluidity of the cell membrane. Paclitaxel 129-132 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 24261922-4 2014 Multiple mechanisms were involved in this effect of NOSC, such as stimulating P-gp ATPase, competitively impeding the binding of PTX with P-gp and reducing the fluidity of the cell membrane. Paclitaxel 129-132 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 24261922-6 2014 Furthermore, it was demonstrated that most of PTX-M as an intact form was delivered at the tumor site, which ensures the synergetic effect of NOSC micelles on drug delivery and P-gp inhibition. Paclitaxel 46-49 ATP binding cassette subfamily B member 1 Homo sapiens 177-181 24332858-1 2014 A group of novel taxoids, with modifications at C-7, C-10, C-3" and C-14 positions of paclitaxel, was synthesized in order to improve their biological profile by decreasing their affinity with P-glycoprotein (P-gp) and increasing cellular permeability. Paclitaxel 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 193-207 24332858-1 2014 A group of novel taxoids, with modifications at C-7, C-10, C-3" and C-14 positions of paclitaxel, was synthesized in order to improve their biological profile by decreasing their affinity with P-glycoprotein (P-gp) and increasing cellular permeability. Paclitaxel 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 209-213 24332858-7 2014 It was thus clear that simultaneous modifications at the C-7, C-10 and C-3" positions of paclitaxel significantly impaired its interactions with P-gp and interfered with P-gp mediated efflux. Paclitaxel 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 24332858-7 2014 It was thus clear that simultaneous modifications at the C-7, C-10 and C-3" positions of paclitaxel significantly impaired its interactions with P-gp and interfered with P-gp mediated efflux. Paclitaxel 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 170-174 24810093-0 2014 Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 38-43 24810093-1 2014 ABCB1 (adenosine triphosphate-binding cassette transporter B1) mediates cellular elimination of many chemotherapeutic agents including paclitaxel, which is commonly used to treat ovarian cancer. Paclitaxel 135-145 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 24810093-3 2014 Variable paclitaxel clearance due to genotype specific differences in ABCB1 activity in cancer cells and/or normal tissues may underlie the association. Paclitaxel 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 24810093-5 2014 Close associations between ABCB1 expression, transporter function and paclitaxel sensitivity were found in lymphoblastoid cell lines, although we could not demonstrate an association with common SNPs. Paclitaxel 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 24810093-7 2014 These results suggest that ABCB1 related survival difference in ovarian cancer patients is more likely to be due to differential whole body paclitaxel clearance mediated by normal cells rather than a direct effect on cancer cells. Paclitaxel 140-150 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 24140176-0 2014 Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Paclitaxel 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 24652302-0 2014 Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 24652302-5 2014 Results indicate that different drugs like paclitaxel and doxorubicin approach the putative binding site of P-gp, and the inner residues are found to be important in this process. Paclitaxel 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 24252806-0 2014 Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel. Paclitaxel 120-130 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 24596624-7 2014 [(3)H]Paclitaxel uptake was markedly inhibited by cyclosporine and verapamil, well-known substrates of P-glycoprotein (P-gp) transporter. Paclitaxel 6-16 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 24596624-7 2014 [(3)H]Paclitaxel uptake was markedly inhibited by cyclosporine and verapamil, well-known substrates of P-glycoprotein (P-gp) transporter. Paclitaxel 6-16 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 24596624-9 2014 These results suggest that P-gp may be involved in paclitaxel transport at the placenta. Paclitaxel 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 23967153-3 2013 Present study assessed a new use of GSP on the MDR reversal activity and its possible molecular mechanisms in MDR1-overpressing paclitaxel resistant ovarian cancer cells. Paclitaxel 128-138 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 23941826-7 2013 Yg-3-46a was found to be a poorer substrate of P-gp compared to paclitaxel, in both binding and ATPase experiments, which is likely responsible for its ability to circumvent P-gp mediated multidrug resistance (MDR). Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 24100466-11 2013 In OMC-2 cells, COX-2 and MDR1 mRNA levels were significantly upregulated by paclitaxel treatment and downregulated by co-administration with etodolac. Paclitaxel 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 24100466-13 2013 Moreover, co-administration of paclitaxel and etodolac suppressed the induction of MDR1 mRNA. Paclitaxel 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 24100466-17 2013 These findings suggest that paclitaxel resistance may be associated with COX-2 and MDR1 expression in cancer cells. Paclitaxel 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 24137413-8 2013 The expression levels of miR-21 and P-gp were upregulated to a greater extent in the paclitaxel-resistant ovarian cancer A2780/taxol cell line compared with the parental A2780 cell line. Paclitaxel 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 23735077-8 2013 Furthermore, the ABCB1 inhibitor verapamil (10 muM) effectively reversed doxorubicin and paclitaxel resistance by 90- and 200-fold, respectively. Paclitaxel 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 22935677-1 2013 Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 246-268 23585021-2 2013 Overexpression of tubulin-beta-III and p-glycoprotein has been linked to paclitaxel resistance in many cancers but has been undercharacterized among USCs. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 39-53 23799854-8 2013 We also demonstrated that BLT2-induced paclitaxel resistance was associated with the upregulation of P-glycoprotein. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 23583215-12 2013 P-glycoprotein correlated with in vitro paclitaxel resistance, but not clinical outcome. Paclitaxel 40-50 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 23673445-7 2013 The observed reversal effect seems to be primarily due to the decreased active efflux of [3H]-paclitaxel in ABCB1 overexpressing cells observed in efflux assay. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 108-113 22935677-1 2013 Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 270-274 22935677-1 2013 Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 289-303 22935677-1 2013 Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 305-309 23478574-2 2013 In the present study, we show that paclitaxel induces MDR1 expression in the MCF-7 breast cancer cell line in a MAPK/Egr-1-dependent manner. Paclitaxel 35-45 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 23875078-0 2013 Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression. Paclitaxel 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 23875078-1 2013 OBJECTIVE: The purpose of this study was to investigate whether selective cyclooxygenase (COX) inhibitors promote paclitaxel-induced apoptosis in taxane-resistant ovarian cancer cells by suppressing MDR1/P-glycoprotein (P-gp) expression. Paclitaxel 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 199-203 23875078-1 2013 OBJECTIVE: The purpose of this study was to investigate whether selective cyclooxygenase (COX) inhibitors promote paclitaxel-induced apoptosis in taxane-resistant ovarian cancer cells by suppressing MDR1/P-glycoprotein (P-gp) expression. Paclitaxel 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 204-218 23875078-11 2013 COX inhibitors could be potent therapeutic tools to promote paclitaxel sensitization of taxane-resistant ovarian cancers by suppressing MDR1/P-gp, which is responsible for the efflux of chemotherapeutic agents. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 23640974-6 2013 Genetic variants of paclitaxel pharmacokinetics tested were CYP3A4*22, CYP2C8*3, CYP2C8*4, and ABCB1 3435 C>T. The association between CYP3A4*22 and neurotoxicity observed in the exploratory cohort was validated in an independent patient cohort (n = 239). Paclitaxel 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 95-100 23466650-3 2013 Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 23466650-3 2013 Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 23466650-3 2013 Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 23434829-11 2013 Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates. Paclitaxel 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 23478574-5 2013 Loss of Egr-1 function in paclitaxel-resistant MCF-7 cells decreased MDR1 expression, whereas inhibiting Erk1/2 activity reduced both Egr-1 accumulation and MDR1 expression. Paclitaxel 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 23478574-6 2013 These findings suggest that Erk1/2-induced Egr-1 accumulation activates MDR1 transcription and thereby induces the drug resistance observed in paclitaxel-resistant MCF-7 cells. Paclitaxel 143-153 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 23478574-8 2013 Indeed, our results suggest a novel pathway by which paclitaxel induces MDR1 expression, possibly illuminating a potential target pathway for the prevention of MDR1-mediated drug resistance. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 23478574-8 2013 Indeed, our results suggest a novel pathway by which paclitaxel induces MDR1 expression, possibly illuminating a potential target pathway for the prevention of MDR1-mediated drug resistance. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 160-164 23313612-3 2013 Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 42-56 23313612-3 2013 Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 23313612-3 2013 Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain. Paclitaxel 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 42-56 23313612-3 2013 Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain. Paclitaxel 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 23313612-6 2013 The elimination of [(3)H]paclitaxel was inhibited by unlabeled paclitaxel and verapamil, suggesting a carrier-mediated transport process via P-gp. Paclitaxel 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 23313612-9 2013 Therefore, the distribution of P-gp dependant drugs including paclitaxel in the central nervous system can be modulated by neurological diseases. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 23442791-7 2013 RESULTS: Using this approach we successfully identify genes involved in paclitaxel resistance in a variety of cancer cell lines, including the multidrug transporter ABCB1, a previously identified major paclitaxel resistance gene. Paclitaxel 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 165-170 23293323-5 2013 TECs show resistance to paclitaxel through greater mRNA expression of multidrug resistance 1, which encodes P-glycoprotein, as compared with normal endothelial cells. Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 70-92 23126604-5 2013 The presence of verapamil and Pluronic both improved the intestinal absorption of PTX, which further certified the effect of Pluronic on P-gp inhibition. Paclitaxel 82-85 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 23178957-3 2013 The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin. Paclitaxel 165-175 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 23178957-6 2013 RESULTS: MDR1 expression levels in PMNs rose rapidly within 24 h post-administration of paclitaxel and carboplatin, whereas MRP and LRP expression levels remained unchanged. Paclitaxel 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 23178957-8 2013 CONCLUSIONS: Modulation of MDR1 gene expression in PMNs after lung cancer treatment with paclitaxel and carboplatin cannot be used as a prognosis marker in these patients. Paclitaxel 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 23038675-3 2012 Gb(3)Cer was increased in all resistant cells, irrespective of whether the resistance was to paclitaxel or cisplatin, and expression of the MDR1 gene and gangliosides was enhanced in paclitaxel-resistant cells, but gangliosides were absent in cisplatin-resistant cells. Paclitaxel 183-193 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 22623106-8 2013 Importantly, saracatinib significantly enhanced the effect of paclitaxel against ABCB1-overexpressing HeLa/v200 cancer cell xenografts in nude mice. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 81-86 23215690-0 2013 2-Hydroxypropyl-beta-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells. Paclitaxel 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 23215690-1 2013 OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 213-227 23215690-1 2013 OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 229-233 23215690-1 2013 OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells. Paclitaxel 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 213-227 23215690-1 2013 OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells. Paclitaxel 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 229-233 23349819-9 2013 Importantly, BIRB796 also enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBV200 cell xenografts in nude mice. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 95-100 23443122-0 2012 Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure. Paclitaxel 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 23443122-4 2012 Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 muM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression. Paclitaxel 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 23443122-7 2012 Interestingly, the combination of both paclitaxel and carboplatin caused increased expression of the MDR1 drug resistance gene rather than the individual treatments. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 23443122-8 2012 These results suggest that carboplatin and paclitaxel may induce drug resistance mediated by MDR1 and MRP3, which may be enhanced by the simultaneous use of both drugs. Paclitaxel 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 23046348-7 2012 Importantly, BBA increased the inhibitory effect of paclitaxel in ABCB1 overexpressing KB-C2 cell xenografts in nude mice. Paclitaxel 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 66-71 22971921-5 2012 SP cells are resistant to paclitaxel because of the upregulation of ABCB1 and ABCB5. Paclitaxel 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 68-73 23023659-2 2012 P-gp regulates the absorption and elimination of a wide range of compounds, such as digoxin, paclitaxel, HIV protease inhibitors and psychotropic drugs. Paclitaxel 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 23030458-10 2012 The human MDR1 gene-transfected and thus paclitaxel-resistant MDCKII-MDR1 P-gp overexpressing cells were used for cytotoxicity evaluation. Paclitaxel 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 23051955-13 2012 Taxol resistance in this cell could be related to overexpression of P-gp and the change of cell cycle profiles. Paclitaxel 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 22622430-4 2012 We generated a direct in vivo xenograft model, and demonstrated that SP cells were resistant to paclitaxel, a substrate of ABCB1, both in vitro and in vivo. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 22734651-3 2012 H23 and DLD-1 cells (human lung and colon adenocarcinoma cell lines) with acquired resistance to carfilzomib displayed marked cross-resistance to YU-101, a closely related proteasome inhibitor, and paclitaxel, a known substrate of Pgp. Paclitaxel 198-208 ATP binding cassette subfamily B member 1 Homo sapiens 231-234 22855252-5 2012 We have shown before that NCI/ADR-RES cells were 1,000-fold less sensitive to paclitaxel than MDA-MB-435 cells in correspondence to P-glycoprotein overexpression and up to 20-fold lower uptake of the drug in the resistant cells. Paclitaxel 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 22855252-10 2012 Thus, structural modifications of taxanes resulting in their decreased P-glycoprotein-related transport probably caused their higher efficiency than paclitaxel in multidrug-resistant NCI/ADR-RES tumour cells. Paclitaxel 149-159 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 22116711-8 2012 In contrast, the IC(50) values of three clinical anticancer drugs, etoposide, paclitaxel and vinblastine were significantly elevated in HER2 and/or P-glycoprotein overexpressing cells. Paclitaxel 79-89 ATP binding cassette subfamily B member 1 Homo sapiens 149-163 22632055-5 2012 Importantly, CCT129202 increased the inhibitory effect of vincristine and paclitaxel on ABCB1 overexpressing KBv200 cell xenografts in nude mice and human esophageal cancer tissue overexpressing ABCB1 ex vivo, respectively. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 22632055-5 2012 Importantly, CCT129202 increased the inhibitory effect of vincristine and paclitaxel on ABCB1 overexpressing KBv200 cell xenografts in nude mice and human esophageal cancer tissue overexpressing ABCB1 ex vivo, respectively. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 195-200 22545578-0 2012 Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells. Paclitaxel 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 17-31 22545578-11 2012 CONCLUSIONS: These results suggested that up-regulation of P-gp is involved in the increased paclitaxel resistance but not cisplatin resistance in ionization radiation-induced human esophageal squamous cancer radioresistant cells. Paclitaxel 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 22120505-0 2012 Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. Paclitaxel 125-135 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 22245726-4 2012 TECs were more resistant to paclitaxel with the up-regulation of multidrug resistance (MDR) 1 mRNA, which encodes the P-glycoprotein, compared with normal ECs. Paclitaxel 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 65-93 23359770-7 2012 RESULTS: The IC50 of paclitaxel in MDR1shRNA-transfected group was significantly reduced (1.986+-0.153) mumol/ml as compared with that in negative control (5.246+-0.107) mumol/ml and empty vector-transfected group (5.212+-0.075) mumol/ml (P<0.05). Paclitaxel 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 23359770-10 2012 CONCLUSION: The present study demonstrated that the eukaryotic expression plasmid of shRNA targeting on MDR1 inhibited the expression of MDR1 effectively, thus enhance the sensitivity of A2780/Taxol cells to paclitaxel. Paclitaxel 208-218 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 23359770-10 2012 CONCLUSION: The present study demonstrated that the eukaryotic expression plasmid of shRNA targeting on MDR1 inhibited the expression of MDR1 effectively, thus enhance the sensitivity of A2780/Taxol cells to paclitaxel. Paclitaxel 208-218 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 21618519-2 2012 One of the resistance factors that protects cancer cells from Taxol-based therapy is multidrug resistance 1 (MDR1). Paclitaxel 62-67 ATP binding cassette subfamily B member 1 Homo sapiens 85-107 21618519-2 2012 One of the resistance factors that protects cancer cells from Taxol-based therapy is multidrug resistance 1 (MDR1). Paclitaxel 62-67 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 21618519-6 2012 Introducing let-7g into ADR-RES cells expressing both IMP-1 and MDR1 reduced expression of both proteins rendering the cells more sensitive to treatment with either Taxol or vinblastine without affecting the sensitivity of the cells to carboplatin, a non-MDR1 substrate. Paclitaxel 165-170 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 22179563-0 2012 Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. Paclitaxel 19-29 ATP binding cassette subfamily B member 1 Homo sapiens 58-63 22800348-1 2012 OBJECTIVE: To investigate the expression of multidrug resistance gene ABCB1 and ABCG2 in FaDu cells (human hypopharyngeal carcinoma cell line) and the multidrug resistance (MDR) cell lines FaDu/T transformed from FaDu cells by taxol and underlying mechanisms of MDR. Paclitaxel 227-232 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 20641759-0 2004 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 279-289 ATP binding cassette subfamily B member 1 Homo sapiens 365-379 20641391-0 2004 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 247-252 ATP binding cassette subfamily B member 1 Homo sapiens 321-335 20641391-0 2004 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 247-252 ATP binding cassette subfamily B member 1 Homo sapiens 337-341 20641391-0 2004 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 247-252 ATP binding cassette subfamily B member 1 Homo sapiens 391-396 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 291-305 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 307-311 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 361-366 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 218-221 ATP binding cassette subfamily B member 1 Homo sapiens 291-305 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 218-221 ATP binding cassette subfamily B member 1 Homo sapiens 307-311 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 218-221 ATP binding cassette subfamily B member 1 Homo sapiens 361-366 20641759-0 2004 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 279-289 ATP binding cassette subfamily B member 1 Homo sapiens 381-385 20641759-0 2004 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2). Paclitaxel 279-289 ATP binding cassette subfamily B member 1 Homo sapiens 434-439 22206665-0 2012 ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression. Paclitaxel 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 21955855-11 2012 Variants in the drug transporter ABCB1 gene are possibly associated with the neutrophil suppressing effect of paclitaxel in patients with ovarian cancer. Paclitaxel 110-120 ATP binding cassette subfamily B member 1 Homo sapiens 33-38 22206665-5 2012 In PC3PR cells, silencing of ETS1 expression by siRNAs inhibited the activity of the MDR1 promoter containing ETS binding sites, reduced the mRNA and protein levels of MDR1 and suppressed paclitaxel resistance. Paclitaxel 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 22206665-7 2012 Our results suggest that ETS1 promotes paclitaxel resistance and invasion in part by up-regulating MDR1 and MMP9 expression. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 23037162-2 2012 HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1. Paclitaxel 183-193 ATP binding cassette subfamily B member 1 Homo sapiens 137-142 23037162-2 2012 HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1. Paclitaxel 183-193 ATP binding cassette subfamily B member 1 Homo sapiens 137-142 23037162-1 2012 Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 157-162 23037162-4 2012 Additionally, the sensitivity of HuH-7/PTX cells to paclitaxel was increased in combination with these Kampo medicines, indicating that takushato and goreisan overcame paclitaxel resistance in the cells by suppressing drug export by MDR-1. Paclitaxel 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 233-238 23037162-5 2012 We further clarified that Alismatis Rhizoma contained in both takushato and goreisan reversed paclitaxel resistance by preventing drug efflux by MDR-1 without affecting the expression levels of MDR-1. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 145-150 23037162-6 2012 Moreover, the principal components of Alismatis Rhizoma, Alisol A, Alisol B, and Alisol B acetate, were found to increase the sensitivity to paclitaxel in HuH-7/PTX by inhibiting drug export by MDR-1 without affecting the expression levels of MDR-1. Paclitaxel 141-151 ATP binding cassette subfamily B member 1 Homo sapiens 194-199 23037162-6 2012 Moreover, the principal components of Alismatis Rhizoma, Alisol A, Alisol B, and Alisol B acetate, were found to increase the sensitivity to paclitaxel in HuH-7/PTX by inhibiting drug export by MDR-1 without affecting the expression levels of MDR-1. Paclitaxel 141-151 ATP binding cassette subfamily B member 1 Homo sapiens 243-248 21982683-4 2012 Notably, P-glycoprotein-overexpressing KBV200 and K562/ADR cells, which are strongly resistant to colchicine, vinorelbine and paclitaxel, were sensitive to YHHU0895 both in vitro and in vivo. Paclitaxel 126-136 ATP binding cassette subfamily B member 1 Homo sapiens 9-23 21660974-1 2011 Intestinal absorption and bioavailability of taxol are limited by its low solubility and P-glycoprotein (Pgp) activity. Paclitaxel 45-50 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 22349379-5 2012 The expression of 17 genes was increased or decreased more than 5 folds in CNE-1/taxol compared with CNE-1.Through analyzing documented drug-resistant genes, MDR1 expression was not detected in each group. Paclitaxel 81-86 ATP binding cassette subfamily B member 1 Homo sapiens 158-162 22701315-4 2012 METHODS AND RESULTS: We report that carbonate apatite-mediated delivery of the siRNAs targeting ABCG2 and ABCB1 gene transcripts in human breast cancer cells which constitutively express both of the transporter genes dose-dependently enhanced chemosensitivity to doxorubicin, paclitaxel and cisplatin, the traditionally used chemotherapeutic agents. Paclitaxel 276-286 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 22044164-4 2011 Importantly, ATIs 5, 8, and 10 were more effective than vinorelbine, vinblastine, and paclitaxel as growth inhibitors of the P-glycoprotein-overexpressing cell line NCI/ADR-RES. Paclitaxel 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 125-139 21660974-1 2011 Intestinal absorption and bioavailability of taxol are limited by its low solubility and P-glycoprotein (Pgp) activity. Paclitaxel 45-50 ATP binding cassette subfamily B member 1 Homo sapiens 105-108 21660974-6 2011 In co-treatment with beta-cyclodextrins, the apical to basolateral taxol flux was 4 to 6 times greater than in untreated monolayers and it was also higher than in cells treated with Pgp inhibitor cyclosporin A. Paclitaxel 67-72 ATP binding cassette subfamily B member 1 Homo sapiens 182-185 21728341-3 2011 This is accomplished with enhanced cellular accumulation and retention of paclitaxel (one of the most effective anticancer drugs in use today and a well-known P-glycoprotein (P-gp) substrate) in a P-gp-overexpressing cancer model. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 175-179 21883677-1 2011 BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel. Paclitaxel 229-239 ATP binding cassette subfamily B member 1 Homo sapiens 30-99 21883677-1 2011 BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel. Paclitaxel 229-239 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 21883677-1 2011 BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel. Paclitaxel 229-239 ATP binding cassette subfamily B member 1 Homo sapiens 121-135 21883677-1 2011 BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel. Paclitaxel 229-239 ATP binding cassette subfamily B member 1 Homo sapiens 137-140 21883677-3 2011 A panel of 17 non-small cell lung cancer (NSCLC) cell lines was used to investigate whether alterations in the ABCB1 gene or its mRNA expression correlated with in vitro chemosensitivity to paclitaxel. Paclitaxel 190-200 ATP binding cassette subfamily B member 1 Homo sapiens 111-116 21883677-7 2011 RESULTS: The variant allele frequencies for four ABCB1 gene polymorphisms were 14.71% for 2677G>T/A, 32.35% for 2734T>C, 23.53% for 3396C>T and 76.47% for 3435C>T. There was a significant positive correlation between ABCB1 mRNA expression and half-maximal inhibitory concentration values for paclitaxel (r=0.5322, P=0.0279). Paclitaxel 304-314 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 21883677-9 2011 CONCLUSIONS: These in vitro results suggest that high ABCB1 mRNA expression may be a predictive biomarker for poor chemosensitivity to paclitaxel. Paclitaxel 135-145 ATP binding cassette subfamily B member 1 Homo sapiens 54-59 21849404-3 2011 As a substrate of P-glycoprotein, a drug efflux pump associated with multidrug resistance, (18)F-fluoropaclitaxel may also be useful in identifying multidrug resistance and predicting tumor response for drugs other than paclitaxel. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 21687948-3 2011 Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 0-22 21687948-3 2011 Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 21728341-3 2011 This is accomplished with enhanced cellular accumulation and retention of paclitaxel (one of the most effective anticancer drugs in use today and a well-known P-glycoprotein (P-gp) substrate) in a P-gp-overexpressing cancer model. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 21728341-9 2011 These findings suggest that when the paclitaxel was delivered as an HFT-T nanoparticle, the drug is better retained within the P-gp-overexpressing cells than the free form of paclitaxel. Paclitaxel 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 21657271-4 2011 Long-term exposure of P-gp-expressing cells to 1 sensitized them to doxorubicin and paclitaxel, both P-gp substrates. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 21775090-9 2011 In conclusion, continuous PTX treatment caused the over-expression of P-gp and acquisition of MDR in colon cancer and glioblastoma cell lines, while some mechanisms of MDR and tumor progression such as GSH detoxification system and VEGF secretion were suppressed. Paclitaxel 26-29 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 21917707-0 2011 Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line. Paclitaxel 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 21657271-4 2011 Long-term exposure of P-gp-expressing cells to 1 sensitized them to doxorubicin and paclitaxel, both P-gp substrates. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 21056987-2 2011 This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter. Paclitaxel 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 205-210 21272926-8 2011 ABCB1 was strongly expressed in the PTX-resistant cells, but not in their parental lines, which are sensitive to PTX. Paclitaxel 36-39 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 21272926-8 2011 ABCB1 was strongly expressed in the PTX-resistant cells, but not in their parental lines, which are sensitive to PTX. Paclitaxel 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 21320484-6 2011 The results indicated that the upregulation of MDR1 gene is the dominating mechanism of the paclitaxel and vincristine drug resistance. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 21163349-5 2011 Unfortunately, paclitaxel is a P-glycoprotein substrate and has poor blood-brain barrier permeability, making it unsuitable for the treatment of human tauopathies. Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 21184150-10 2011 Paclitaxel-loaded PBCA as well as blank PBCA nanoparticles decreased P-gp function in a dose-dependent manner, suggesting the efficacy of the drug-loaded nanoparticle system on overcoming MDR. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 21184150-12 2011 CONCLUSIONS: Paclitaxel-loaded PBCA nanoparticles can enhance cytotoxicity and overcome MDR through a mechanism of the inhibition of P-gp function caused by the nanoparticles system. Paclitaxel 13-23 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 21440934-6 2011 In the Caco-2 transport studies, the presence of verapamil and NOSC both improved the transport of Taxol( ), which further certified the effect of NOSC on P-gp inhibition, and PTX-M enhanced the permeability of PTX compared with Taxol( ). Paclitaxel 99-104 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 21440934-7 2011 The apparent permeability coefficient (Papp) of PTX-M decreased significantly at 4 C in comparison with at 37 C, which indicated a predominant active endocytic mechanism for the transport of PTX-M, a P-gp-independent way. Paclitaxel 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 202-206 21262849-5 2011 Overexpression of P-gp also resulted in significantly decreased cell susceptibility to docetaxel, paclitaxel, and vinblastine. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 21402712-3 2011 In ABCB1-overexpressing cells, nontoxic doses of sildenafil inhibited resistance and increased the effective intracellular concentration of ABCB1 substrate drugs such as paclitaxel. Paclitaxel 170-180 ATP binding cassette subfamily B member 1 Homo sapiens 3-8 21402712-3 2011 In ABCB1-overexpressing cells, nontoxic doses of sildenafil inhibited resistance and increased the effective intracellular concentration of ABCB1 substrate drugs such as paclitaxel. Paclitaxel 170-180 ATP binding cassette subfamily B member 1 Homo sapiens 140-145 21508398-0 2011 Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Paclitaxel 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 21508398-8 2011 CONCLUSION: BCL-2 and MDR1 overexpression may predict the inefficacy of paclitaxel-based chemoradiotherapy. Paclitaxel 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 20368717-1 2011 The primary purpose of this study was to evaluate the effect of CYP2C8*3 and three genetic ABCB1 variants on the elimination of paclitaxel. Paclitaxel 128-138 ATP binding cassette subfamily B member 1 Homo sapiens 91-96 21056987-11 2011 The correlation of G2677T/A with 6alpha-hydroxypaclitaxel has not been described previously but supports other findings of the ABCB1 transporter playing a part in paclitaxel metabolism. Paclitaxel 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 127-132 21224536-1 2010 Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy. Paclitaxel 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 20869436-6 2010 Similarly, 50muM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and (99m)Tc-MIBI into the Pgp(+) cells. Paclitaxel 17-27 ATP binding cassette subfamily B member 1 Homo sapiens 137-140 20869436-6 2010 Similarly, 50muM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and (99m)Tc-MIBI into the Pgp(+) cells. Paclitaxel 29-33 ATP binding cassette subfamily B member 1 Homo sapiens 137-140 20125118-4 2010 Increased ABCB1 transcript expression coincident with acquisition of resistance to epirubicin or paclitaxel was temporally associated with hypomethylation of the ABCB1 downstream promoter in the absence of gene amplifications or changes in mRNA stability. Paclitaxel 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 20125118-7 2010 Furthermore, our data suggest that allele-specific reductions in ABCB1 promoter methylation regulate promoter usage within paclitaxel-resistant cells. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 65-70 20934246-3 2011 Herein, we have identified protein kinase D isoform 2 (PKD2) as an important regulator of MDR and P-gp expression in paclitaxel-treated breast cancer cell lines. Paclitaxel 117-127 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 20934246-7 2011 Treatment with paclitaxel was shown to induce both PKD2 phosphorylation and P-gp expression in a time-dependent manner. Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 20934246-9 2011 Concurrent with the decrease in drug resistance, paclitaxel-induced expression of P-gp was also significantly reduced in PKD knockdown cells. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 20934246-10 2011 These results indicate that PKD2 is required for paclitaxel-induced MDR and expression of P-gp. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 20623213-8 2010 The effects of the Cys431Leu variation, due to MDR1 (GT1292-3TG) nucleotide transition, on P-gp-dependent intracellular substrate accumulation appeared to be substrate dependent where doxorubicin, vinblastine, and paclitaxel exhibit an increased accumulation (p < 0.05), while verapamil and Hoechst33342 exhibit a decreased intracellular concentration compared with wild type (p < 0.05). Paclitaxel 214-224 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 20623213-8 2010 The effects of the Cys431Leu variation, due to MDR1 (GT1292-3TG) nucleotide transition, on P-gp-dependent intracellular substrate accumulation appeared to be substrate dependent where doxorubicin, vinblastine, and paclitaxel exhibit an increased accumulation (p < 0.05), while verapamil and Hoechst33342 exhibit a decreased intracellular concentration compared with wild type (p < 0.05). Paclitaxel 214-224 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 21224536-1 2010 Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy. Paclitaxel 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 21224536-1 2010 Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy. Paclitaxel 124-127 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 21224536-1 2010 Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy. Paclitaxel 124-127 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 20624637-7 2010 RESULTS: The expression levels of miR-27a and P-gp were up-regulated in paclitaxel-resistant ovarian cancer cell line A2780/Taxol as compared with its parental line A2780. Paclitaxel 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 20876799-9 2010 Importantly, apatinib significantly enhanced the effect of paclitaxel against the ABCB1-resistant KBv200 cancer cell xenografts in nude mice. Paclitaxel 59-69 ATP binding cassette subfamily B member 1 Homo sapiens 82-87 20699370-10 2010 Overexpression of CDX2 in HT-29 cells revealed increased resistance to the known substrate of MDR1, vincristine and paclitaxel, which was reversed by an MDR1 inhibitor, verapamil. Paclitaxel 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 20862794-0 2004 6,7-Dimethoxy-2-[3-(5-[(11)C]methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-propyl]-1,2,3,4-tetrahydro-isoquinoline One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by way of a multidrug resistance (MDR-1) gene protein (1, 2). Paclitaxel 287-297 ATP binding cassette subfamily B member 1 Homo sapiens 377-402 20041327-7 2010 RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 156-159 20041327-7 2010 RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 247-250 20862795-0 2004 6,7-Dimethoxy-2-{3-[4-[(11)C]methoxy-3,4-dihydro-2H-naphthalen-(1E)-ylidene]-propyl}-1,2,3,4-tetrahydro-isoquinoline One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by way of a multidrug resistance (MDR-1) protein (1, 2). Paclitaxel 291-301 ATP binding cassette subfamily B member 1 Homo sapiens 381-401 20553861-5 2010 Based on detailed kinetic analysis, using liposomes to model paclitaxel diffusion through cell membranes, efflux slowdown can be attributed to reduction in the rate constant of drug diffusion through Pgp, and not to Pgp blockage. Paclitaxel 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 200-203 20553861-6 2010 Chemosensitization was consistently-better for paclitaxel (cytosol-operating) than for doxorubicin (nuclear-operating) implying linkage between P-glycoprotein localization and loci of drug action. Paclitaxel 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 144-158 20944127-2 2010 Treatment response to paclitaxel has been shown to correlate with ABCB1 gene polymorphisms. Paclitaxel 22-32 ATP binding cassette subfamily B member 1 Homo sapiens 66-71 20822025-3 2010 Verapamil hydrochloride was adopted as the active control to investigate the bilateral transport activity of paclitaxel regulated by fangchinoline in MDR1-MDCK II cells. Paclitaxel 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 20309692-6 2010 However, MDR1 (2005T) cells were less resistant to paclitaxel (28.2 +/- 2.1 vs. 91.8 +/- 3.5 nM; P < 0.05) and etoposide (119.7 +/- 6.5 vs. 546.8 +/- 9.5 nM; P < 0.05). Paclitaxel 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 20822025-0 2010 [Transmembrane transport activity of paclitaxel regulated by fangchinoline in MDR1-mDCK II cells]. Paclitaxel 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 20822025-1 2010 OBJECTIVE: To research the regulation of transmembrane transport activity of paclitaxel influenced by fangchinoline in MDR1-MDCK II cells. Paclitaxel 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 20822025-4 2010 RP-HPLC was applied to determine the concentration of paclitaxel in the transporting medium, which was used to calculate apparent permeability coefficient of paclitaxel across MDR1-MDCK I1 monolayer cells. Paclitaxel 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 176-180 20822025-4 2010 RP-HPLC was applied to determine the concentration of paclitaxel in the transporting medium, which was used to calculate apparent permeability coefficient of paclitaxel across MDR1-MDCK I1 monolayer cells. Paclitaxel 158-168 ATP binding cassette subfamily B member 1 Homo sapiens 176-180 20099200-1 2010 MCF-7/ADR cells, a doxorubicin-resistant human breast cancer cell line, acquires resistance to several chemotherapeutic agents, such as anthracylines and taxol, via overexpression of the multidrug resistance1 (MDR1) gene. Paclitaxel 154-159 ATP binding cassette subfamily B member 1 Homo sapiens 187-208 20724802-8 2010 Using paclitaxel as a known P-gp substrate, erythromycin demonstrated only partial P-gp inhibitory capacity, maintaining an efflux ratio over 100. Paclitaxel 6-16 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 22069634-3 2010 P-glycoprotein mediates resistance to various classes of anticancer drugs including vinblastine, daunorubicin, and paclitaxel, by actively extruding the drugs from the cells. Paclitaxel 115-125 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 20460821-0 2010 Effect of Thai plant extracts on P-glycoprotein function and viability in paclitaxel-resistant HepG2 cells. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 33-47 19820208-7 2010 Although disulfiram has been shown to inhibit multidrug resistance-1 P-glycoprotein (P-gp) in vitro, our data demonstrate that the known P-gp substrate paclitaxel is not affected by coadministration of disulfiram. Paclitaxel 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 20099200-1 2010 MCF-7/ADR cells, a doxorubicin-resistant human breast cancer cell line, acquires resistance to several chemotherapeutic agents, such as anthracylines and taxol, via overexpression of the multidrug resistance1 (MDR1) gene. Paclitaxel 154-159 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 22966274-3 2010 The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism. Paclitaxel 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 197-202 19956892-0 2010 Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Paclitaxel 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 19-24 19956892-10 2010 Our data suggest that the ABCB1 polymorphism at 3435 is associated with clinical outcomes after paclitaxel-based combined chemotherapy in advanced gastric cancer patients. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 22966274-3 2010 The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism. Paclitaxel 255-260 ATP binding cassette subfamily B member 1 Homo sapiens 197-202 20641310-0 2004 [N-methyl-(11)C]4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenyl-N-methyl-butanamide One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by a multidrug resistance (MDR-1) gene protein (1, 2). Paclitaxel 270-280 ATP binding cassette subfamily B member 1 Homo sapiens 353-378 19699770-14 2009 CONCLUSIONS: In the present study a novel siRNA delivery carrier system with an MDR1-targeting siRNA (siMDR1) effectively reduced the expression of MDR1 in human colon CSCs (CD133+ enriched cell population), resulting in significantly increasing the chemosensitivity to paclitaxel. Paclitaxel 270-280 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 19699770-14 2009 CONCLUSIONS: In the present study a novel siRNA delivery carrier system with an MDR1-targeting siRNA (siMDR1) effectively reduced the expression of MDR1 in human colon CSCs (CD133+ enriched cell population), resulting in significantly increasing the chemosensitivity to paclitaxel. Paclitaxel 270-280 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 19609211-7 2009 In addition, mtDNA-depleted cells displayed a decreased sensitivity and accumulation of chemotherapeutic drugs (doxorubicin, vincristine, and paclitaxel), potentially because of the upregulated expression of multidrug resistance 1 (MDR1) gene and its product P-glycoprotein. Paclitaxel 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 208-230 19427995-5 2009 Nilotinib also significantly enhances the accumulation of paclitaxel in cell lines overexpressing ABCB1. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 19823672-4 2009 Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 276-280 19410561-4 2009 FG020326 significantly potentiated the cytotoxicity of paclitaxel, doxorubicin, and vincristine in the ABCB1 (P-glycoprotein, P-gp) overexpressing cells KBv200 and MCF-7/adr, but not in the ABCB1 negative parental cell lines KB and MCF-7. Paclitaxel 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 19410561-4 2009 FG020326 significantly potentiated the cytotoxicity of paclitaxel, doxorubicin, and vincristine in the ABCB1 (P-glycoprotein, P-gp) overexpressing cells KBv200 and MCF-7/adr, but not in the ABCB1 negative parental cell lines KB and MCF-7. Paclitaxel 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 110-124 19123050-5 2009 However, MDR1 (1199A) cells displayed greater resistance to vinblastine, vincristine, paclitaxel, and VP-16 (11-, 2.9-, 1.9-, and 2.9-fold, respectively). Paclitaxel 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 19138818-0 2009 G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Paclitaxel 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 19424643-8 2009 It enhanced the sensitivity of A2780/taxol cells to paclitaxel with down-regulation of P-glycoprotein, XIAP and survivin. Paclitaxel 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 19138818-6 2009 Ethnic differences in the G-T haplotype of the ABCB1 gene may be a biomarker for paclitaxel sensitivity, and future clinical validation is necessary to confirm our findings. Paclitaxel 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 19383919-0 2009 Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Paclitaxel 16-26 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 18828019-4 2009 RESULTS: Paclitaxel selected resistant cell lines expressed high levels of ABCB1 (but not ABCC1 or ABCG2/BCRP) did not demonstrate cross-resistance to either ET-743 or PM00104. Paclitaxel 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 18828019-8 2009 siRNA down-regulation of ABCB1 expression in doxorubicin selected cell lines caused partial sensitization to both doxorubicin and paclitaxel but not to either ET-743 or PM00104. Paclitaxel 130-140 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 19247716-0 2009 MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Paclitaxel 108-113 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 19247716-7 2009 RESULTS: The MDR cell line induced by Taxol (Hep-2T cell) was more invasive than its parent cell line (Hep-2 cell), which was at least in part mediated through the overexpressed MDR1/P-pg. Paclitaxel 38-43 ATP binding cassette subfamily B member 1 Homo sapiens 178-182 18618115-4 2009 Combination of MDR-1 gene silencing and nanoparticle-mediated delivery significantly influenced the cytotoxic activity of PTX in SKOV3(TR) cells similar to what was observed in drug sensitive SKOV3 cells. Paclitaxel 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 19399413-0 2009 Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells. Paclitaxel 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 19399413-9 2009 It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 19059384-5 2009 In ABCB1-overexpressing cells, non-toxic doses of AG1478 were found to partially inhibit resistance to ABCB1 substrate anticancer drugs as well as increase intracellular accumulation of [3H]-paclitaxel. Paclitaxel 191-201 ATP binding cassette subfamily B member 1 Homo sapiens 3-8 18836089-0 2009 Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 19-24 18623213-8 2009 However, resistance to ptx was reversed by verapamil, which indicated that a sustained inhibition of Pgp was required for ptx to induce cytotoxicity in MDR cells. Paclitaxel 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 101-104 18836089-3 2009 We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G>T/A or 3435C>T. PATIENTS AND METHODS: Patients with metastatic breast cancer were treated with 175 mg/m(2) paclitaxel per 3-week cycle. Paclitaxel 79-89 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 18836089-3 2009 We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G>T/A or 3435C>T. PATIENTS AND METHODS: Patients with metastatic breast cancer were treated with 175 mg/m(2) paclitaxel per 3-week cycle. Paclitaxel 288-298 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 18836089-10 2009 CONCLUSIONS: ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients. Paclitaxel 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 19881253-10 2009 These results indicate that enhanced expression and function of P-gp may be a predominant mechanism of paclitaxel resistance in PR-HepG2 cells and the reduced influx via OATP1B3 may also serve to lower intracellular paclitaxel concentration in cooperation with P-gp-mediated efflux. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 19143748-1 2009 The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients. Paclitaxel 176-186 ATP binding cassette subfamily B member 1 Homo sapiens 87-92 19143748-6 2009 Patients heterozygous for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 19143748-6 2009 Patients heterozygous for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 19143748-7 2009 A lower clearance of paclitaxel was found for patients heterozygous for CYP2C8*3 when stratified according to the ABCB1 G2677T/A genotype. Paclitaxel 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 19143748-10 2009 Our findings suggest that interindividual variability in paclitaxel pharmacokinetics might be predicted by ABCB1 and CYP2C8 genotypes and provide useful information for individualized chemotherapy. Paclitaxel 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 19881253-1 2009 Paclitaxel-resistant HepG2 (PR-HepG2) cells were established by long-term exposure of HepG2 cells to paclitaxel and expression and function of efflux (P-glycoprotein, MRP2) and influx (OATP1B3) transporters for paclitaxel were examined to understand the mechanisms underlying the resistance. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 151-165 19881253-10 2009 These results indicate that enhanced expression and function of P-gp may be a predominant mechanism of paclitaxel resistance in PR-HepG2 cells and the reduced influx via OATP1B3 may also serve to lower intracellular paclitaxel concentration in cooperation with P-gp-mediated efflux. Paclitaxel 216-226 ATP binding cassette subfamily B member 1 Homo sapiens 261-265 18945821-0 2009 Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Paclitaxel 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 18829547-9 2008 Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 18945821-11 2009 Finally, Q2 was shown to inhibit the transport of radiolabeled paclitaxel (Taxol) in MCF-7/DX1 cells, and it completely reversed the P-gp-mediated paclitaxel resistance phenotype. Paclitaxel 147-157 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 18845169-9 2008 Consistent with decreased P-gp pumping activity, confocal microscopic observation revealed that KB3-1 effectively diminished the expression of P-gp in paclitaxel (TAX)-treated MES-SA/DX-5 cells. Paclitaxel 151-161 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 19000447-9 2008 The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P<0.05). Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 19000447-9 2008 The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P<0.05). Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 181-185 19000447-9 2008 The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P<0.05). Paclitaxel 36-39 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 18974132-5 2008 In addition, taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR. Paclitaxel 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 111-114 18723777-6 2008 Although there was a minimal effect on doxorubicin and daunorubicin, the MDR1-dependent resistance on vinblastine, vincristine, paclitaxel, and etoposide was reduced by approximately 5-fold. Paclitaxel 128-138 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 18703598-4 2008 The functional activities of MDR1 shRNA were determined by paclitaxel uptake and sensitivity to doxorubicin. Paclitaxel 59-69 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 18574456-2 2008 For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P-glycoprotein (P-gp) at the blood-brain barrier. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 107-121 18574456-2 2008 For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P-glycoprotein (P-gp) at the blood-brain barrier. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 18765553-0 2008 ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Paclitaxel 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 18765553-0 2008 ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Paclitaxel 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 7-12 18765553-1 2008 PURPOSE: The human ABCB1 gene encodes P-glycoprotein, which transports a broad range of anticancer drugs, including paclitaxel. Paclitaxel 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 19-24 18765553-1 2008 PURPOSE: The human ABCB1 gene encodes P-glycoprotein, which transports a broad range of anticancer drugs, including paclitaxel. Paclitaxel 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 18703598-9 2008 The inhibition of P-glycoprotein expression by shRNA enhanced the intracellular accumulation of paclitaxel, the cellular retention of which is mediated by P-glycoprotein, thereby increasing sensitivity to the anticancer drug. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 18703598-9 2008 The inhibition of P-glycoprotein expression by shRNA enhanced the intracellular accumulation of paclitaxel, the cellular retention of which is mediated by P-glycoprotein, thereby increasing sensitivity to the anticancer drug. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 155-169 18625294-5 2008 These findings suggest that Hexyl-ALA could be used to selectively reduce P-gp expression in overcoming resistance to chemotherapy agents such as doxorubicin and paclitaxel. Paclitaxel 162-172 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 18673531-8 2008 MTT assay showed that Pgp inhibitors such as cyclosporine A, verapamil and PSC833 sensitized Colo320HSR (colon, highest MDR1 expression) but not SNU-668 (gastric, highest) and SNU-C5 (gastric, no expression) to paclitaxel. Paclitaxel 211-221 ATP binding cassette subfamily B member 1 Homo sapiens 22-25 18006847-4 2007 Our findings show that erlotinib significantly potentiated the sensitivity of established ABCB1 or ABCG2 substrates and increased the accumulation of paclitaxel or mitoxantrone in ABCB1- or ABCG2-overexpressing cells. Paclitaxel 150-160 ATP binding cassette subfamily B member 1 Homo sapiens 180-185 18441325-6 2008 Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Paclitaxel 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 18441325-6 2008 Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Paclitaxel 191-196 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 18324624-5 2008 Following transient expression of MDR-1 and MCJ, changes in the sensitivity of Sk-Ov-3 cells to paclitaxel were detected whereas expression of Src, Bcl-2 and Bcl-X(L) decreased the sensitivity of Sk-Ov-3 cells to carboplatin. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 18518845-3 2008 However, so far only genetic variants of ABCB1 have been indicated to be associated with response and pharmacokinetics of paclitaxel. Paclitaxel 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 41-46 18275843-4 2008 In parallel, apicidin resistance to the apoptotic potential of paclitaxel is associated with induction of P-gp expression in HeLa cells, as evidenced by specific inhibition of P-gp function using either the pharmacological inhibitor verapamil or RNA silencing. Paclitaxel 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 18234154-6 2008 Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells. Paclitaxel 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 43-46 18762730-1 2008 In previous reports, the effects of 12 Ca2+ antagonists on a multidrug resistant transporter, P-glycoprotein/MDR1, were evaluated in terms of those on MDR1-mediated transport of [3H]digoxin and the sensitivity of vinblastine sulfate or paclitaxel, and they were able to be classified into 4 subgroups based on their actions, as those with transport inhibition and sensitivity recovery, those with or without transport inhibition but marginal sensitivity recovery, and those without both. Paclitaxel 236-246 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 18762730-1 2008 In previous reports, the effects of 12 Ca2+ antagonists on a multidrug resistant transporter, P-glycoprotein/MDR1, were evaluated in terms of those on MDR1-mediated transport of [3H]digoxin and the sensitivity of vinblastine sulfate or paclitaxel, and they were able to be classified into 4 subgroups based on their actions, as those with transport inhibition and sensitivity recovery, those with or without transport inhibition but marginal sensitivity recovery, and those without both. Paclitaxel 236-246 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 18762730-1 2008 In previous reports, the effects of 12 Ca2+ antagonists on a multidrug resistant transporter, P-glycoprotein/MDR1, were evaluated in terms of those on MDR1-mediated transport of [3H]digoxin and the sensitivity of vinblastine sulfate or paclitaxel, and they were able to be classified into 4 subgroups based on their actions, as those with transport inhibition and sensitivity recovery, those with or without transport inhibition but marginal sensitivity recovery, and those without both. Paclitaxel 236-246 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 18433974-7 2008 Also inhibition of MDR1 was monitored by measuring digoxin transport on Caco-2 monolayers and paclitaxel toxicity on K562-MDR cells. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 18433974-9 2008 Digoxin permeability and paclitaxel cytotoxicity studies revealed that these herbicides are potent inhibitors of MDR1 that can modulate drug absorption and cause chemosensitization of cells. Paclitaxel 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 17828752-0 2008 ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. Paclitaxel 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 17828752-1 2008 P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 17828752-1 2008 P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 17828752-1 2008 P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 38-43 17828752-3 2008 We analyzed the allelic distribution of the G1199T/A and other polymorphisms in exons 11 and 12 of the ABCB1 gene in ovarian cancer patients treated with paclitaxel and carboplatin in order to evaluate their predictive value in vivo. Paclitaxel 154-164 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 17828752-8 2008 Genotyping of the ABCB1 gene may be important for determining the tumor resistance to paclitaxel and provide useful information for individualized therapy. Paclitaxel 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 18-23 17954267-1 2007 A multidrug-resistant lung cancer cell line PTX250, established by treatment with the anti-cancer drug paclitaxel, has been demonstrated to have an increased copy number in the 7q21.12 region including the MDR1/ABCB1 gene. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 211-216 17906456-5 2007 Due to substantial interindividual diversity observed in paclitaxel pharmacokinetics actual research focuses on common single nucleotide polymorphisms in genes encoding metabolizing enzymes and drug transporters such as CYP450, P-glycoprotein and the organic anion transporting polypeptide OATP1B3. Paclitaxel 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 228-242 17954267-1 2007 A multidrug-resistant lung cancer cell line PTX250, established by treatment with the anti-cancer drug paclitaxel, has been demonstrated to have an increased copy number in the 7q21.12 region including the MDR1/ABCB1 gene. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 206-210 17903587-8 2007 CONCLUSION: More emphasis should be laid on MDR1/Pgp, the non-Pgp substrate chemotherapeutic agents, and the changes of cell cycle distribution to prevent MDR induced by Taxol. Paclitaxel 170-175 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 17701008-4 2007 The effects of patient characteristics, including single-nucleotide polymorphisms of MDR1(ABCB1), CYP2C8, CYP3A4, and CYP3A5, on the total body clearance of paclitaxel were evaluated. Paclitaxel 157-167 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 17701008-4 2007 The effects of patient characteristics, including single-nucleotide polymorphisms of MDR1(ABCB1), CYP2C8, CYP3A4, and CYP3A5, on the total body clearance of paclitaxel were evaluated. Paclitaxel 157-167 ATP binding cassette subfamily B member 1 Homo sapiens 90-95 17440963-12 2007 Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 17440963-12 2007 Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 17440963-12 2007 Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 82-87 17440963-12 2007 Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 193-197 17440963-12 2007 Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Paclitaxel 227-237 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 17440963-12 2007 Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Paclitaxel 227-237 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 17440963-12 2007 Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Paclitaxel 227-237 ATP binding cassette subfamily B member 1 Homo sapiens 82-87 17697605-0 2007 [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Paclitaxel 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 17487377-4 2007 Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells. Paclitaxel 238-248 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 17487377-4 2007 Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells. Paclitaxel 238-248 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 17487377-4 2007 Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells. Paclitaxel 238-248 ATP binding cassette subfamily B member 1 Homo sapiens 209-213 17697605-1 2007 OBJECTIVE: To investigate the reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel. Paclitaxel 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 17697605-13 2007 CONCLUSION: MDR1 and MDR3 gene silencing could recover sensitivity of A2780/taxol cells to paclitaxel and induce cell apoptosis, thus reversing cell resistance to paclitaxel. Paclitaxel 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 17697605-13 2007 CONCLUSION: MDR1 and MDR3 gene silencing could recover sensitivity of A2780/taxol cells to paclitaxel and induce cell apoptosis, thus reversing cell resistance to paclitaxel. Paclitaxel 163-173 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 17686239-12 2007 CONCLUSION: Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 37-40 17331135-6 2007 We also demonstrated that hematopoietic cells transduced with MDR1 gene were enriched in vivo after paclitaxel chemotherapy determined by the higher percentage of human Rh-123(dull) CD45+ cells in bone marrow of mice. Paclitaxel 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 17190787-1 2007 By comparing ovarian carcinoma-derived KF28 cells with the corresponding anticancer drug-resistant cells, the taxol- and cisplatin-resistant properties were found to be closely related with MDR1 and BSEP, and MRP2 transporters, respectively. Paclitaxel 110-115 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 17471022-1 2007 OBJECTIVE: To evaluate the specific killing effects of the adenoviral vector in which the CD::UPP genes were directed by the MDR1 promoter on Taxol-resistance ovarian cancer cells in vitro and in vivo. Paclitaxel 142-147 ATP binding cassette subfamily B member 1 Homo sapiens 125-129 17645840-1 2007 OBJECTIVE: To explore the effect of hypoxia and hypoxia-inducible factor-1alpha (HIF-1alpha) on the expression of multidrug resistance gene-1 (mdr-1) and its coded p-glyeoprotein (P-gp) as well as the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism. Paclitaxel 263-273 ATP binding cassette subfamily B member 1 Homo sapiens 114-148 17245652-1 2007 PURPOSE: The aim of the study was to investigate whether 2"-ethylcarbonate-linked paclitaxel (TAX-2"-Et) circumvents P-glycoprotein (P-gp)-mediated cellular efflux and cytotoxicity enhanced by TAX-2"-Et activation within human culture cells transfected with a rabbit liver carboxylesterase (Ra-CES) cDNA. Paclitaxel 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 17245652-1 2007 PURPOSE: The aim of the study was to investigate whether 2"-ethylcarbonate-linked paclitaxel (TAX-2"-Et) circumvents P-glycoprotein (P-gp)-mediated cellular efflux and cytotoxicity enhanced by TAX-2"-Et activation within human culture cells transfected with a rabbit liver carboxylesterase (Ra-CES) cDNA. Paclitaxel 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 17645840-12 2007 CONCLUSION: Hypoxia can decrease the chemotherapeutic sensitivity of human ovarian cancer A2780 cells to paclitaxel through HIF-1alpha regulating the expression of mdr-1 and p-gp. Paclitaxel 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 164-169 16904325-6 2006 In addition, in vitro metabolism studies of 23a with a subset of human CYP-450 isoforms revealed that, unlike XR9576, 23a inhibited CYP3A4, an enzyme that colocalizes with P-gp in the intestine and contributes to tumor cell chemoresistance by enhancing the biodisposition of anticancer drugs such as paclitaxel toward metabolism. Paclitaxel 300-310 ATP binding cassette subfamily B member 1 Homo sapiens 172-176 17029589-10 2007 Paclitaxel-stimulated ATPase activity of MDR1 is enhanced in the presence of stigmasterol, sitosterol and campesterol, as well as cholesterol, but not ergosterol. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 18261374-0 2007 Enhancement of paclitaxel transport and cytotoxicity by 7,3",4"-trimethoxyflavone, a P-glycoprotein inhibitor. Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 85-99 18261374-2 2007 The aim of this study was to select a P-glycoprotein (Pgp)- inhibitory flavonoid to enhance paclitaxel bioavailability in the Caco-2 cell monolayer. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 18261374-2 2007 The aim of this study was to select a P-glycoprotein (Pgp)- inhibitory flavonoid to enhance paclitaxel bioavailability in the Caco-2 cell monolayer. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 54-57 18261374-10 2007 In addition, AP loading of TMF increased the paclitaxel sensitivity of paclitaxel-resistant SK-MES-1/PT4000 cells overexpressing Pgp on the BL side. Paclitaxel 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 129-132 18261374-10 2007 In addition, AP loading of TMF increased the paclitaxel sensitivity of paclitaxel-resistant SK-MES-1/PT4000 cells overexpressing Pgp on the BL side. Paclitaxel 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 129-132 17113177-0 2007 Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 81-95 17113177-5 2007 dosing with PTX formulated in Cremophor EL (PTX(CrEL)) induced a two-fold increase in mRNA levels of MDR1 after a 14-day dosing period. Paclitaxel 12-15 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 17113177-5 2007 dosing with PTX formulated in Cremophor EL (PTX(CrEL)) induced a two-fold increase in mRNA levels of MDR1 after a 14-day dosing period. Paclitaxel 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 17143487-0 2007 Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Paclitaxel 38-43 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 17143487-7 2007 Selective small interfering RNAs (siRNA) of P-gp with MDR1-targeted short hairpin RNAs (shRNA) expression vector sensitized the cells to Taxol. Paclitaxel 137-142 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 17166391-4 2006 For example, paclitaxel is regarded as a relatively sensitive drug and may be chosen for the tumors with high expression of p53, while it is predicted as relatively resistant drug and should be avoided for the tumors with high expression of P-glycoprotein (P-gp). Paclitaxel 13-23 ATP binding cassette subfamily B member 1 Homo sapiens 241-255 17166391-4 2006 For example, paclitaxel is regarded as a relatively sensitive drug and may be chosen for the tumors with high expression of p53, while it is predicted as relatively resistant drug and should be avoided for the tumors with high expression of P-glycoprotein (P-gp). Paclitaxel 13-23 ATP binding cassette subfamily B member 1 Homo sapiens 257-261 16773437-4 2006 We hypothesized that patients whose tumors expressed higher amounts of IL-6 or PGP would be less likely to respond to paclitaxel, an agent affected by the PGP pathway. Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 79-82 16773437-4 2006 We hypothesized that patients whose tumors expressed higher amounts of IL-6 or PGP would be less likely to respond to paclitaxel, an agent affected by the PGP pathway. Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 155-158 16995873-2 2006 In accordance with previous reports, taxol and cisplatin resistance was closely correlated with expression of the multidrug resistance 1 and bile acid export pump, and multidrug resistance-associated protein 2 genes, respectively. Paclitaxel 37-42 ATP binding cassette subfamily B member 1 Homo sapiens 114-136 16950614-0 2006 Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Paclitaxel 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 16917872-6 2006 Compared to MDR1(wt), MDR1(G1199A) exhibited an increased resistance to doxorubicin, paclitaxel, vinblastine, and vincristine. Paclitaxel 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 16950614-1 2006 Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 16950614-1 2006 Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 16950614-1 2006 Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 16950614-1 2006 Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics. Paclitaxel 104-109 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 16950614-6 2006 This pilot study suggests that paclitaxel-induced neuropathy and neutropenia might be linked to inherited variants of ABCB1 through a mechanism that is unrelated to altered plasma pharmacokinetics. Paclitaxel 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 118-123 16713148-0 2006 Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Paclitaxel 44-54 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 17062699-0 2006 Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Paclitaxel 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 5-10 16969354-2 2006 Paclitaxel has high affinity for the P-glycoprotein (P-gp) (drug efflux pump) in the gastrointestinal tract causing low and variable oral bioavailability. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 16969354-2 2006 Paclitaxel has high affinity for the P-glycoprotein (P-gp) (drug efflux pump) in the gastrointestinal tract causing low and variable oral bioavailability. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 16969354-3 2006 Previously, we demonstrated that oral paclitaxel plus the P-gp inhibitor cyclosporin (CsA) is safe and results in adequate exposure to paclitaxel. Paclitaxel 135-145 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 17001553-0 2006 Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 17020983-12 2006 However, the statistically higher paclitaxel deposition in the periphery of metastatic brain tumors provides functional evidence corroborating reports of decreased P-glycoprotein expression in metastatic versus primary brain tumors. Paclitaxel 34-44 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 16713148-2 2006 The objective of the study is to investigate whether a P-gp substrate, paclitaxel, delivered to MDR tumor cells in poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles is susceptible to P-gp - mediated drug efflux. Paclitaxel 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 16713148-2 2006 The objective of the study is to investigate whether a P-gp substrate, paclitaxel, delivered to MDR tumor cells in poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles is susceptible to P-gp - mediated drug efflux. Paclitaxel 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 185-189 16713148-6 2006 Resistance to nanoparticle-encapsulated paclitaxel was reversed by verapamil, a P-gp inhibitor. Paclitaxel 40-50 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 16713148-7 2006 Further, sustained inhibition of P-gp was necessary for sustaining the cytotoxicity of nanoparticle-encapsulated paclitaxel in drug-resistant cells. Paclitaxel 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 16713148-9 2006 In conclusion, our studies suggest that P-gp substrates, such as paclitaxel, delivered to MDR cells by PLGA nanoparticles, are susceptible to efflux by P-gp. Paclitaxel 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 16713148-9 2006 In conclusion, our studies suggest that P-gp substrates, such as paclitaxel, delivered to MDR cells by PLGA nanoparticles, are susceptible to efflux by P-gp. Paclitaxel 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 16713148-10 2006 Inhibition of P-gp restores sensitivity to paclitaxel; however, sustained inhibition of P-gp is required for sustained therapeutic efficacy of nanoparticle-encapsulated drug. Paclitaxel 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 17025021-2 2006 In this study, we found that MGS also enhanced the cytotoxicity of vinblastine, vincristine, and taxol in P-glycoprotein-overexpressing VJ-300 cells and P388/VCR cells. Paclitaxel 97-102 ATP binding cassette subfamily B member 1 Homo sapiens 106-120 16574387-8 2006 CONCLUSION: Paclitaxel modifies the uptake of tumor-diagnostic tracers in both P-gp-dependent and independent manners. Paclitaxel 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 16574387-9 2006 Interpretation of the multifactorial effects of paclitaxel may promote a correct in vivo diagnosis of P-gp-positive and P-gp-negative tumors. Paclitaxel 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 16574387-0 2006 Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 16574387-9 2006 Interpretation of the multifactorial effects of paclitaxel may promote a correct in vivo diagnosis of P-gp-positive and P-gp-negative tumors. Paclitaxel 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 16574387-1 2006 AIM: To study how paclitaxel treatment modifies the accumulation of tumor-diagnostic radiotracers in P-glycoprotein (P-gp) positive and negative cancer cells. Paclitaxel 18-28 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 16753005-6 2006 A 4.4-fold (p = 0.005) enhancement of CYP2C8 expression and a 5.6-fold (p = 0.001) increase of multidrug resistance (MDR)1 expression was observed in resistant cells exposed to paclitaxel. Paclitaxel 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 95-122 16574387-1 2006 AIM: To study how paclitaxel treatment modifies the accumulation of tumor-diagnostic radiotracers in P-glycoprotein (P-gp) positive and negative cancer cells. Paclitaxel 18-28 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 16574387-6 2006 Paclitaxel (1-70microM) increased the (18)FDG uptake (up to 200%) of both P-gp-positive and P-gp-negative cells, whereas it did not modulate their (11)C-choline uptake. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 16574387-6 2006 Paclitaxel (1-70microM) increased the (18)FDG uptake (up to 200%) of both P-gp-positive and P-gp-negative cells, whereas it did not modulate their (11)C-choline uptake. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 15990222-3 2006 Cells (UL-3A, UL-3B) that recovered from cisplatin (Cis) and paclitaxel (Tax) treatments showed higher levels of p53, mdr-1 and chemoresistance than untreated controls. Paclitaxel 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 118-123 16803472-4 2006 We therefore examined the relationship of the paclitaxel pharmacokinetics in 13 patients with ovarian cancer to polymorphisms in CYP2C8, CYP3A5, ABCB1, and PXR. Paclitaxel 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 145-150 16803472-8 2006 ABCB1 T-129C, T1236C, and G2677(A,T), however, was associated with lower area under the plasma concentration-time curve (AUC) of paclitaxel. Paclitaxel 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 16803472-0 2006 Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Paclitaxel 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 16803472-9 2006 We also observed a significant correlation between the AUC (r=-0.721) or the total clearance of paclitaxel (CL(tot)) (r= 0.673) and the ABCB1 mutant allele dosage in each patient. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 136-141 16803472-1 2006 Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 184-189 16803472-10 2006 Taken together, our findings suggest that interindividual variability in paclitaxel pharmacokinetics could be predicted by ABCB1 genotyping. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 16803472-1 2006 Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 215-219 16803472-1 2006 Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 222-236 16596196-6 2006 We therefore conclude that IGFBP-3, RhoGDI and MDR-1 were correlated with paclitaxel resistance. Paclitaxel 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 16467099-0 2006 mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Paclitaxel 101-111 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 16467099-1 2006 PURPOSE: P-glycoprotein, encoded by the mdr-1 gene, confers multidrug resistance to a variety of antineoplastic agents, e.g., paclitaxel. Paclitaxel 126-136 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 16467099-1 2006 PURPOSE: P-glycoprotein, encoded by the mdr-1 gene, confers multidrug resistance to a variety of antineoplastic agents, e.g., paclitaxel. Paclitaxel 126-136 ATP binding cassette subfamily B member 1 Homo sapiens 9-23 16380805-8 2006 Furthermore, western blots showed an overexpression of MDR-1 in the taxol-resistant clone, while alpha- and beta-tubulins and p48/IRF9 were expressed in equal amounts in both cell lines. Paclitaxel 68-73 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 16467099-12 2006 CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy. Paclitaxel 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 16467099-12 2006 CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy. Paclitaxel 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 155-169 16467099-12 2006 CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy. Paclitaxel 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 16467099-12 2006 CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy. Paclitaxel 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 155-169 16402278-4 2006 We conducted a prospective, randomized study to assess if Pgp inhibition by TAM alters deposition of paclitaxel in cerebrospinal fluid (CSF). Paclitaxel 101-111 ATP binding cassette subfamily B member 1 Homo sapiens 58-61 16454695-6 2006 The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods. Paclitaxel 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 56-59 16402278-11 2006 CONCLUSIONS: The trend towards lower paclitaxel CSF concentrations when given with TAM is consistent with the published finding that Pgp"s localization in the endothelial cells of the choroid plexus works in an opposite direction and keeps drugs in the CSF. Paclitaxel 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 133-136 16402278-13 2006 Conceptually, this finding implies that the Pgp in the BBB and BCSFB keeps natural toxins such as paclitaxel, from entering the brain (BBB) and, if they do enter the brain, keeps them in the CSF (BCSFB) where they may be less harmful than if they re-entered the brain. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 44-47 15875185-10 2005 Furthermore, the enhancement of antitumor effect by ningalins, at least in parts, are due to inhibiting Pgp which was supported by the observation that the ningalins compete for [3H]azidopine binding to Pgp, increase the cellular accumulation of VBL or taxol, and inhibit drug efflux from the tumor cells. Paclitaxel 253-258 ATP binding cassette subfamily B member 1 Homo sapiens 104-107 16361573-0 2005 Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Paclitaxel 159-169 ATP binding cassette subfamily B member 1 Homo sapiens 111-125 16361573-4 2005 EXPERIMENTAL DESIGN: We evaluated the expression and localization of YB-1 and P-glycoprotein in breast cancer tissues obtained from 27 patients before and after treatment with paclitaxel. Paclitaxel 176-186 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 16361573-7 2005 The effects of paclitaxel on MDR1 promoter activity were examined by luciferase assay. Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 16361573-8 2005 RESULTS: Of 27 breast cancer tissues treated with paclitaxel, nine (33%) showed translocation of YB-1 from the cytoplasm to the nucleus together with increased expression of P-glycoprotein during the course of treatment. Paclitaxel 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 174-188 16361573-12 2005 Furthermore, binding of YB-1 to the Y-box of MDR1 promoter was increased in response to treatment with paclitaxel. Paclitaxel 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 16361573-13 2005 In addition, MDR1 promoter activity was significantly up-regulated by paclitaxel in MCF7 cells (P<0.001). Paclitaxel 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 16299241-0 2005 Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Paclitaxel 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 43-48 16299241-1 2005 PURPOSE: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol). Paclitaxel 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 17657173-7 2006 SNU-449, the most resistant cell line and the only one overexpressing P-glycoprotein, was 3- to 39-fold more resistant to paclitaxel, docetaxel, and doxorubicin than were other cell lines. Paclitaxel 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 15945097-11 2005 In conclusion, we could remark that proteasome inhibitors (especially PS341) attenuate the resistance of MCF7/ADR cells for P-gp substrate drugs of doxorubicin and paclitaxel. Paclitaxel 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 16288028-8 2005 Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines. Paclitaxel 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 16288028-8 2005 Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines. Paclitaxel 95-105 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 15856231-2 2005 Studies on the metabolism and disposition of paclitaxel have shown that it is primarily eliminated via hepatic metabolism by P450 enzymes (2C8 and 3A4) to essentially inactive metabolites, and that biliary and gut transport by P-glycoprotein (PGP) as well as urinary elimination of the parent compound play relatively minor roles. Paclitaxel 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 227-241 16023314-14 2005 The influx permeability of substrates increased significantly (rhodamine123=70%, taxol=220%, digoxin=290%) after the P-gp inhibitor (GF120918) was introduced, whereas the influx permeability of P-gp inhibitor and non-substrates was not affected by GF120918. Paclitaxel 81-86 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 15856231-2 2005 Studies on the metabolism and disposition of paclitaxel have shown that it is primarily eliminated via hepatic metabolism by P450 enzymes (2C8 and 3A4) to essentially inactive metabolites, and that biliary and gut transport by P-glycoprotein (PGP) as well as urinary elimination of the parent compound play relatively minor roles. Paclitaxel 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 243-246 15856231-3 2005 Recent studies in vitro have shown that paclitaxel treatment increases the level of CYP2C8 and CYP3A4 in human hepatocytes as well as PGP in colon tumor cells. Paclitaxel 40-50 ATP binding cassette subfamily B member 1 Homo sapiens 134-137 15856231-8 2005 The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure. Paclitaxel 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 60-63 15856231-8 2005 The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure. Paclitaxel 151-161 ATP binding cassette subfamily B member 1 Homo sapiens 60-63 15876424-7 2005 In the Be-Wo cell line, methadone and paclitaxel uptake was also increased in the presence of the P-gp inhibitor cyclosporin A. Paclitaxel 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 15955594-8 2005 However, clinically achievable levels of gefitinib moderately reversed the Pgp-mediated resistance to paclitaxel and docetaxel in Pgp overexpressing cells. Paclitaxel 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 75-78 15955594-8 2005 However, clinically achievable levels of gefitinib moderately reversed the Pgp-mediated resistance to paclitaxel and docetaxel in Pgp overexpressing cells. Paclitaxel 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 130-133 15650019-5 2005 In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression. Paclitaxel 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 16158930-0 2005 In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Paclitaxel 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 73-87 15650019-5 2005 In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression. Paclitaxel 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 227-231 20641303-3 2004 One of the mechanisms of cells to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and taxol, is to limit their presence inside the cells by a multidrug resistance (MDR-1) gene protein. Paclitaxel 168-173 ATP binding cassette subfamily B member 1 Homo sapiens 246-251 15565326-6 2005 These genes included MDR1, a gene often implicated in both in vitro and in vivo resistance to multiple chemotherapeutics, including paclitaxel. Paclitaxel 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 15746064-7 2005 Inhibition of the drug efflux protein P-glycoprotein with verapamil resensitized SW480 cells to treatment with low doses of paclitaxel alone and in combination with IR. Paclitaxel 124-134 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 15635178-8 2005 This suggests that the increase in paclitaxel sensitivity by Glycyrrhizae Radix, Rhei Rhizoma, Poria or Ephedrae Herba was caused, in part, by the inhibition of MDR1 function, and the change in paclitaxel sensitivity by the other herbal extracts was not always dependent on this. Paclitaxel 35-45 ATP binding cassette subfamily B member 1 Homo sapiens 161-165 16193644-7 2005 Among these examples are the coadministration of paclitaxel with CsA, a CYP3A4 substrate with P-glycoprotein (P-gp) modulating activity, and topotecan combined with the BCRP/P-gp transport inhibitor elacridar. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 16193644-7 2005 Among these examples are the coadministration of paclitaxel with CsA, a CYP3A4 substrate with P-glycoprotein (P-gp) modulating activity, and topotecan combined with the BCRP/P-gp transport inhibitor elacridar. Paclitaxel 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 15380635-5 2004 Lack of paclitaxel brain uptake is thought to be associated with the p-glycoprotein (p-gp) efflux transporter. Paclitaxel 8-18 ATP binding cassette subfamily B member 1 Homo sapiens 69-83 15700849-7 2004 Differential sensitivity in a set of Taxol-resistant lines correlated to the expression of P-glycoprotein (P-gp), and its importance was demonstrated directly. Paclitaxel 37-42 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 15700849-7 2004 Differential sensitivity in a set of Taxol-resistant lines correlated to the expression of P-glycoprotein (P-gp), and its importance was demonstrated directly. Paclitaxel 37-42 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 15380635-5 2004 Lack of paclitaxel brain uptake is thought to be associated with the p-glycoprotein (p-gp) efflux transporter. Paclitaxel 8-18 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 15380635-10 2004 The results suggest that entrapment of paclitaxel in nanoparticles significantly increases the drug brain uptake and its toxicity toward p-glycoprotein expressing tumor cells. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 137-151 15262121-12 2004 The mRNA for MDR-1 was uniquely overexpressed in the cisplatin-resistant cell line A2780-CR9 initially treated with low doses of cisplatin and paclitaxel, but was not amplified in A2780 (P < 0.01). Paclitaxel 143-153 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 15556294-9 2004 In light of the overexpression of MGC4175 in association with taxol exposure, drug resistance, the coexpression of MDR1 and the mitochondrial localization of its protein, we propose to name this transcript MDR1 and Mitochondrial Taxol Resistance Associated Gene (MM-TRAG) and suggest that MM-TRAG may play a role in the development of taxol resistance in human cancer. Paclitaxel 335-340 ATP binding cassette subfamily B member 1 Homo sapiens 206-210 15047220-0 2004 Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Paclitaxel 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 14-36 15252144-7 2004 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of siRNA-treated cells demonstrated 7- to 12.4-fold reduction of paclitaxel resistance in the lines treated with the synthesized siRNA of ABCB1 and 4.7- to 7.3-fold reduction of paclitaxel resistance in the cell lines transfected with siRNA of ABCB1 expressing vectors. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 206-211 15252144-7 2004 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of siRNA-treated cells demonstrated 7- to 12.4-fold reduction of paclitaxel resistance in the lines treated with the synthesized siRNA of ABCB1 and 4.7- to 7.3-fold reduction of paclitaxel resistance in the cell lines transfected with siRNA of ABCB1 expressing vectors. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 312-317 15252144-9 2004 These results indicate that siRNA targeted to ABCB1 can sensitize paclitaxel-resistant ovarian cancer cells in vitro and suggest that siRNA treatment may represent a new approach for the treatment of ABCB1-mediated drug resistance. Paclitaxel 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 46-51 15252144-9 2004 These results indicate that siRNA targeted to ABCB1 can sensitize paclitaxel-resistant ovarian cancer cells in vitro and suggest that siRNA treatment may represent a new approach for the treatment of ABCB1-mediated drug resistance. Paclitaxel 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 200-205 15252144-3 2004 Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene. Paclitaxel 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 15252144-3 2004 Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene. Paclitaxel 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 15252144-3 2004 Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 165-170 15252144-4 2004 In this study, we demonstrate that paclitaxel-resistant cell lines overexpress both ABCB1 and ABCB4 (MDR3). Paclitaxel 35-45 ATP binding cassette subfamily B member 1 Homo sapiens 84-89 15060738-1 2004 PURPOSE: The taxanes paclitaxel and docetaxel are substrates for P-glycoprotein (Pgp), an ATP-binding cassette (ABC) transport protein associated with multidrug resistance (MDR). Paclitaxel 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 15060738-1 2004 PURPOSE: The taxanes paclitaxel and docetaxel are substrates for P-glycoprotein (Pgp), an ATP-binding cassette (ABC) transport protein associated with multidrug resistance (MDR). Paclitaxel 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 81-84 15047220-1 2004 OBJECTIVES: The role of MDR1 in clinical paclitaxel resistance remains poorly characterized. Paclitaxel 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 15047220-2 2004 This study sought to identify the incidence and significance of P-glycoprotein (P-gp) over-expression on survival, tumor response to paclitaxel and the effect of prior cytotoxic exposure on P-gp expression in patients with paired primary and recurrent ovarian cancer samples. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 14671431-3 2003 Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel. Paclitaxel 202-207 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 14671431-3 2003 Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel. Paclitaxel 202-207 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 14671431-3 2003 Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel. Paclitaxel 212-222 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 14671431-3 2003 Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel. Paclitaxel 212-222 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 14705863-4 2003 Increased expression of MDR1 reduces the bioavailability of MDR1 substrates such as digoxin, cyclosporin, and taxol. Paclitaxel 110-115 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 14705863-4 2003 Increased expression of MDR1 reduces the bioavailability of MDR1 substrates such as digoxin, cyclosporin, and taxol. Paclitaxel 110-115 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 14617793-2 2003 Although the cytotoxic taxanes paclitaxel and docetaxel are substrates for Pgp-mediated efflux, the semisynthetic taxane analogue ortataxel inhibits drug efflux mediated by Pgp as well as, as we recently demonstrated, MRP-1 and BCRP. Paclitaxel 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 75-78 12967311-3 2003 Significantly, like laulimalide, these analogues are poor substrates for the drug transport protein P-glycoprotein (Pgp) and are thus effective against Taxol-resistant cell lines. Paclitaxel 152-157 ATP binding cassette subfamily B member 1 Homo sapiens 100-114 14512701-3 2003 P-Glycoprotein expression was only slightly increased by Taxol, however, P-glycoprotein-mediated pumping efficiency was significantly increased. Paclitaxel 57-62 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 14512701-4 2003 Preincubation of cells with an anti-MDR1 monoclonal antibody prior to the drug treatment, coincubation of cells with a potent CYP3A4 inhibitor--ketoconazole--or with both compounds increased Taxol toxicity and proapoptotic activity, indicating that the P-glycoprotein system has a major role in Taxol disposition in hepatoblastoma cells. Paclitaxel 191-196 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 14655754-4 2003 Inhibition of PGP activity by verapamil or PSC 833 enhanced the cytotoxic effects of vincristine, doxorubicin, teniposide and taxol. Paclitaxel 126-131 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 12967311-3 2003 Significantly, like laulimalide, these analogues are poor substrates for the drug transport protein P-glycoprotein (Pgp) and are thus effective against Taxol-resistant cell lines. Paclitaxel 152-157 ATP binding cassette subfamily B member 1 Homo sapiens 116-119 12731085-10 2003 By administering paclitaxel, the proportions of P-glycoprotein- and gp91-positive cells were increased in all the four mice examined. Paclitaxel 17-27 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 12851680-5 2003 Using reporter assays and RT-PCR analysis, we demonstrate that paclitaxel-induced cell death was associated with an increase in NF-kappaB activation and MDR-1 gene expression. Paclitaxel 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 153-158 12851680-6 2003 Abrogation of these effects by the dominant negative IkappaB adenoviral construct suggests that induction and/or constitutive activation of NF-kappaB can block the paclitaxel-induced apoptotic signaling pathways in this cell line, possibly by increasing the expression of anti-apoptotic and MDR-1 gene products, leading to development of chemoresistance in these cells. Paclitaxel 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 291-296 12773051-4 2003 More importantly, compound 10 was found to be equipotent in MES-SA cells and paclitaxel-resistant, p-glycoprotein overexpressed MES-SA/DX5 cells. Paclitaxel 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 12902425-2 2003 To provide insight into both the dynamics of the pump and the effects of MDR, we radiolabeled paclitaxel, a substrate for the Pgp pump, with (18)F to study MDR in vivo with PET. Paclitaxel 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 126-129 14566676-5 2003 Western blot analysis demonstrated P-glycoprotein (P-gp) overexpression in taxol-resistant cells. Paclitaxel 75-80 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 14566676-5 2003 Western blot analysis demonstrated P-glycoprotein (P-gp) overexpression in taxol-resistant cells. Paclitaxel 75-80 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 14566676-10 2003 CONCLUSIONS: Taxol-resistance was primarily mediated by P-gp overexpression in KK47/TX30 cells. Paclitaxel 13-18 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 12731085-11 2003 When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year. Paclitaxel 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 14501017-3 2003 This study has focused on strategies to overcome P-gp-mediated efflux of Taxol analogs, MT-stabilizing agents that could be used to treat brain tumors and, potentially, neurodegenerative diseases such as Alzheimer"s disease. Paclitaxel 73-78 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 12831511-5 2003 The IC(50) values for paclitaxel, an MDR1 substrate, were 1.0 and 547 nM, respectively, whereas the cytotoxicity of 5-fluorouracil was comparable in both cells. Paclitaxel 22-32 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 12570657-7 2003 This review also explores pharmacologic attempts to modulate paclitaxel resistance, principally through inhibition of the MDR-1 drug efflux pump. Paclitaxel 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 122-127 12562644-1 2003 BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel. Paclitaxel 213-223 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 12538833-0 2003 Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling. Paclitaxel 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 25-39 12538833-1 2003 Intracellular concentration of paclitaxel is determined by the extracellular drug concentration, the level of the mdr1 P-glycoprotein (Pgp), and binding to intracellular proteins including tubulins/microtubules. Paclitaxel 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 12538833-1 2003 Intracellular concentration of paclitaxel is determined by the extracellular drug concentration, the level of the mdr1 P-glycoprotein (Pgp), and binding to intracellular proteins including tubulins/microtubules. Paclitaxel 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 135-138 12538833-4 2003 The parameters representing Pgp-mediated drug efflux and intracellular drug binding (i.e., number of Pgp and binding sites and binding affinity) were altered systematically and used to generate computer simulations depicting the intracellular paclitaxel pharmacokinetics at clinically relevant extracellular (e.g., plasma) drug concentrations. Paclitaxel 243-253 ATP binding cassette subfamily B member 1 Homo sapiens 28-31 12538833-4 2003 The parameters representing Pgp-mediated drug efflux and intracellular drug binding (i.e., number of Pgp and binding sites and binding affinity) were altered systematically and used to generate computer simulations depicting the intracellular paclitaxel pharmacokinetics at clinically relevant extracellular (e.g., plasma) drug concentrations. Paclitaxel 243-253 ATP binding cassette subfamily B member 1 Homo sapiens 101-104 14501017-4 2003 However, taxol is a strong P-gp substrate that limits its distribution across the BBB and therapeutic potential in the CNS. Paclitaxel 9-14 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 14501017-5 2003 We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models. Paclitaxel 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 14501017-5 2003 We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models. Paclitaxel 85-90 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 14501017-6 2003 Our studies demonstrate the feasibility of making small chemical modifications to Taxol to generate analogs with reduced affinity for the P-gp but retention of MT-stabilizing properties, i.e., a taxane that may reach and treat therapeutic targets in the CNS. Paclitaxel 82-87 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 12608532-9 2003 CONCLUSIONS: Our findings suggest that about 54% of a paclitaxel oral dose is extruded to the gut lumen by P-glycoprotein. Paclitaxel 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 107-121 14705770-0 2003 Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Paclitaxel 30-35 ATP binding cassette subfamily B member 1 Homo sapiens 69-83 14705770-1 2003 Our aim was to compare Taxol-based chemotherapy response of non-small cell lung cancer (NSCLC) with P-glycoprotein (Pgp) or lung resistance protein expression (LRP). Paclitaxel 23-28 ATP binding cassette subfamily B member 1 Homo sapiens 100-114 14705770-1 2003 Our aim was to compare Taxol-based chemotherapy response of non-small cell lung cancer (NSCLC) with P-glycoprotein (Pgp) or lung resistance protein expression (LRP). Paclitaxel 23-28 ATP binding cassette subfamily B member 1 Homo sapiens 116-119 14705770-6 2003 We concluded that Taxol-based chemotherapy response of patients with NSCLC was related to Pgp but not LPR expression. Paclitaxel 18-23 ATP binding cassette subfamily B member 1 Homo sapiens 90-93 12608532-0 2003 Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Paclitaxel 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 12608532-10 2003 Thus, the bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031. Paclitaxel 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 12608532-1 2003 PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel. Paclitaxel 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 12608535-1 2003 PURPOSE: We have reported that overexpression of mdr1 P-glycoprotein (Pgp) is associated with a higher sensitivity to paclitaxel-induced apoptosis (1,2). Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 12608532-1 2003 PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel. Paclitaxel 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 12608532-1 2003 PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel. Paclitaxel 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 12608535-1 2003 PURPOSE: We have reported that overexpression of mdr1 P-glycoprotein (Pgp) is associated with a higher sensitivity to paclitaxel-induced apoptosis (1,2). Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 12608532-1 2003 PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel. Paclitaxel 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 12608535-1 2003 PURPOSE: We have reported that overexpression of mdr1 P-glycoprotein (Pgp) is associated with a higher sensitivity to paclitaxel-induced apoptosis (1,2). Paclitaxel 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 12608532-4 2003 These results show that P-glycoprotein plays a major role in the oral bioavailability of paclitaxel. Paclitaxel 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 24-38 12608535-11 2003 This finding is identical to our previous finding with paclitaxel, where equal intracellular drug concentration resulted in greater apoptosis in the Pgp-rich BC19 cells. Paclitaxel 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 149-152 12608535-12 2003 CONCLUSIONS: These data, together with the opposite effects of paclitaxel and vincristine on microtubules (i.e., polymerization versus depolymerization), indicate that the enhanced apoptosis in Pgp-rich cells is specific for antimicrotubule agents but is not related to the polymerization of microtubules. Paclitaxel 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 194-197 12528803-0 2003 Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Paclitaxel 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 12415630-2 2002 METHODS: We investigated if P-gp expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six commonly used chemotherapeutic agents (doxorubicin, daunorubicin, mitoxantrone, vinblastine, paclitaxel, and colchicine). Paclitaxel 223-233 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 12584388-0 2003 Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Paclitaxel 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 12584388-9 2003 CONCLUSIONS: Although Pgp expression in NSCLC does not fully predict chemotherapy response to paclitaxel-based therapy, detection of Pgp expression will aid in planning paclitaxel-based therapy for patients with advanced NSCLC. Paclitaxel 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 133-136 12435109-3 2002 Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp. Paclitaxel 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 190-193 12435109-3 2002 Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp. Paclitaxel 153-163 ATP binding cassette subfamily B member 1 Homo sapiens 26-29 12435109-3 2002 Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp. Paclitaxel 153-163 ATP binding cassette subfamily B member 1 Homo sapiens 190-193 12144824-0 2002 Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 0-27 12144824-19 2002 CONCLUSION: MDR-1 gene expression may be a useful predictor for PTX-based chemotherapy. Paclitaxel 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 12-17 12079522-12 2002 Except for HAC-2 cells, expression of MRP genes was related to CDDP resistance, and MDR-1 gene expression was associated with PTX resistance. Paclitaxel 126-129 ATP binding cassette subfamily B member 1 Homo sapiens 84-89 12678980-6 2003 RESULTS: The resistance to chemotherapeutic agents such as cochicine, Vp-16, vincristine, doxorubcin and paclitaxel were elevated markedly by 10.6, 10.4, 11.2, 4.2 and 14.2 folds in KG1a cell line transduced with MDR1 gene. Paclitaxel 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 213-217 12435109-3 2002 Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp. Paclitaxel 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 26-29 12359058-0 2002 Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Paclitaxel 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 12359058-6 2002 Cell survival assay revealed that verapamil and cepharanthine, conventional P-gp modulators, could completely overcome paclitaxel resistance. Paclitaxel 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 11959083-6 2002 P-glycoprotein had a substantially greater effect on paclitaxel accumulation, efflux and bi-directional transport than for morphine. Paclitaxel 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 11959083-8 2002 These results reinforce the substantial role P-glycoprotein has in paclitaxel transport. Paclitaxel 67-77 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 12121008-6 2002 Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 12121008-6 2002 Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP. Paclitaxel 101-111 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 12121008-1 2002 P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clinical use of paclitaxel and docetaxel. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 12121008-1 2002 P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clinical use of paclitaxel and docetaxel. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 12121008-6 2002 Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP. Paclitaxel 101-111 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 12121008-6 2002 Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP. Paclitaxel 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 11945073-6 2002 P-glycoprotein (PGP), a drug exporter encoded by ABCB1, exports both paclitaxel and colchicine. Paclitaxel 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 11945073-6 2002 P-glycoprotein (PGP), a drug exporter encoded by ABCB1, exports both paclitaxel and colchicine. Paclitaxel 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 16-19 11945073-6 2002 P-glycoprotein (PGP), a drug exporter encoded by ABCB1, exports both paclitaxel and colchicine. Paclitaxel 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 11945073-11 2002 The glucocorticoid/paclitaxel combination also increased reporter gene expression in BE(2)C cells, which constitutively express high levels of PGP. Paclitaxel 19-29 ATP binding cassette subfamily B member 1 Homo sapiens 143-146 11945073-13 2002 Glucocorticoids augment colchicine- or paclitaxel-mediated enhancement of transgene expression most likely by reducing drug egress through PGP. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 139-142 11890691-3 2002 The sensitivity to paclitaxel, an MDR1 substrate, in Caco-2 cells pretreated with digoxin was lower than that in non-treated cells. Paclitaxel 19-29 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 12467215-4 2002 Subtoxic concentrations of PDMP sensitized drug-selected MCF7/AdrR and Pgp-overexpressing MDA435/LCC6MDR1 (MDR1 gene-transfected) cell lines to Taxol and vincristine but did not alter the chemosensitivity of the wild-type cells. Paclitaxel 144-149 ATP binding cassette subfamily B member 1 Homo sapiens 71-74 11931848-2 2002 The overexpression of the P-glycoprotein (P-gp) and/or alteration in the cellular microtubules is associated with the development of paclitaxel resistance. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 11931848-2 2002 The overexpression of the P-glycoprotein (P-gp) and/or alteration in the cellular microtubules is associated with the development of paclitaxel resistance. Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 11839680-2 2002 Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM). Paclitaxel 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 11839680-2 2002 Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM). Paclitaxel 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 11862425-1 2002 BACKGROUND: Recent studies in mice and patients have shown that the low oral bioavailability of paclitaxel can be increased by coadministration of P-glycoprotein blockers. Paclitaxel 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 147-161 11862425-4 2002 METHODS: Paclitaxel was administered to mdr1ab P-glycoprotein knockout mice with either the conventional (controls) or a seven-fold higher amount of Cremophor EL (test group). Paclitaxel 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 11801563-5 2002 The Pgp substrates paclitaxel (Taxol), Adriamycin, and vinblastine were all effective using this type of combination treatment, although the chemotherapy protocols showed little or no effect as monotherapies. Paclitaxel 19-29 ATP binding cassette subfamily B member 1 Homo sapiens 4-7 11801563-5 2002 The Pgp substrates paclitaxel (Taxol), Adriamycin, and vinblastine were all effective using this type of combination treatment, although the chemotherapy protocols showed little or no effect as monotherapies. Paclitaxel 31-36 ATP binding cassette subfamily B member 1 Homo sapiens 4-7 12467215-4 2002 Subtoxic concentrations of PDMP sensitized drug-selected MCF7/AdrR and Pgp-overexpressing MDA435/LCC6MDR1 (MDR1 gene-transfected) cell lines to Taxol and vincristine but did not alter the chemosensitivity of the wild-type cells. Paclitaxel 144-149 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 11564553-4 2001 In addition, (+)-discodermolide is active in Taxol-resistant cell lines that overexpress P-glycoprotein, the multidrug-resistant transporter. Paclitaxel 45-50 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 11990771-3 2002 Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator. Paclitaxel 238-248 ATP binding cassette subfamily B member 1 Homo sapiens 51-54 11990771-3 2002 Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator. Paclitaxel 238-248 ATP binding cassette subfamily B member 1 Homo sapiens 188-191 11990771-3 2002 Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator. Paclitaxel 238-248 ATP binding cassette subfamily B member 1 Homo sapiens 188-191 11990771-3 2002 Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator. Paclitaxel 238-248 ATP binding cassette subfamily B member 1 Homo sapiens 188-191 11710832-6 2001 Importantly, when Mdr-1 cDNA was stably expressed in the wild-type cell line to generate a highly Taxol-resistant sub-line, 1847/MDR5, ERK1/2 MAP kinases again became activated. Paclitaxel 98-103 ATP binding cassette subfamily B member 1 Homo sapiens 18-23 11710832-7 2001 This result demonstrated that the increased activity of the signalling pathway in the Taxol-resistant lines was directly attributable to MDR-1 overexpression and was not due to the effects of Taxol itself. Paclitaxel 86-91 ATP binding cassette subfamily B member 1 Homo sapiens 137-142 11606389-7 2001 Moreover, low concentrations of SCH66336 exhibit synergy with the Pgp substrate/inhibitors paclitaxel, tamoxifen, and vinblastine respectively by significantly potentiating their inhibition of Pgp. Paclitaxel 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 66-69 11606389-7 2001 Moreover, low concentrations of SCH66336 exhibit synergy with the Pgp substrate/inhibitors paclitaxel, tamoxifen, and vinblastine respectively by significantly potentiating their inhibition of Pgp. Paclitaxel 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 193-196 11606393-3 2001 The common cellular phenotypes associated with paclitaxel resistance are an increased expression of the drug transport protein P-glycoprotein (P-gp), an alteration in the levels of beta-tubulin isotypes, and/or changes in the drug binding affinity of the microtubules. Paclitaxel 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 11606393-3 2001 The common cellular phenotypes associated with paclitaxel resistance are an increased expression of the drug transport protein P-glycoprotein (P-gp), an alteration in the levels of beta-tubulin isotypes, and/or changes in the drug binding affinity of the microtubules. Paclitaxel 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 11925927-6 2001 Messenger RNA of MDR1 located on chromosomal region of 7q11.2-21 was overexpressed in the paclitaxel-resistant cell lines and recognized as a potential mechanism of acquired paclitaxel-resistance. Paclitaxel 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 11925927-6 2001 Messenger RNA of MDR1 located on chromosomal region of 7q11.2-21 was overexpressed in the paclitaxel-resistant cell lines and recognized as a potential mechanism of acquired paclitaxel-resistance. Paclitaxel 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 11780384-10 2001 The chemoresistance to taxol decreased to 58% of SKOV3/mdr1 with mdr1 antisense ODN treatment. Paclitaxel 23-28 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 11780384-10 2001 The chemoresistance to taxol decreased to 58% of SKOV3/mdr1 with mdr1 antisense ODN treatment. Paclitaxel 23-28 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 11780384-11 2001 Compared with SKOV3/mdr1 cells in the control group, under a certain range of drug concentrations, the number of drug resistance colonies in mdr1 antisense ODNs treated SKOV3/mdr1 cells for taxol and doxorubicin decreased by 8.6 +/- 0.8 fold and 3.1 +/- 0.6 fold, respectively. Paclitaxel 190-195 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 11780384-11 2001 Compared with SKOV3/mdr1 cells in the control group, under a certain range of drug concentrations, the number of drug resistance colonies in mdr1 antisense ODNs treated SKOV3/mdr1 cells for taxol and doxorubicin decreased by 8.6 +/- 0.8 fold and 3.1 +/- 0.6 fold, respectively. Paclitaxel 190-195 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 11504826-4 2001 A computational model of intracellular paclitaxel pharmacokinetics was developed to analyze for the Pgp efflux parameters. Paclitaxel 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 100-103 11504826-0 2001 Kinetics of P-glycoprotein-mediated efflux of paclitaxel. Paclitaxel 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 11504826-8 2001 In conclusion, our results indicate that the Pgp-mediated efflux represents a major efflux mechanism of paclitaxel at the low end of the clinically observed drug concentration range, but accounts for only a minor part of the efflux at higher concentrations in BC19 cells. Paclitaxel 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 45-48 11504826-1 2001 Paclitaxel is a substrate of the mdr1 P-glycoprotein (Pgp). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 11504826-1 2001 Paclitaxel is a substrate of the mdr1 P-glycoprotein (Pgp). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 11668581-5 2001 However, heightening the Taxol sensitivity of GFP-EMTB-TC-7 cells by pre-incubating cells with the p-glycoprotein inhibitor, verapamil, did result in selective killing of cells highly expressing GFP-EMTB. Paclitaxel 25-30 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 11504826-1 2001 Paclitaxel is a substrate of the mdr1 P-glycoprotein (Pgp). Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 54-57 11504826-2 2001 The objective of the present study was to determine the kinetics of the Pgp-mediated efflux and its contribution to the overall efflux of paclitaxel at the clinically achievable concentration range of 1 to 1500 nM. Paclitaxel 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 72-75 11504769-8 2001 RESULTS: Pgp-expressing cells treated with IDN-5109 or with the taxane-based drug resistance reversal agent tRA96023, which blocks Pgp activity, retained 8.1- and 9.4-fold more Rh-123 (P =.0001), respectively, and 1.7- and 1.9-fold more doxorubicin (P =.001), respectively, than cells treated with paclitaxel. Paclitaxel 298-308 ATP binding cassette subfamily B member 1 Homo sapiens 9-12 11552225-5 2001 The paclitaxel/doxorubicin interaction was found to be paclitaxel-dose dependent, doxorubicin concentration-dependant, and may be the result of competition for elimination mechanisms, possibly competition for hepatic and biliary transporter proteins such as p-glycoprotein, as a result of the formulation vehicle polyethoxylated castor oil (cremophor EL). Paclitaxel 4-14 ATP binding cassette subfamily B member 1 Homo sapiens 258-272 11552225-5 2001 The paclitaxel/doxorubicin interaction was found to be paclitaxel-dose dependent, doxorubicin concentration-dependant, and may be the result of competition for elimination mechanisms, possibly competition for hepatic and biliary transporter proteins such as p-glycoprotein, as a result of the formulation vehicle polyethoxylated castor oil (cremophor EL). Paclitaxel 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 258-272 11605182-11 2001 Acquired resistance to paclitaxel can be mediated by several mechanisms, including overexpression of p-glycoprotein, altered expression of beta-tubulin isotypes, intrinsic or acquired mutations in beta-tubulin, and expression of novel genes. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 11504769-1 2001 BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 11504769-1 2001 BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells. Paclitaxel 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 182-185 11504769-1 2001 BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells. Paclitaxel 35-40 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 11504769-1 2001 BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells. Paclitaxel 35-40 ATP binding cassette subfamily B member 1 Homo sapiens 182-185 11504769-2 2001 The orally active paclitaxel analog IDN-5109 has been reported to overcome Pgp-mediated drug resistance. Paclitaxel 18-28 ATP binding cassette subfamily B member 1 Homo sapiens 75-78 11496948-0 2001 Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein. Paclitaxel 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 11496948-1 2001 PURPOSE: We previously reported that in patient tumors the expression of the mdrl p-glycoprotein (Pgp) resulted in a lower paclitaxel-induced inhibition of DNA precursor incorporation, but a higher apoptosis (Clin. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 11496948-1 2001 PURPOSE: We previously reported that in patient tumors the expression of the mdrl p-glycoprotein (Pgp) resulted in a lower paclitaxel-induced inhibition of DNA precursor incorporation, but a higher apoptosis (Clin. Paclitaxel 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 98-101 11496948-5 2001 METHODS: To separate the effect of Pgp on intracellular paclitaxel accumulation from its effects on drug sensitivity, we compared the drug activity at various extracellular and intracellular drug concentrations using the human breast MCF7 tumor cells and its mdr1-transfected variant BC19 cells. Paclitaxel 56-66 ATP binding cassette subfamily B member 1 Homo sapiens 35-38 11496948-11 2001 CONCLUSIONS: These results confirm our previous observations in patient tumors and indicate that enhanced Pgp expression is associated with enhanced sensitivity to the apoptotic effect of paclitaxel and reduced sensitivity to its G2/M block effect, via yet-unknown mechanisms that are unrelated to the effect of Pgp on intracellular drug accumulation. Paclitaxel 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 106-109 11288109-3 2001 In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol. Paclitaxel 218-223 ATP binding cassette subfamily B member 1 Homo sapiens 37-40 11410497-0 2001 The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Paclitaxel 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 11392446-8 2001 In conclusion, the uptake, accumulation, and retention of paclitaxel in solid tumors are determined by (a) factors that are independent of biological changes in tumor cells induced by paclitaxel, i.e., ratio of extracellular and intracellular concentrations, and drug binding to extracellular and intracellular macromolecules, and (b) factors that are dependent on the time- and drug concentration-dependent biological changes induced by paclitaxel, i.e., induction of apoptosis, enhancement of tubulin/microtubule production, and induction of Pgp expression. Paclitaxel 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 544-547 11288109-3 2001 In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol. Paclitaxel 218-223 ATP binding cassette subfamily B member 1 Homo sapiens 165-168 11139311-1 2001 Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp). Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 131-145 11329060-3 2001 Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 11329060-3 2001 Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance. Paclitaxel 12-17 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 11157479-7 2001 It is concluded here that P-gp-mediated efflux of paclitaxel, and perhaps GST-mediated detoxification of carboplatin, results in relative sparing of CFU-Meg, which may then respond to locally high levels of stromal cell-derived Tpo. Paclitaxel 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 11159798-0 2001 A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein. Paclitaxel 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 141-155 11465412-5 2001 Following competitive inhibition of Pgp by various Pgp modulators and substrates, even low concentrations of vinblastine, colchicine and paclitaxel substantially decreased TEER. Paclitaxel 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 36-39 11465412-5 2001 Following competitive inhibition of Pgp by various Pgp modulators and substrates, even low concentrations of vinblastine, colchicine and paclitaxel substantially decreased TEER. Paclitaxel 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 51-54 11139311-1 2001 Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp). Paclitaxel 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 11139311-2 2001 We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at least 7-fold by co-administration of the P-gp blocker cyclosporin A (CsA). Paclitaxel 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 11891611-0 2001 Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer. Paclitaxel 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 11891611-11 2001 Because Tc-TF chest images can correctly represent the expression of Pgp in NSCLC, it can accurately predict the chemotherapeutic response to paclitaxel. Paclitaxel 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 11104578-6 2000 Results unambiguously indicate the exceptional activity of the novel taxanes toward P-gp positive cells (up to >400 fold higher potency than that of paclitaxel). Paclitaxel 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 10918072-6 2000 Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells. Paclitaxel 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 11205313-1 2000 BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel. Paclitaxel 214-224 ATP binding cassette subfamily B member 1 Homo sapiens 147-152 11205313-1 2000 BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel. Paclitaxel 214-224 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 11205313-1 2000 BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel. Paclitaxel 214-224 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 11106232-2 2000 In experimental systems, hormonal agents, including megestrol acetate (MA), have been shown to be capable of reversing P-glycoprotein-mediated multidrug resistance to natural products, including paclitaxel. Paclitaxel 195-205 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 11106232-10 2000 Although pharmacokinetic studies were not performed as a component of this study, prior evaluation of MA pharmacokinetics and in vitro data examining the concentrations of the agent required to reverse P-glycoprotein-mediated paclitaxel resistance suggest that the majority of our patient population achieved levels of MA theoretically capable of producing this desired effect. Paclitaxel 226-236 ATP binding cassette subfamily B member 1 Homo sapiens 202-216 11218898-7 2000 Under effect of Taxol 5 ng/ml, the relative percents of drug-resistant colony in mdr1-ASON treated SKOV3/mdr1 cells and in SKOV3/mdr1 cells was 8% and 63%, respectively, (P < 0.01). Paclitaxel 16-21 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 11205313-4 2000 CONCLUSION: Drug resistance modulator PSC 833 abolished the P-gp-mediated multidrug-resistance to paclitaxel and paclitaxel-induced apoptosis in human myeloid leukemia (HL-60/VCR) cells in vitro. Paclitaxel 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 11205313-4 2000 CONCLUSION: Drug resistance modulator PSC 833 abolished the P-gp-mediated multidrug-resistance to paclitaxel and paclitaxel-induced apoptosis in human myeloid leukemia (HL-60/VCR) cells in vitro. Paclitaxel 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 10918072-6 2000 Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells. Paclitaxel 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 10745175-4 2000 Unlike in previous reports the mdr1 promoter was no more active in two cancer cell lines with mutations in the p53 gene than in two other lines with wild-type p53, and its expression level could not be increased by either doxorubicin or taxol. Paclitaxel 237-242 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 10912951-3 2000 In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed. Paclitaxel 3-13 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 10912951-3 2000 In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed. Paclitaxel 3-13 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 11876985-4 2000 The effect of Taxol at different concentrations on mdr1 gene transfer cells was determined by FCM. Paclitaxel 14-19 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 11876985-9 2000 Taxol at a certain concentration can enrich mdr1 gene transferred cells. Paclitaxel 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 10741911-11 2000 Expression of multidrug resistance (MDR1) mRNA, which was not observed in KF28 and KFr13 cells, was observed after induction of taxol resistance. Paclitaxel 128-133 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 10755318-4 2000 Recent in vitro studies in human colon cancer cells have linked DPPE enhancement of paclitaxel, doxorubicin and vinblastine cytotoxicity to inhibition of the P-glycoprotein (P-gp) pump. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 158-172 11809106-6 2000 The non-responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders (P < 0.05). Paclitaxel 34-39 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 10872505-1 2000 The MDR1 multidrug resistance gene encodes a high molecular weight membrane-spanning cell surface protein, P-glycoprotein, that confers multidrug resistance by pumping various cytotoxic drugs, including vinblastine, doxorubicin or paclitaxel, out of cells. Paclitaxel 231-241 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 10872505-1 2000 The MDR1 multidrug resistance gene encodes a high molecular weight membrane-spanning cell surface protein, P-glycoprotein, that confers multidrug resistance by pumping various cytotoxic drugs, including vinblastine, doxorubicin or paclitaxel, out of cells. Paclitaxel 231-241 ATP binding cassette subfamily B member 1 Homo sapiens 107-121 10430060-0 1999 Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 11036469-10 2000 In contrast, the expression level of P-glycoprotein was much more pronounced and showed a positive correlation (p < 0.05) with the response to paclitaxel. Paclitaxel 146-156 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 11036469-11 2000 Reversal of P-glycoprotein function by verapamil or Cremophor EL enhanced the growth inhibitory effects of paclitaxel and further supported the role of P-glycoprotein for paclitaxel sensitivity of human RCCs. Paclitaxel 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 11036469-11 2000 Reversal of P-glycoprotein function by verapamil or Cremophor EL enhanced the growth inhibitory effects of paclitaxel and further supported the role of P-glycoprotein for paclitaxel sensitivity of human RCCs. Paclitaxel 171-181 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 11036469-11 2000 Reversal of P-glycoprotein function by verapamil or Cremophor EL enhanced the growth inhibitory effects of paclitaxel and further supported the role of P-glycoprotein for paclitaxel sensitivity of human RCCs. Paclitaxel 171-181 ATP binding cassette subfamily B member 1 Homo sapiens 152-166 11036469-13 2000 Moreover, expression and function of P-glycoprotein markedly contribute to paclitaxel responsiveness, although other as yet undefined drug resistance mechanisms are effective in human RCCs as well. Paclitaxel 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 11052631-9 2000 CONCLUSIONS: These results suggest that the exposure duration, DT, and expression of MDR-1, bcl-2 and bax each contribute to paclitaxel sensitivity of human colorectal carcinoma cells. Paclitaxel 125-135 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Paclitaxel 166-176 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Paclitaxel 166-176 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Paclitaxel 166-176 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 11498350-2 1999 Since Taxol is a substrate for P-glycoprotein, overexpression of this transport system is recognized as a relevant mechanism of resistance. Paclitaxel 6-11 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 10602425-9 1999 This strategy also allowed a selective killing of HL60/TX cells which express MDR-1, with the only difference being that the second drug, paclitaxel, was substituted for epothilones, non-Pgp substrates. Paclitaxel 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Paclitaxel 313-318 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Paclitaxel 313-318 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 10576649-8 1999 Taxol, an allosteric inhibitor of [3H]-vinblastine binding to P-gp, could only displace 40% of [3H]-vinblastine (Ki = 400+/-140 nM). Paclitaxel 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 10803921-1 2000 PURPOSE: We investigated the relationship between the basal and treatment-induced change in the tumor expression of the drug resistance gene MDR1 and the cellular injury response gene GADD153, and clinical response to paclitaxel treatment. Paclitaxel 218-228 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 10430060-1 1999 The MDR1 multidrug resistance gene confers resistance to natural-product anticancer drugs including paclitaxel. Paclitaxel 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 10430060-2 1999 We conducted a clinical gene therapy study to determine whether retroviral-mediated transfer of MDR1 in human hematopoietic cells would result in stable engraftment, and possibly expansion, of cells containing this gene after treatment with myelosuppressive doses of paclitaxel. Paclitaxel 267-277 ATP binding cassette subfamily B member 1 Homo sapiens 96-100 10430060-14 1999 One patient remained positive for the MDR1 transgene throughout all six cycles of paclitaxel therapy, whereas the other 2 patients showed a decrease in the number of cells containing the transgene to undetectable levels. Paclitaxel 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 10430060-15 1999 Despite the low level of engraftment of MDR1-marked cells, a correlation was observed between the relative number of granulocytes containing the MDR1 transgene and the granulocyte nadir after paclitaxel therapy. Paclitaxel 192-202 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 11550305-2 1999 We examined paclitaxel-induced killing in seven cell lines derived from human malignant astrocytic gliomas and medulloblastomas with the goal of characterizing range of sensitivity, contribution of P-glycoprotein 170-mediated drug efflux to resistance, and cross-resistance with alkylating agents. Paclitaxel 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 198-212 10193934-10 1999 Immunofluorescence and Western immunoblotting of cultures showed that 1 x 10(-6) M paclitaxel increased P-glycoprotein expression in Caco-2 and LoVo cells. Paclitaxel 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 10193934-14 1999 Increased P-glycoprotein expression appears to be correlated with paclitaxel resistance in polyposis and cancerous colonic cells. Paclitaxel 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 9572489-4 1998 Since mdr-1-encoded p-glycoprotein (p170mdr-1) has been implicated in Taxol resistance, we next examined the p170mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol. Paclitaxel 70-75 ATP binding cassette subfamily B member 1 Homo sapiens 6-11 10100591-11 1999 In conclusion, Ro 32-2241, acting directly on Pgp (rather than, or in addition to, an effect on PKC), is effective in reducing or reversing resistance to doxorubicin, taxol and vinblastine in human tumour cells with a clinically relevant degree of MDR. Paclitaxel 167-172 ATP binding cassette subfamily B member 1 Homo sapiens 46-49 9780138-6 1998 P-glycoprotein effluxes a variety of anticancer drugs, such as doxorubicin, vinca alkaloids, etoposide and taxol, and thereby allows cancer cells to show resistance to these drugs. Paclitaxel 107-112 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 9738565-0 1998 Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. Paclitaxel 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 164-168 10453729-1 1999 PURPOSE: The purpose of this study was to investigate the effect of high-dose progesterone, an inhibitor of P glycoprotein, on the pharmacokinetics and toxicity of paclitaxel. Paclitaxel 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Paclitaxel 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Paclitaxel 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Paclitaxel 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 9865905-9 1998 The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors. Paclitaxel 187-197 ATP binding cassette subfamily B member 1 Homo sapiens 92-95 9865905-9 1998 The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors. Paclitaxel 187-197 ATP binding cassette subfamily B member 1 Homo sapiens 210-213 9803961-6 1998 Saquinavir, ritonavir and nelfinavir significantly inhibited the efflux of [3H]paclitaxel and [3H]vinblastine in P-gp-positive cells, resulting in an increase in intracellular accumulation of these drugs. Paclitaxel 79-89 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 9572489-4 1998 Since mdr-1-encoded p-glycoprotein (p170mdr-1) has been implicated in Taxol resistance, we next examined the p170mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol. Paclitaxel 70-75 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 9572489-4 1998 Since mdr-1-encoded p-glycoprotein (p170mdr-1) has been implicated in Taxol resistance, we next examined the p170mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol. Paclitaxel 189-194 ATP binding cassette subfamily B member 1 Homo sapiens 6-11 9531522-11 1998 These data support the conclusion that rapid passive diffusion of taxol through the intestinal epithelium is partially counteracted by the action of an outwardly directed efflux pump, presumably P-glycoprotein. Paclitaxel 66-71 ATP binding cassette subfamily B member 1 Homo sapiens 195-209 9625436-3 1998 TET (3.0 microM), FAN (3.0 microM) and VER (10.0 microM) reduced the paclitaxel (TAX) concentration required to achieve 50% inhibition of cell growth (EC50) to HCT15 (P-gp-positive) cells about 3100-, 1900- and 410-fold, and these compounds also reduced the EC50 value of actinomycin D (AMD) about 36.0-, 45.9- and 18.2-fold in the cells, respectively. Paclitaxel 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 9516927-0 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Paclitaxel 125-130 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 9510502-3 1998 KR-30035 potentiated the paclitaxel-induced cytotoxicity to HCT15 [P-glycoprotein (P-gp)-expressed cells] to over 15-fold greater than that of verapamil and KR-30032 was equipotent with verapamil (EC50: 0.07, 5.0 and 3.3 nM at 1.0 microg/ml). Paclitaxel 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 9510502-3 1998 KR-30035 potentiated the paclitaxel-induced cytotoxicity to HCT15 [P-glycoprotein (P-gp)-expressed cells] to over 15-fold greater than that of verapamil and KR-30032 was equipotent with verapamil (EC50: 0.07, 5.0 and 3.3 nM at 1.0 microg/ml). Paclitaxel 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 9516927-0 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Paclitaxel 125-130 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 9516927-7 1998 Compared with Pgp-negative tumors, a significant increase in doxorubicin and Taxol resistance was seen for breast cancers that expressed Pgp, regardless of prior treatment. Paclitaxel 77-82 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 9516927-7 1998 Compared with Pgp-negative tumors, a significant increase in doxorubicin and Taxol resistance was seen for breast cancers that expressed Pgp, regardless of prior treatment. Paclitaxel 77-82 ATP binding cassette subfamily B member 1 Homo sapiens 137-140 9516927-8 1998 A strong correlation between the degree of Pgp expression and in vitro resistance to Taxol and doxorubicin (but not to 5-fluorouracil) was found when either IHC scores or image analysis-based methods were used to quantify Pgp expression (n = 185, P < 0.0001). Paclitaxel 85-90 ATP binding cassette subfamily B member 1 Homo sapiens 43-46 9516927-8 1998 A strong correlation between the degree of Pgp expression and in vitro resistance to Taxol and doxorubicin (but not to 5-fluorouracil) was found when either IHC scores or image analysis-based methods were used to quantify Pgp expression (n = 185, P < 0.0001). Paclitaxel 85-90 ATP binding cassette subfamily B member 1 Homo sapiens 222-225 9380024-5 1997 Multidrug-resistant human colon and ovarian carcinoma cells overexpressing P-glycoprotein, which are 900- and 2800-fold resistant to paclitaxel, respectively, relative to the parental lines, retained significant sensitivity to discodermolide (25- and 89-fold more resistant relative to the parental lines). Paclitaxel 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 75-89 9815684-5 1997 B. Deisseroth, Cancer Gene Ther., 1: 21-25, 1994), which involve transplantation of mouse marrow cells modified with the human MDR-1 cDNA, showed that the majority of the marrow cells of these animals were resistant to repetitive administration of myelotoxic doses of Taxol, a MDR-1-transported drug. Paclitaxel 268-273 ATP binding cassette subfamily B member 1 Homo sapiens 127-132 9070502-5 1997 This activity was pronounced in sublines expressing tubulin-associated and P-glycoprotein-mediated drug resistance, indicating involvement of these mechanisms in paclitaxel resistance and their modulation by CEL. Paclitaxel 162-172 ATP binding cassette subfamily B member 1 Homo sapiens 75-89 9105396-0 1997 Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Paclitaxel 15-20 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 9105396-0 1997 Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Paclitaxel 15-20 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 9105396-4 1997 In contrast, the 2008/13 clones followed the classical P-glycoprotein-mediated resistance phenotype until a 245-fold taxol-resistant clone (2008/13/2) was obtained, which was followed by a further increase in the degree of resistance but significant down-regulation of P-glycoprotein expression in the 252-fold taxol-resistant 2008/13/4 cells. Paclitaxel 117-122 ATP binding cassette subfamily B member 1 Homo sapiens 269-283 9219509-0 1997 Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Paclitaxel 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 9009089-3 1997 We also determined how these mechanisms would affect the accumulation and cytotoxicity of a PGP substrate, such as Taxol (paclitaxel). Paclitaxel 115-120 ATP binding cassette subfamily B member 1 Homo sapiens 92-95 9009089-3 1997 We also determined how these mechanisms would affect the accumulation and cytotoxicity of a PGP substrate, such as Taxol (paclitaxel). Paclitaxel 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 92-95 9009089-8 1997 PGP, but not MRP, overexpression significantly impaired paclitaxel accumulation and paclitaxel-induced apoptosis, as well as reduced its cytotoxic effects as determined by the MTT assay. Paclitaxel 56-66 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 9009089-8 1997 PGP, but not MRP, overexpression significantly impaired paclitaxel accumulation and paclitaxel-induced apoptosis, as well as reduced its cytotoxic effects as determined by the MTT assay. Paclitaxel 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 9219509-6 1997 RESULTS: Cross-resistance to paclitaxel in P-glycoprotein-expressing sublines was shown to be comparable to that of other drugs transported by P-glycoprotein. Paclitaxel 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 9272128-7 1997 Our studies of combinations of high-dose cyclosporin (CsA) or PSC 833 with etoposide, doxorubicin, or paclitaxel have produced data regarding the role of Pgp in the clinical pharmacology of these agents. Paclitaxel 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 154-157 9219509-7 1997 Sensitivity to paclitaxel could be modulated by cyclosporin A in unselected cell lines expressing P-glycoprotein and not in P-glycoprotein-negative cell lines. Paclitaxel 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 98-112 9219509-8 1997 Resistance to paclitaxel was reduced tenfold by increasing the duration of exposure in P-glycoprotein-expressing cells. Paclitaxel 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 9219509-10 1997 CONCLUSIONS: These studies extend observations on the schedule dependence of paclitaxel cytotoxicity and the role of P-glycoprotein in mediating paclitaxel sensitivity. Paclitaxel 145-155 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 9219509-11 1997 The schedule dependence of relative resistance suggests that infusional paclitaxel may help in overcoming P-glycoprotein-mediated resistance. Paclitaxel 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 106-120 9042212-0 1996 Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Paclitaxel 85-90 ATP binding cassette subfamily B member 1 Homo sapiens 29-32 21544450-0 1996 P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A. Paclitaxel 40-45 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8831715-7 1996 For example, lower levels of taxol resistance are associated with overexpression of MRP than with overexpression of P-glycoprotein. Paclitaxel 29-34 ATP binding cassette subfamily B member 1 Homo sapiens 116-130 8616855-11 1996 To investigate the basis of the variable tumor response to taxol, we determined the expression of multidrug resistance P-glycoprotein (Pgp), p53, and bcl-2 proteins, using immunohistochemical staining and Western blot analysis. Paclitaxel 59-64 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 8616855-15 1996 Pgp expression correlated differently with taxol-induced inhibition of DNA synthesis than with apoptosis; Pgp-positive tumors showed a significantly higher Emax (63%) and IC30 (4.2 microM) but also a higher apoptotic index (17%) than Pgp-negative tumors (Emax 36%; IC30, 0.3 microM; and apoptotic index; 6%; P < 0.05 for all cases). Paclitaxel 43-48 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 8616855-15 1996 Pgp expression correlated differently with taxol-induced inhibition of DNA synthesis than with apoptosis; Pgp-positive tumors showed a significantly higher Emax (63%) and IC30 (4.2 microM) but also a higher apoptotic index (17%) than Pgp-negative tumors (Emax 36%; IC30, 0.3 microM; and apoptotic index; 6%; P < 0.05 for all cases). Paclitaxel 43-48 ATP binding cassette subfamily B member 1 Homo sapiens 106-109 8616855-15 1996 Pgp expression correlated differently with taxol-induced inhibition of DNA synthesis than with apoptosis; Pgp-positive tumors showed a significantly higher Emax (63%) and IC30 (4.2 microM) but also a higher apoptotic index (17%) than Pgp-negative tumors (Emax 36%; IC30, 0.3 microM; and apoptotic index; 6%; P < 0.05 for all cases). Paclitaxel 43-48 ATP binding cassette subfamily B member 1 Homo sapiens 106-109 8616855-18 1996 Pgp overexpression appears to protect cells from the antiproliferative effect of taxol but correlated with a higher apoptosis. Paclitaxel 81-86 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 8877707-5 1996 Transfer of the selectable marker multidrug resistance 1 (mdr1), FMEV, in contrast to conventional MoMuLV-related vectors currently in use for clinical protocols, mediated background-free selectability of transduced human HPC in the presence of myeloablative doses of the cytostatic agent paclitaxel in vitro. Paclitaxel 289-299 ATP binding cassette subfamily B member 1 Homo sapiens 34-56 8877707-5 1996 Transfer of the selectable marker multidrug resistance 1 (mdr1), FMEV, in contrast to conventional MoMuLV-related vectors currently in use for clinical protocols, mediated background-free selectability of transduced human HPC in the presence of myeloablative doses of the cytostatic agent paclitaxel in vitro. Paclitaxel 289-299 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 9816243-1 1996 The multiple drug resistance (MDR) gene P-glycoprotein product is a transmembrane efflux pump that prevents toxicity of a variety of chemotherapeutic agents, including the anthracyclines, Vinca alkaloids, podophyllins, and taxol. Paclitaxel 223-228 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 8573197-4 1996 Although verapamil, an inhibitor of P-glycoprotein function, markedly increased the efficacy of taxol against the rodent cells (WS, WR, and CHO), the expression of P-glycoprotein was found only at low levels in the WR cells. Paclitaxel 96-101 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 8573197-4 1996 Although verapamil, an inhibitor of P-glycoprotein function, markedly increased the efficacy of taxol against the rodent cells (WS, WR, and CHO), the expression of P-glycoprotein was found only at low levels in the WR cells. Paclitaxel 96-101 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 8573197-10 1996 These results lead us to propose the presence in the rodent cells of an alternative taxol transport system that is distinct from the P-glycoprotein and MRP systems. Paclitaxel 84-89 ATP binding cassette subfamily B member 1 Homo sapiens 133-147 7669666-1 1995 The MDR1 gene product P-glycoprotein (P-gp) extrudes several anticancer drugs including taxol and fluorescent dyes such as rhodamine (Rh123). Paclitaxel 88-93 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 7669666-1 1995 The MDR1 gene product P-glycoprotein (P-gp) extrudes several anticancer drugs including taxol and fluorescent dyes such as rhodamine (Rh123). Paclitaxel 88-93 ATP binding cassette subfamily B member 1 Homo sapiens 22-36 7669666-1 1995 The MDR1 gene product P-glycoprotein (P-gp) extrudes several anticancer drugs including taxol and fluorescent dyes such as rhodamine (Rh123). Paclitaxel 88-93 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 7552988-0 1995 Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Paclitaxel 14-19 ATP binding cassette subfamily B member 1 Homo sapiens 115-120 7622101-8 1995 Finally, resistance to taxol may be mediated by enhanced expression of P-glycoprotein, while presumed other mechanisms such as alterations in tubulin structure, the cellular "target" of taxol, and changes in polymerization of tubulin are still largely unresolved. Paclitaxel 23-28 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 7670142-3 1995 The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide. Paclitaxel 207-212 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 7552989-0 1995 Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Paclitaxel 27-32 ATP binding cassette subfamily B member 1 Homo sapiens 174-179 7645972-4 1995 The SKVLB cells overexpressed the multidrug resistant gene (MDR-1) which confers a resistance to taxol. Paclitaxel 97-102 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 7749130-15 1995 Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 7749130-15 1995 Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 84-106 7749130-15 1995 Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function. Paclitaxel 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 108-113 7749130-15 1995 Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function. Paclitaxel 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 7749130-15 1995 Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function. Paclitaxel 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 84-106 7749130-15 1995 Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function. Paclitaxel 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 108-113 8104544-4 1993 Significant differences in sensitivity to taxol among these cell lines were observed; the most resistant cell line SK-N-FI is characterized by very high levels of MDR1 expression and the most sensitive SK-N-AS by very low levels. Paclitaxel 42-47 ATP binding cassette subfamily B member 1 Homo sapiens 163-167 7912530-4 1993 In human tumors resistant to Taxol, P-glycoprotein could be responsible for maintaining the drug below cytotoxic levels. Paclitaxel 29-34 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 7912530-5 1993 Analyses of the MDR promoters that are involved in P-glycoprotein expression and overproduction revealed an interesting recombination event in a Taxol-resistant cell line. Paclitaxel 145-150 ATP binding cassette subfamily B member 1 Homo sapiens 51-65 8105099-4 1993 Overexpression of P-glycoprotein is one mechanism of in vitro resistance to a number of currently used cytotoxic agents including paclitaxel. Paclitaxel 130-140 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 8105099-5 1993 PURPOSE: Our aim was to develop a bioassay to measure plasma levels of Cremophor and to determine whether or not plasma levels of Cremophor achieved during paclitaxel therapy are sufficient to inhibit the activity of the P-glycoprotein. Paclitaxel 156-166 ATP binding cassette subfamily B member 1 Homo sapiens 221-235 8105099-16 1993 CONCLUSION: The concentrations of Cremophor measured in plasma drawn from patients after a 3-hour infusion of paclitaxel at 135 or 175 mg/m2 were found to be sufficient to inhibit P-glycoprotein activity in vitro. Paclitaxel 110-120 ATP binding cassette subfamily B member 1 Homo sapiens 180-194